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Abstract 
Enteropathogenic Escherichia coli (EPEC) are non-invasive foodborne 
diarrhoeal pathogens that are a leading cause of infant death in the developing 
world. As antibiotic resistance increases amongst pathogens, new treatments 
are required to reduce infant mortality. Probiotic bacteria could offer a solution, 
and Lactobacillus reuteri have been shown to alleviate diarrhoea and reduce 
EPEC colonisation in clinical studies. Here, we utilised mucus and non-mucus 
producing human intestinal epithelial cell lines as well as human duodenal 
biopsies to investigate the effects of L. reuteri ATCC PTA 6475 and ATCC 
53608 on EPEC infection, with particular focus on pathogen adherence, host 
mucin production, and innate immune response. 
Short-term protection assays demonstrated that pre-incubation with an excess 
of L. reuteri inhibited EPEC epithelial binding, independently of secreted 
products and probiotic epithelial adhesion. Increased pre-incubation times 
enhancing L. reuteri adhesion reduced EPEC binding to HT-29 cells by ATCC 
PTA 6475. While this strain did not inhibit EPEC adhesion to LS174T cells, 
ATCC PTA 6475 significantly reduced cell to cell spread of EPEC, a 
characteristic which has not previously been described. 
In addition to reducing EPEC adherence, incubation with L. reuteri ATCC PTA 
6475 increased MUC2 protein production in LS174T cells. In contrast, EPEC 
infection reduced MUC2 protein levels and this effect was diminished by co-
incubation with ATCC PTA 6475, suggesting that L. reuteri protect against 
EPEC-mediated MUC2 degradation. L. reuteri also demonstrated anti-
inflammatory characteristics, as ATCC PTA 6475 and ATCC 53608 inhibited 
EPEC-induced interleukin-8 protein expression in HT-29 cells.  
Taken together, our findings suggest that L. reuteri protects against EPEC 
infection by reducing pathogen binding and modulating host mucus production 
and inflammation. These effects are strain-specific and dependent on the host 
model system used. Therefore, the probiotic potential of L. reuteri strains 
needs to be carefully evaluated in relevant systems before application in 
clinical practice.  
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1.1. Enteropathogenic E. coli 
Escherichia coli are rod shaped, Gram-negative, facultative anaerobes which 
colonise the infant gastrointestinal (GI) tract (GIT) within hours after birth 
(Kaper et al., 2004). These microbes were originally isolated from the stools 
of infants by Theodor Escherich in 1885 (Bacterium coli commune) and were 
seen as harmless commensals in the GIT (Reprinted in English, Escherich 
(1988)). However, the identification of Bacterium coli var. neapolitanum, which 
would later be renamed enteropathogenic E. coli (EPEC), as the causative 
agent of “summer diarrhoea” in the UK in the 1940’s demonstrated that this 
bacterial species could also have pathogenic tendencies (Bray, 1945; Bray & 
Beavan, 1948; Levine et al., 1978). Since the identification of EPEC, numerous 
other E. coli pathotypes have been described, which have been broadly 
classified as either diarrhoeagenic or extra-intestinal pathogenic E. coli 
(ExPEC) (Figure 1.1) (Kaper et al., 2004).  
 
 
Figure 1.1: The colonisation sites of the major E. coli pathotypes 
Modified from Croxen and Finlay (2010). 
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The diarrhoeagenic E. coli pathotypes are EPEC, enterohaemorrhagic E. coli 
(EHEC), enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAEC), 
enteroinvasive E. coli (EIEC), and diffusely adherent E. coli (DAEC) (Croxen 
et al., 2013). The recently described pathotype adherent invasive E. coli 
(AIEC) is also found in the GIT, where it has been linked to the development 
of ileal Crohn’s disease. However, this strain is not specifically associated with 
the development of diarrhoea (Darfeuille-Michaud, 2002). The ExPEC 
pathotypes which have been described are uropathogenic E. coli (UPEC) and 
neonatal meningitis E. coli (NMEC) which colonise the bladder and brain, 
respectively (Croxen & Finlay, 2010). The evolution of these distinct E. coli 
pathotypes is facilitated thorough the plasticity of the E. coli genome, which 
contains a core genome (genes located in at least 95% of publically available 
sequenced E. coli genomes) of approximately 3050 genes and a pan-genome 
(genes located in fewer than 95% of publically available sequenced E. coli 
genomes) of over 16,300 genes (Kaas et al., 2012). The expansive pan-
genome contains the E. coli virulence repertoire which enables E. coli to infect 
the host and induce diarrhoea.  
Diarrhoeal disease is currently the second largest killer of children under the 
age of 5, responsible for the deaths of an estimated 800,000 children per year 
in 2010, primarily from sub-Saharan Africa and south east Asia (Liu et al., 
2012a). In the developing world, socio-economic status is inversely 
proportional to the risk of moderate to severe diarrhoea (MSD), as children 
from parents with higher wealth status, greater access to clean water, and 
more highly educated mothers, were less likely to present with MSD than 
children from poorer backgrounds (Kotloff et al., 2013). While there are 
numerous etiological factors which cause this diarrhoeal health burden, 
diarrhoeagenic E. coli are a major contributor as the pathotypes ETEC and 
EIEC (Shigella) have been identified as two of the four major causes for MSD 
(Kotloff et al., 2013). While the incidence of EPEC infection was lower than 
ETEC and EIEC, the presence of EPEC in cases of MSD was significantly 
associated with infant death (Kotloff et al., 2013). Furthermore, a systematic 
review of diarrhoeal mortality from 1990 to 2011 estimated that EPEC was the 
second major cause of death (after rotavirus) in children under 5 years of age 
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in 2011 (Lanata et al., 2013). Crucially, a rotavirus vaccine has been 
developed in recent years which has shown a high clinical efficacy (Vesikari 
et al., 2006). However, no vaccines have been developed for the prevention 
of EPEC infection so far.  
Thus, EPEC remains an important diarrhoeal pathogen and further research 
into the pathogenic mechanisms is required. In this section, I will discuss the 
current knowledge regarding EPEC infection. 
 
1.1.1. Epidemiology 
1.1.1.1. Emergence and classification 
The bacterial species Bacterium coli var. neapolitanum, later classified as 
EPEC serogroup O111, were first described in the United Kingdom by John 
Bray, who found that these bacteria were present in children with “summer 
diarrhoea” but were mostly absent from healthy infants (Bray, 1945; Levine, 
1987). Infections mainly affected infants (average age of 6 months) and were 
associated with high mortality (20 deaths out of 51 reported cases) (Bray, 
1945). The researchers identified these bacteria by developing an antiserum, 
which was used in the slide-agglutination test to differentiate EPEC from non-
pathogenic E. coli strains (Bray & Beavan, 1948; Levine, 1987). The use of 
this technique for E. coli recognition, as well as the development of O and H 
antigen serotyping by Kauffman in 1947, led to the detection of E. coli 
associated with diarrhoea in children across Europe and the United States of 
America (Levine, 1987; Robins-Browne, 1987). This pathotype was 
subsequently renamed enteropathogenic E. coli by Neter and colleagues and 
further divided into the classical EPEC serotypes O26, O55, O86, O111, O114, 
O119, O125, O126, O127, O128, O142, and O158 (Neter et al. (1955) and 
reviewed in Robins-Browne (1987), Levine (1987), Nataro and Kaper (1998), 
and Croxen et al. (2013)).  
With the identification of the E. coli pathotypes EIEC and ETEC in the 
subsequent decades, popular scientific thought suggested that EPEC was a 
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derivative of ETEC which had lost its enterotoxin plasmid during storage 
(Gross et al., 1976). However, the absence of toxins in diarrhoea which had 
an EPEC presence refuted this allegation (Gross et al., 1976). Definitive 
confirmation of a distinct EPEC pathotype was finally achieved by volunteer 
studies performed by Levine and colleagues, who demonstrated that EPEC 
strains of the serotype O127:H6 and O142:H6, which had been stored for 7 
years, were able to induce diarrhoea, but did not produce heat-stable or heat-
liable enterotoxins, which were characteristic for ETEC (Levine et al., 1978).  
In 1995, the EPEC pathotype underwent further redefinition and now 
encompasses two groups, typical and atypical EPEC (aEPEC), which are 
characterised by the presence or absence of the bundle forming pilus (BFP) 
encoded on the EPEC adherence factor (EAF) plasmid, respectively (Nataro 
& Kaper, 1998; Trabulsi et al., 2002). The EAF plasmid has an important role 
in the induction of diarrhoea by typical EPEC, as the loss of the EAF plasmid 
reduced the incidence of diarrhoea relative to the parent strain in adult 
volunteer studies (Levine et al., 1985). While aEPEC lack the EAF plasmid, 
these strains may have acquired additional virulence factors which 
compensate for the functionality of the EAF plasmid. 
While typical EPEC are a relatively homogenous group, with similar virulence 
factors between strains, aEPEC demonstrate greater heterogeneity and are 
thought to be more closely related to EHEC, with 81% of aEPEC strains not 
belonging to classical EPEC O-serotypes and 26.6% of aEPEC strains being 
“O-non-typeable” (Hernandes et al., 2009). Interestingly, the aEPEC serotype 
O55:H7 appears to share a common ancestor with EHEC O157:H7, with 
divergence of these pathotypes approximately 400 years ago (Whittam et al., 
1993; Zhou et al., 2010).  
As my focus in this PhD project was on the typical EPEC strain O127:H6 
E2348/69, the term EPEC will refer exclusively to typical EPEC and atypical 
EPEC will be referred to as aEPEC throughout this thesis. 
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1.1.1.2. Incidence, reservoirs, and transmission 
When EPEC were initially identified, infection was widespread in developed 
countries (Nataro & Kaper, 1998). While infection rates have decreased in the 
developed world, EPEC infection has become prevalent in the developing 
world (Nataro & Kaper, 1998). This shift in burden has been associated with 
improvements in hygiene and medical treatment however, it is also important 
to note that EPEC-induced diarrhoea in the developed world may be 
underreported and thus, the incidence of EPEC infection may be 
underestimated (Nataro & Kaper, 1998).  
The prevalence of EPEC amongst isolated diarrhoeagenic E. coli can vary 
between locations, with EPEC comprising 3.2% of diarrhoeagenic E. coli in 
Thailand (Ratchtrachenchai et al., 2004) compared to 15.5% in India (Dutta et 
al., 2013). While typical EPEC were originally thought to be more prominent in 
the developing world, in recent years the detection of aEPEC has increased 
relative to typical EPEC in children presenting with diarrhoea, as studies in 
India (Dutta et al., 2013; Nair et al., 2010), Iran (Nakhjavani et al., 2013), 
Kuwait (Albert et al., 2009), Thailand (Ratchtrachenchai et al., 2004), and 
Vietnam (Nguyen et al., 2005; Thompson et al., 2015) have predominantly 
isolated aEPEC from stools, with a previous study estimating that 78% of 
isolated EPEC were attributable to the aEPEC group (Ochoa et al., 2008). 
However, the role of aEPEC in the induction of diarrhoea is currently 
controversial, as the detection of aEPEC was greater in control patients than 
those presenting with diarrhoea (50% controls versus 18% with diarrhoea; 
Thompson et al. (2015)). In contrast, other studies have found a significant 
association between the presence of aEPEC and diarrhoeal symptoms (2.3% 
controls versus 12.8% with diarrhoea; Robins-Browne et al. (2004)). As the 
contribution of aEPEC to diarrhoea remains uncertain, further study is required 
to determine whether aEPEC, or other factors, are the causative agent. 
A key issue when interpreting epidemiological data is the difference in protocol 
and inclusion criteria amongst different studies. However, the recent Global 
Enteric Multicentre Study (GEMS) has provided an up-to-date evaluation on 
the causes of MSD in children up to 5 years old in seven case-controlled 
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populations in sub-Saharan Africa (Kenya, Mali, Mozambique, and The 
Gambia) and South Asia (Bangladesh, India, and Pakistan), with standard 
operating procedures across all sites (Kotloff et al., 2013). This landmark study 
analysed the role of pathogens associated with MSD in 9439 children and 
found that while EPEC were not a major cause of diarrhoea (with a significant 
association to MSD only found in Kenya), this pathogen was significantly 
associated with death (2.6-fold increased risk) when present in infants with 
MSD (Kotloff et al., 2013). In contrast, aEPEC were not significantly associated 
with either the development of MSD or the likelihood of death when present. 
Risk of death from typical EPEC infection may be linked to specific allele 
variants, in particular nleG; however, while the function of this gene is known 
(E3 ubiquitin ligase), the specific cellular target has not yet been defined 
(Donnenberg et al., 2015). Thus, while the incidence of typical EPEC has 
reduced in recent years, this pathotype still represents a serious threat to infant 
health. 
While EPEC infection has been well documented, no specific reservoir in the 
environment has yet been identified. As humans are the only known natural 
hosts for EPEC, current thought suggests that both symptomatic and 
asymptomatic humans are the primary reservoirs (Croxen et al., 2013; Levine 
& Edelman, 1984). The spread of EPEC from one host to the next occurs 
through faecal-oral transmission, a route shared amongst all diarrhoeagenic 
E. coli, with bacterial transfer facilitated through contact with both infected 
people and soiled surfaces. Additionally, contaminated water may also be a 
pathogen reservoir, as EPEC infection is particularly prevalent in bottle-fed 
infants (Levine & Edelman, 1984). While infection is predominant in children 
under the age of two, adult infection has been observed in volunteer studies, 
where a dose of 108 to 1010 EPEC were sufficient to induce diarrhoea, if the 
gastric acid was neutralised prior to inoculation (Levine et al., 1978). However, 
due to the high infectious dose, and the need for gastric acid neutralisation, 
the study by Levine and colleagues suggested that natural adult infection was 
unlikely (Levine et al., 1978). The dose required for the infection of infants is 
currently unknown, although it is thought to be much lower than the observed 
dose for adults (Nataro & Kaper, 1998).  
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1.1.2. Pathogenesis 
EPEC demonstrates tropism to the duodenum, with EPEC adhesion to the 
intestinal epithelium being defined as a three-step process (Croxen et al., 
2013; Donnenberg & Kaper, 1992). Firstly, EPEC adhesins, such as BFP, bind 
to the epithelial surface and form an initial attachment to the mucosa. 
Secondly, the type 3 secretion system (T3SS) transfers translocated intimin 
receptor (Tir) into the host cell, which self-inserts into the host cell membrane. 
Finally, Tir attaches to EPEC-bound intimin, forming an intimate attachment 
between EPEC and the host cell. Concurrent with the transfer of Tir, further 
effector proteins are translocated into the host cell through the T3SS, which 
subsequently modify host cell processes and mediate the formation of the 
attaching and effacing (A/E) lesion. The attachment of EPEC to the intestinal 
epithelium is a key step in the development of diarrhoea. This process has 
been thoroughly investigated and we now have a good understanding of the 
individual stages required for attachment to the host. 
 
1.1.2.1. Initial attachment 
The initial attachment of EPEC to the epithelium is mediated through EPEC-
bound adhesins such as BFP, a type IV pilus encoded on the EAF plasmid, 
which adheres to phosphatidylethanolamine (PE), a phospholipid present in 
the host cell membrane (Figure 1.2A) (Foster et al., 1999; Giron et al., 1991; 
Khursigara et al., 2001). The role of the BFP in initial binding has been 
demonstrated on cancer cell lines, as an isogenic Δbfp strain showed 
significantly reduced adhesion compared to the wildtype, when incubated on 
Caco-2 cells (Cleary et al., 2004). Furthermore, strains which were unable to 
intimately adhere but produced BFP demonstrated comparable binding to the 
wildtype strain when incubated on Caco-2 cells (Cleary et al., 2004). 
Additionally, the blockage of BFP with antiserum reduced EPEC binding to 
HeLa cells (Giron et al., 1991). These cancer cell line-based studies imply an 
important role for BFP in epithelial binding. However, investigations with more 
complex model systems, such as in vitro organ culture (IVOC) of human 
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duodenal biopsies, are less conclusive, as an EPEC strain cured of the EAF 
plasmid was unable to adhere to the intestinal epithelium, whereas an isogenic 
Δbfp strain demonstrated comparable binding to the wildtype when incubated 
on duodenal biopsies (Hicks et al., 1998; Knutton et al., 1987). These findings 
suggested that while the EAF plasmid is required for epithelial colonisation, 
adhesion was not mediated by BFP. In human volunteer studies, the absence 
of either the EAF plasmid or the bfp gene reduced the incidence of diarrhoea, 
indicating that while BFP is not essential for infection, this adhesin is 
associated with the onset of diarrhoea in vivo (Bieber et al., 1998; Levine et 
al., 1985).  
 
Figure 1.2: EPEC adhesins which facilitate initial contact with the host 
epithelium 
Electron micrographs of EPEC BFP (A), ECP (B), EspA (C), and flagella (D). 
Arrows indicate the appendage of interest. Scale bars: 1 µm (A), 0.1 µm (B), 
0.25 µm (C), and 0.7 µm (D). Images adapted from Cleary et al. (2004) (A), 
Saldana et al. (2009) (B), Knutton et al. (1998) (C), and Girón et al. (2002) (D). 
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In addition to BFP, the E. coli common pilus (ECP) has also been implicated 
in EPEC adhesion to host cells (Figure 1.2B). The ECP, which is shared 
amongst both pathogenic and commensal E. coli strains, can mediate 
epithelial binding, as the expression of ecp in the non-adherent E. coli strain 
HB101 demonstrated comparable adhesion to a HB101 strain expressing bfp, 
when incubated on HeLa and HT-29 cells (Rendón et al., 2007; Saldana et al., 
2009). Furthermore, while the isogenic ecp mutant showed comparable 
adhesion to wildtype EPEC, the loss of both ecp and espA significantly 
reduced EPEC binding relative to the single gene mutant strains, suggesting 
an accessory role in mediating EPEC attachment to the epithelium (Saldana 
et al., 2009). In addition to BFP and ECP, the presence of long polar fimbriae 
(LPF) on EPEC has been identified as a potential adhesin however, the role 
of these fimbriae during EPEC infection is poorly understood, with the current 
knowledge suggesting that LPF are not involved in EPEC binding to the 
intestinal epithelium (Tatsuno et al., 2006). A recent study found that the 
production of LPF may be suppressed in EPEC, as inactivation of Histone-like 
nucleoid structuring (H-NS), which represses LPF expression, enhanced 
EPEC binding to Caco-2 cells, but did not significantly increase colonisation of 
murine small intestinal epithelium (Hu et al., 2015). However, H-NS is a global 
regulator of the EPEC genome, and as such this protein may modify the 
expression of other adhesins which could improve EPEC binding to epithelial 
cells (Atlung & Ingmer, 1997; Hu et al., 2015).  
The translocon of the T3SS, comprised of E. coli secreted protein A (EspA) 
monomers, has also been implicated in the initial attachment of EPEC to the 
intestinal epithelium (Figure 1.2C) (Cleary et al., 2004; Knutton et al., 1998). 
However, the interaction of EspA with the host cell is relatively weak, as 
vigorous washing displaced EPEC isogenic mutant strains which lacked BFP 
and intimin however, the use of a gentler washing technique increased 
bacterial adhesion (Cleary et al., 2004). These findings suggest that while the 
EspA translocon assists in establishing initial contact with the epithelium, this 
role would appear to be supportive rather than a dominant effect.  
While flagella have primarily been investigated for their role in motility, this 
appendage can also adhere to the host epithelium, as the loss of the flagellum 
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reduced EPEC binding to HeLa and T84 cells (Figure 1.2D) (Girón et al., 2002; 
Sampaio et al., 2009). However, EPEC strains which were flagellated but did 
not produce BFP and EspA were non-adherent to Caco-2 cells, indicating that 
the flagellum is unable to compensate for the loss of other adhesins (Cleary et 
al., 2004). A potential target for flagella are mucins, glycoproteins which are 
produced by the intestinal epithelium, as EPEC flagella adhere to bovine 
intestinal mucus (Erdem et al., 2007). Interestingly, flagella from the probiotic 
E. coli Nissle 1917 interact with the mucus component gluconate, and this 
interaction mediated persistence in the host mucus (Troge et al., 2012).  
The cell surface protein lymphocyte inhibitory factor (LifA) is the largest known 
effector protein to be produced by A/E E. coli, with a predicted molecular mass 
of 366 kDa, and is thought to have a role in bacterial adhesion to the host 
(Deng et al., 2012; Klapproth et al., 2000). A similar gene has been identified 
in the A/E pathogens C. rodentium (lifA) and EHEC (efa1) where it is essential 
for the onset of disease in both murine and bovine models, respectively 
(Klapproth et al., 2005; Stevens et al., 2002). Interestingly, an EPEC lifA 
mutant strain demonstrated both localised adherence as well as the formation 
of A/E lesions when incubated with HeLa cells, implying that this protein is not 
essential for EPEC binding (Klapproth et al., 2000). However, LifA may play 
an accessory role in EPEC adherence to epithelial cells, as the loss of both 
lifA and bfp significantly reduced adhesion relative to an EPEC strain deficient 
in bfp (Badea et al., 2003).  
While numerous EPEC appendages have been associated with facilitating the 
initial contact between EPEC and the host epithelium, the principle factor 
which is responsible for initial binding appears to be the BFP. However, the 
presence of additional adhesins supports the formation of these initial 
interactions and thus enhances EPEC binding to IECs. Further research is 
required to determine how different adhesins interact with the host, which 
could aid in the development of new vaccines against EPEC infection.  
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1.1.2.2. Formation of the A/E lesion 
1.1.2.2.1. Intimate attachment 
After establishing initial binding to the host cell, EPEC firmly attaches to the 
intestinal epithelium by forming an A/E lesion, characterised by intimate 
attachment, microvillous effacement, and actin pedestal formation. The 
development of the A/E lesion is mediated through the T3SS, which is 
encoded by the locus of enterocyte effacement (LEE) pathogenicity island 
(PAI), as the transfer of the LEE into non-pathogenic E. coli K12 was sufficient 
to enable A/E lesion formation on Caco-2 cells (McDaniel & Kaper, 1997; 
Pallen et al., 2005). Interestingly, the LEE PAI appears to have been acquired 
via horizontal gene transfer, as this region has a GC content of 39%, which is 
substantially lower than the 51% GC content of the total E. coli genome 
(McDaniel et al., 1995). 
The T3SS is an approximately 3.5 MDa complex which is produced by a 
number of Gram-negative pathogens, including Salmonella, Yersinia, and 
EPEC (Puhar & Sansonetti, 2014). This structure spans the inner and outer 
bacterial membranes and facilitates the transfer of effector proteins from the 
bacterium into the host cell (Puhar & Sansonetti, 2014). The T3SS is 
composed of approximately 25 proteins, which include a cytoplasmic ATPase 
(EscN), a periplasmic needle-like structure (EscQ, EscJ, EscD, EscC, and 
EscF), a hollow filament which extrudes away from the bacterial cell 
(composed of EspA monomers), and a pore-forming domain at the tip of the 
filament (EspB and EspD) (Figure 1.3) (Pallen et al., 2005; Puhar & 
Sansonetti, 2014). After pore-formation in the cell membrane, bacterial 
effector proteins are translocated from the bacterium to the host, at a rate of 
up to 60 molecules per second (Puhar & Sansonetti, 2014).  
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Figure 1.3: The structure of the EPEC T3SS 
Taken from Pallen et al. (2005). IM, inner membrane; PG, peptidoglycan layer; 
OM, outer membrane; EM, eukaryotic membrane. 
 
One of the first effector proteins transferred into the cell is Tir, which inserts 
into the host cell membrane and binds to intimin, encoded by eaeA, located 
on the bacterial cell surface (Deibel et al., 1998; Donnenberg & Kaper, 1991; 
Kenny et al., 1997; Rosenshine et al., 1992; Rosenshine et al., 1996). The 
interaction between intimin and Tir is essential for the intimate attachment of 
EPEC to the host cell, bringing EPEC to within 10 nm of the epithelial surface 
(Frankel et al., 2001; Kenny et al., 1997; Knutton et al., 1987). 
In addition to the transfer of Tir into the host cell, the EPEC T3SS delivers 
further effector proteins into the cell which manipulate a multitude of host 
processes (Dean & Kenny, 2009). These virulence factors are divided into 
LEE-encoded (7 confirmed, including Tir) and non-LEE-encoded (Nle) (at least 
20 identified) effector proteins (Deng et al., 2012). A core repertoire of 21 
effector proteins, which include the 7 LEE proteins, are shared amongst all 
A/E pathogens and contribute to the formation of the A/E lesion, as well as 
having other roles in the subversion of host cell processes (effector proteins 
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with known functions in EPEC are shown in Table 1.1) (Wong et al., 2011). 
Variation in the number of Nle effector proteins amongst different isolates is 
common, which may be a reflection of different infection strategies (Wong et 
al., 2011).  
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Table 1.1: EPEC effector proteins with known functions 
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1.1.2.2.2. Effacement of microvilli 
The effacement of microvilli is a defining characteristic of the A/E lesion (an 
absence of microvilli underneath EPEC is shown in Figure 1.4A). Microvillous 
effacement is thought to contribute to the production of diarrhoea by reducing 
the absorptive surface available for the uptake of water and nutrients by the 
host (Croxen et al., 2013). Microvillous effacement during EPEC infection of 
the small intestinal epithelium is dependent on a functional T3SS, which 
suggests that this process is mediated by secreted effector proteins (Shaw et 
al., 2005). The effector protein Tir has been implicated in this process on Caco-
2 cells however, Tir is not essential for the effacement of microvilli on duodenal 
biopsy tissue, demonstrating conflicting data dependent on the model system 
used (Dean et al., 2006; Dean et al., 2013; Shaw et al., 2005). It is important 
to note that tir-deficient EPEC demonstrate reduced adhesion to the duodenal 
epithelium, which may inhibit Tir-associated microvillous effacement (Schuller 
et al., 2007; Shaw et al., 2005).  
The effacement of microvilli has been attributed to collaborative action of the 
effectors EspF, Map, and Tir on Caco-2 cells, implying that the effectors 
involved may demonstrate functional redundancy (Dean et al., 2006). Whether 
these proteins work in concert to efface microvilli at the duodenal epithelium 
remains to be determined. 
 
1.1.2.2.3. Formation of the actin pedestal 
The actin pedestal is a hallmark characteristic of A/E E. coli infection of 
epithelial cells, which has been demonstrated on both in vitro and ex vivo 
intestinal epithelial models (examples of ex vivo pedestals shown in Figure 
1.4) (Knutton et al., 1989). These pedestals were first identified by Knutton 
and colleagues, who noted that EPEC which were intimately attached to the 
epithelium were surrounded by “cuplike projections” and later identified that 
these projections contained high concentrations of filamentous actin (Knutton 
et al., 1989; Knutton et al., 1987).  
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Figure 1.4: Actin pedestal formation on EPEC-infected duodenal tissue 
Transmission (A) and scanning (B) electron micrographs of EPEC mounted 
on actin pedestals (indicated by arrows). MV = microvilli. Images were taken 
from Knutton et al. (1987) (A) and this study (B). 
 
The formation of the actin pedestal involves substantial cytoskeletal 
reorganisation, as filamentous actin is recruited from the host cell cytoskeleton 
and transferred to the apical surface, underneath the EPEC bacterium 
(Knutton et al., 1989). This process, which was initially documented using 
cancer cell lines, is instigated through the binding of intimin to Tir which causes 
the cytoplasmic C-terminal domain of Tir to cluster together (Campellone et 
al., 2004a). The phosphorylation of the tyrosine 474 (Y474) residue on Tir by 
host cell kinases forms a binding site for the host cell adaptor protein Nck, 
which subsequently recruits the host protein neural Wiskott-Aldrich syndrome 
protein (N-WASP) to the Tir complex (Bommarius et al., 2007; Gruenheid et 
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al., 2001; Phillips et al., 2004; Swimm et al., 2004). N-WASP activates the 
actin-related protein 2/3 (ARP 2/3) complex which initiates the nucleation of 
actin filaments underneath EPEC (Gruenheid et al., 2001; Kalman et al., 
1999).  
Interestingly, in the absence of Y474, EPEC infection still results in weak actin 
recruitment. This is mediated by phosphorylation of the tyrosine 454 (Y454) 
residue on Tir and is independent of Nck (Campellone & Leong, 2005). While 
these processes have been documented in vitro, studies using tissue explants 
have demonstrated that Tir was essential for epithelial colonisation, but 
phosphorylation of the Y454 and Y474 domains was not required for N-WASP 
recruitment and formation of actin pedestals, suggesting Tir-independent actin 
recruitment ex vivo (Schuller et al., 2007). Furthermore, an atypical EPEC 
O125:H6 isolate lacking the Y474 domain on Tir demonstrated intimate 
adherence and microvilli effacement, despite a lack of actin pedestal formation 
(Bai et al., 2008). This suggests an uncoupling of intimate attachment/ 
microvillous effacement from actin pedestal formation (Frankel & Phillips, 
2008).  
While Tir is the only EPEC effector protein required to form the actin pedestal 
in vitro, other effectors modulate this process. The LEE-encoded EspH protein 
influences actin pedestal length by promoting the recruitment of N-WASP to 
the site of EPEC infection (Tu et al., 2003; Wong et al., 2012). In contrast to 
EspH, effector proteins Mitochondrial associated protein (Map) and EspJ 
inhibit the formation of the actin pedestal. EspJ reduces actin polymerisation 
by inhibiting host kinases (Young et al., 2014). This effector protein could 
prevent the formation of actin pedestals by secondary bacteria, promoting the 
translocation of non-adhered EPEC away from the site of infection (Marchès 
et al., 2008; Young et al., 2014). The effector Map temporarily antagonises the 
formation of the actin pedestal on HeLa cells however, this process is 
subsequently inhibited by the phosphorylation of Tir (Kenny et al., 2002). 
Whether Map interacts with the development of the actin pedestal when using 
a more physiologically relevant model system remains to be investigated. 
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1.1.2.3. Additional mechanisms contributing to diarrhoea 
1.1.2.3.1. Disruption of tight junctions 
The intestinal epithelium is comprised of a single layer of enterocytes, which 
prevent access of intestinal contents into underlying tissue (Turner, 2009). 
These enterocytes are linked via tight junction (TJ) proteins, such as occludin 
and claudin, which regulate the access of water, ions, and nutrients into the 
host through paracellular channels, as well as inhibiting bacterial access to the 
underlying tissues (Turner, 2009). Upon infection with EPEC, permeability of 
the intestinal barrier increases, allowing the movement of ions and water into 
the lumen, instigating the production of diarrhoea (Viswanathan et al., 2009). 
One of the key effector proteins involved in the disruption of the TJ barrier is 
EspF, as the loss of this effector significantly reduced the change in 
transepithelial electrical resistance (TER) (a measure of the epithelial barrier 
integrity) of EPEC-infected T84 cells (McNamara et al., 2001; Muza‐Moons et 
al., 2004; Thanabalasuriar et al., 2010). TJ integrity was reduced through the 
inhibition of TJ protein (zonula occludens-1 (ZO-1), occludin, and claudin-1) 
recycling from the cytosol to the TJ, weakening the epithelial barrier 
(McNamara et al., 2001; Muza‐Moons et al., 2004; Thanabalasuriar et al., 
2010). In addition to in vitro studies, the infection of mice with wildtype EPEC 
induced occludin relocalisation and reduced TER in the terminal ileum, 
whereas infection with EPEC deficient in espF demonstrated no effect on 
either of these parameters, despite comparable levels of intestinal colonisation 
(Shifflett et al., 2005). Similarly, claudin relocalisation has been observed in 
mice infected with wildtype C. rodentium, whereas an espF-deficient mutant 
did not induce TJ protein rearrangement (Guttman et al., 2006). Furthermore, 
the water content of faeces in the mouse colon was reduced in mice infected 
with the espF mutant relative to those infected with the wildtype, further 
strengthening the link between EspF-induced changes in epithelial barrier 
function and water secretion (Guttman et al., 2006).  
Other effector proteins have been associated with an increased epithelial 
permeability such as Map, which induced a comparable decrease in TER as 
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EspF when incubated on polarised Caco-2 cells (Dean & Kenny, 2004). 
However, these effects are disputed in vivo, as TJ localisation was near 
identical between mice infected with map-deficient C. rodentium mutant and 
those infected with wildtype pathogen (Guttman et al., 2006). TJ protein 
recycling between the cytosol and the lateral surface is an important procedure 
in the maintenance of epithelial barrier function and thus, this process 
represents a key target to induce epithelial permeability (Glotfelty et al., 
2014a). The effector protein NleA inhibits cell protein trafficking in the host cell 
and as a consequence, disrupts the exchange of TJ proteins at the epithelium 
with those in the cytosol of the IEC (Thanabalasuriar et al., 2010). A similar 
mechanism has been implicated for LEE-encoded EspG1 and its non-LEE-
encoded homologue EspG2, which fragment microtubules in the host cell via 
the degradation of α-tubulin (Tomson et al., 2005). The role of EspG1/2 in TJ 
disruption appears to be of less importance than EspF, as the deletion of 
EspG1/2 delayed, but did not prevent, the decrease in TER induced by EPEC 
infection of polarised IECs (Glotfelty et al., 2014b; Matsuzawa et al., 2005; 
Tomson et al., 2005). These findings suggest that Map, NleA, and EspG1/2 
may have an accessory role in altering the permeability of the epithelial barrier.  
 
1.1.2.3.2. Ion transporter and aquaporin dysfunction 
While TJ proteins control molecular access through the paracellular pathway, 
transporters regulate the movement of ions and nutrients through the 
transcellular pathway. Ion transporters such as Downregulated in adenoma 
(DRA), Na+ /H+ -exchange protein 3 (NHE3), and the sodium-glucose linked 
transporter-1 (SGLT-1) move ions from the lumen into the cell to maintain the 
uptake of water into the host (Viswanathan et al., 2009). 
DRA, an anion exchanger which removes Cl- from the intestinal lumen by 
exchanging bicarbonate, has a decreased expression during EPEC infection, 
which has been associated with microtubule degrading effector proteins 
EspG1/2 (Gill et al., 2007). These effectors decrease DRA levels via the 
simultaneous increase in DRA endocytosis from the epithelial surface 
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alongside the inhibition of DRA exocytosis, through the manipulation of the 
microtubule network (Gill et al., 2007; Gujral et al., 2015). Other T3S effector 
proteins inhibit ion transporters such as EspF, which reduced NHE3 levels in 
intestinal Caco-2 and PS120 fibroblast cells (Hecht et al., 2004; Hodges et al., 
2008). Similarly, EspF, Map, and Tir work in unison to partially inactivate the 
SGLT-1 transporter of polarised Caco-2 cells (Dean et al., 2006). As mice 
infected with a C. rodentium isogenic espF mutant demonstrated decreased 
luminal water content, this supports an in vivo role for EspF in ion transporter 
dysfunction, although it is important to note that this effect may be associated 
with TJ disruption (Guttman et al., 2006).  
In addition to the disruption of ion transporters, C. rodentium effectors EspF 
and EspG have a partial role in removing aquaporins, transporters which 
rapidly move water across the apical membrane (Guttman et al., 2007). 
However, deletion of both espF and espG was not sufficient in preventing 
aquaporin redistribution, implying that other effector proteins may be involved, 
as only the infection of mice with an T3SS-deficient mutant demonstrated 
comparable aquaporin distribution to the non-treated controls (Guttman et al., 
2007). The mechanism remains to be defined however, the previously 
discussed roles of EspF and EspG on actin and microtubule networks, 
respectively, may provide a clue to the mechanisms responsible.  
 
1.1.2.4. Clinical significance: symptoms, diagnosis, and 
treatment 
EPEC infection is characterised by the rapid onset of acute watery diarrhoea. 
In addition, abdominal cramps, nausea, vomiting, and fever have been 
associated with EPEC infection (Donnenberg et al., 1993b; Levine & Edelman, 
1984; Nataro & Kaper, 1998). 
As the classification of EPEC has become more complex, detection methods 
have adapted to distinguish between individual strains. While older diagnostic 
methods focused on phenotypic features of EPEC, such as O and H serotypes 
(which would exclude approximately a quarter of all aEPEC strains), more 
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modern techniques have focussed on histopathological characteristics, such 
as actin pedestal formation, as well as distinct genetic sequences (Croxen et 
al., 2013). In laboratories with cell culture facilities, actin pedestals can be 
identified on EPEC-infected HeLa cells using the fluorescent actin stain (FAS) 
test, which utilises fluorescein isothiocyanate (FITC) conjugated to the 
phalloidin toxin to target filamentous actin (Knutton et al., 1989). While the FAS 
test distinguishes between E. coli pathotypes, as only EPEC and EHEC form 
actin pedestals, genetic analysis is required for further identification, utilising 
either DNA probes or PCR screens to target eaeA, bfp, and stx, which encodes 
Shiga toxin (Croxen et al., 2013). While molecular analysis of genetic 
sequences is the current standard for the classification of EPEC strains, the 
reliance on less accurate diagnostic methods in resource-poor environments, 
such as serotyping, may underestimate the prevalence of aEPEC in patients 
with diarrhoea. 
As infections are generally self-limiting, current therapies are similar to most 
diarrhoeal treatments, with a focus on rehydration of the patient with oral 
rehydration therapy (Croxen et al., 2013). However, oral rehydration therapy 
can fail in patients with severe EPEC diarrhoea (possibly due to dysfunction 
of the SGLT-1 transporter) and thus antibiotic treatment is occasionally 
required (Croxen et al., 2013; Dean et al., 2006). As with other pathogens, 
antibiotic resistance is increasing with recent clinical isolates demonstrating 
resistance to multiple antibiotics, particularly penicillins, quinolones, and 
cephalosporins (Canizalez-Roman et al., 2013; Garcia et al., 2011; Malvi et 
al., 2015; Nakhjavani et al., 2013; Sang et al., 2012; Scaletsky et al., 2010). 
The development of a vaccine against EPEC infection remains an area of 
particular interest, as none are currently available (Croxen et al., 2013). 
Interestingly, IgA antibodies against the EPEC cell-associated proteins EspA, 
intimin, EspB, and BFP have been identified in the breast milk of Mexican 
mothers, which may represent potential targets for vaccine development 
(Parissi-Crivelli et al., 2000).  
An alternative solution could be the use of probiotics; a meta-analysis of 63 
studies demonstrated that probiotics can reduce acute infectious diarrhoea 
(Allen et al., 2010). However, these findings are limited by variable treatment 
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regimens and the range of probiotic species investigated thus, further study is 
required on specific strains to determine the mechanisms behind these anti-
diarrhoeal effects (Allen et al., 2010). 
 
1.2. Probiotic Lactobacillus 
1.2.1. The history of probiotics 
The concept of probiotic bacteria was originally established by the Russian 
scientist Élie Metchnikoff at the start of the last century, who believed that the 
long life of Bulgarian peasants was associated with the consumption of 
fermented milk products, which contained lactic acid bacteria (Brown & 
Valiere, 2004; Holzapfel & Schillinger, 2002; Metchnikoff, 1907). Metchnikoff 
noted, “The dependence of the intestinal microbes on the food makes it 
possible to adopt measures to modify the flora in our bodies and to replace 
the harmful microbes by useful microbes”, suggesting that certain bacteria 
could deliver health benefits to the host (FAO/WHO, 2001; Metchnikoff, 1907). 
While these findings received some initial attention, the probiotic concept 
remained unproven and interest diminished during the following decades until 
the 1970’s (FAO/WHO, 2001). The term “probiotic” (meaning: for life) was 
conceived approximately 50 years after Metchnikoff’s observations, originally 
in reference to products which aid the gut microbiota, a contrast to the 
detrimental effects of antibiotics on microbes (Hamilton-Miller et al., 2003; 
Holzapfel & Schillinger, 2002; Kollath, 1953; Vergin, 1954). The word 
“probiotic” was then adapted by Lilly and Stillwell (1965) to refer to microbial 
products which stimulated the growth of other microbes (Holzapfel & 
Schillinger, 2002).  
Parker (1974) further revised the term “probiotic” to a definition similar to the 
modern usage, interpreting probiotics as ‘organisms and substances which 
contribute to intestinal microbial balance’ (Hamilton-Miller et al., 2003). 
Probiotics were further redefined by Fuller (1989) as, “A live microbial feed 
supplement which beneficially affects the host animal by improving its 
intestinal balance”, which referred specifically to live microbes, now an 
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essential component for the consideration of a product as a probiotic 
(FAO/WHO, 2001).  
The most recent and widely used definition for probiotics was conceived by 
Guarner and Schaafsma (1998) and selected by the Food and Agriculture 
Organisation (FAO) and the World Health Organisation (WHO) expert 
Consultation on Health and Nutritional properties of powder milk with live lactic 
acid bacteria in 2001 as an appropriate definition (FAO/WHO, 2001). This 
definition was recently grammatically updated (Hill et al., 2014) and its most 
current form is as follows: 
 
“Live microorganisms that, when administered in adequate amounts, confer 
a health benefit on the host”. 
  
This definition encompasses the three core components required for a product 
to be characterised as a probiotic, namely that bacteria in the product must be 
viable, that any health effect is associated with the minimum required dose, 
and that the minimum dose is present whenever the product is administered 
i.e. at the end of the products shelf life (Hill et al., 2014).  
Probiotic strains are generally derived from either the Lactobacillus or 
Bifidobacterium genera, although others such as E. coli Nissle 1917 and 
Streptococcus salivarius ssp. thermophilus also demonstrate probiotic 
characteristics (Holzapfel et al., 1998). As Lactobacillus species are naturally 
present in the GIT and contribute to the maintenance of the intestinal 
microbiota, these bacteria are an obvious choice in the investigation for 
probiotics with novel characteristics (Holzapfel & Schillinger, 2002). However, 
before discussing probiotic effects which have been associated with specific 
Lactobacillus strains, it is important to first understand the role and function of 
the commensal gut microbiota. 
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1.2.2. The microbiota of the gastrointestinal tract 
The microbiota has previously been referred to as a “virtual organ” due to its 
substantial metabolic activity, which plays an essential role in the normal 
functioning of the host (O'Hara & Shanahan, 2006). In physical terms, 
microbial cells far outnumber the cells of the host, with an approximate 10-fold 
difference between the two (O'Hara & Shanahan, 2006; Shanahan, 2002).  
However, at the genetic level this difference is even larger, with the combined 
microbial genome being over 100-fold greater than the human genome 
(O'Hara & Shanahan, 2006; Shanahan, 2002). The majority of these microbes 
are located in the GIT and are comprised of 92.9% bacteria, 5.8% viruses, and 
the remaining 1.3% consisting of archaea and eukaryotes (Arumugam et al., 
2011; Turnbaugh et al., 2007). The bacterial load changes dependent on the 
location within the GIT, as the stomach and duodenum contain between 101 
and 103 colony forming units (CFU)/ mL which increases along the intestine to 
between 1011 and 1012 CFU/ mL located in the adult colon (Figure 1.5) (O'Hara 
& Shanahan, 2006; Suau et al., 1999).  
 
 
Figure 1.5: Bacterial concentration within the human GIT 
The bacterial load of the GIT increases in density from the stomach and 
duodenum to the distal colon. Image taken from O'Hara and Shanahan (2006). 
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The microbiota of the GIT is unique to an individual however, species from the 
Bacteroidetes and Firmicutes phyla are generally predominant (Ottman et al., 
2012). The composition of the microbiota is influenced by numerous factors 
throughout the life of the host organism, including the delivery method of the 
neonate, diet, use of antimicrobial products, and host genetics. The general 
consensus on the development of the microbiota is that the infant gut in utero 
is sterile and upon birth, the neonatal GIT is colonised by pioneer species 
which are primarily delivered from the mother, principally through the birthing 
process, breast feeding, and physical contact (Palmer et al., 2007). Children 
delivered via Caesarean section have greater numbers of C. difficile and E. 
coli, whereas neonates delivered via vaginal birth have a greater number of 
Bacteroides fragilis (Penders et al., 2006). Similar increases in C. difficile and 
E. coli have also been observed in infants who are exclusively formula-fed 
rather than breast-fed (Penders et al., 2006). As the infant continues onto solid 
food and grows into a toddler, the microbiota continues to develop, reaching 
peak complexity during adulthood wherein the microbial community stabilises 
until old age and diversity begins to decrease (Figure 1.6) (Ottman et al., 2012; 
Palmer et al., 2007).  
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Figure 1.6: The composition of the gut microbiota develops through age 
and external factors 
Image taken from Ottman et al. (2012). 
 
The constituent members of the intestinal microbiota are unique to each 
individual, but key metabolic pathways are almost universally present amongst 
examined microbiomes, such as carbohydrate metabolism and vitamin 
biosynthesis (Human Microbiome Project Consortium, 2012). This 
demonstrates a functional redundancy amongst commensal bacterial species, 
where numerous bacteria possess the genes required to synthesise a 
particular product, for example riboflavin, and any of these bacterial species 
can inhabit this particular niche (Human Microbiome Project Consortium, 
2012). One of the essential functions that the gut microbiota performs is the 
synthesis of vitamins, micronutrients used in the production of essential 
enzymes, as the human host lacks the biosynthetic pathways required for 
these processes (LeBlanc et al., 2013). In addition to vitamin synthesis, the 
microbiota also aids in the uptake of energy by the host, as germ-free mice 
have a 60% increase in body fat after inoculation with a “conventional” 
microbiota, even if the overall calorie intake is reduced (Bäckhed et al., 2004). 
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Alongside occupying metabolic niches, the microbiota also has an important 
role in the physical development of the intestinal tract, as the morphology of 
the intestine differs between germ-free and conventionally raised mice 
(Sommer & Bäckhed, 2013). Histological analysis of the GIT of germ-free mice 
has revealed a thinner mucus layer, thinner villi, and smaller, immature 
immune features such as Peyer’s patches (Sommer & Bäckhed, 2013). This 
demonstrates that the microbiota interacts with the intestinal mucosa to 
develop both the physiological and immunological processes of the host. 
Furthermore, while the immune response can clear potential insults, the 
microbiota also acts as a barrier to infection, known as colonisation resistance, 
which can prevent the access of GI pathogens such as Salmonella enterica 
serovar Typhimurium to the epithelium (Stecher et al., 2007). 
 
1.2.2.1. Dysbiosis of the intestinal microbiota 
In most individuals, the microbiota supports the host through the functions 
previously discussed in 1.2.2. However, dysfunction in the microbiota has 
been associated with the development of numerous pathologies. Dysbiosis, 
defined as a change in the “balance” of microbes in the microbiota, can be 
induced through numerous stimuli including antibiotic use, diet, hygiene, and 
host immune function (Figure 1.7) (Sommer & Bäckhed, 2013; Tamboli et al., 
2004). This alteration in the intestinal microbiota has been associated with 
diseases such as inflammatory bowel disease (IBD), obesity, and antibiotic-
associated diarrhoea (AAD), which I will briefly discuss here. 
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Figure 1.7: Factors associated with dysbiosis of the intestinal microbiota 
Image taken from Sommer and Bäckhed (2013). 
 
IBD is a term that primarily refers to ulcerative colitis (UC) and Crohn’s disease 
(CD), two conditions which are characterised by severe abdominal pain, 
vomiting, bloody diarrhoea, and weight loss which drastically decrease the 
quality of life of affected patients (Pizzi et al., 2006). The exact causes behind 
IBD are presently unknown, with the current consensus suggesting that both 
CD and UC have multiple triggers, including those shown in Figure 1.7 (for a 
more thorough analysis of these factors, see Bernstein and Shanahan (2008)). 
Of particular interest is the role of the microbiota, as diversity is decreased in 
patients with CD and UC relative to patients without IBD (Ott et al., 2004; 
Walker et al., 2011). The underlying reason for this decrease is unknown, 
although the use of antibiotics in early childhood has been correlated with an 
increased risk of developing IBD (Hviid et al., 2011; Kronman et al., 2012; 
Shaw et al., 2010, 2011). Additionally, IBD has been linked to decreased levels 
of Akkermansia muciniphila and increased numbers of Ruminococcus gnavus 
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and Ruminococcus torques (Belzer & de Vos, 2012; Png et al., 2010). 
Crucially, while changes in the levels of a particular microbial species has been 
associated with IBD, it is important to note that no single microbe has been 
definitively implicated in the development of these diseases. Thus, it remains 
to be determined whether the decrease in the diversity of the microbiota is a 
cause or symptom of IBD (Joossens et al., 2011; Manichanh et al., 2012; Sokol 
et al., 2006; Walker et al., 2011; Willing et al., 2009).  
Obesity is a global health crisis, as more than 1.9 billion adults were reported 
as overweight in 2014, with 600 million of those classified as obese, 
representing 39% and 13% of the world’s adult population, respectively (WHO, 
2015). Similar to IBD, obesity is a multifactorial disease based on lifestyle, 
environmental, and genetic influences (Figure 1.7). One component which is 
thought to contribute to the development of obesity is the gut microbiota, due 
to the role these bacteria play in the digestion of food and the acquisition of 
energy. The role of the microbiota in obesity was first demonstrated by 
Turnbaugh et al. (2006), who demonstrated that transfer of the microbiota from 
obese mice into germ-free mice significantly increased body fat relative to 
control mice with a “healthy” microbiota after 2 weeks. Interestingly, this 
change in body fat was not due to an increased calorific intake, but rather an 
increased energy harvest (Turnbaugh et al., 2006). Similar findings have also 
been reported in germ-free mice which were inoculated with the faecal 
microbiota of twins who were discordant for obesity, as mice with the obese 
microflora showed higher adiposity than those with the lean microbiota 
(Ridaura et al., 2013). A reported difference between the healthy and obese 
microbiota is the level of diversity, as diet-induced obese mice, as well as 
obese humans, have a distinct decrease in microbial diversity (Turnbaugh et 
al., 2008; Turnbaugh et al., 2009). This reduction in humans is associated with 
lifestyle factors, as diets have changed to more energy dense foods, the 
microbiota has adapted to utilise this increased energy resource. Obesity and 
associated metabolic disorders, such as type II diabetes, will likely be a key 
health challenge of the 21st century and as such, a thorough understanding of 
the role of the gut microbiota in obesity, and how we can modify it, may offer 
solutions to this epidemic. 
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While there are multiple factors contributing to the onset of obesity and IBD, 
the development of AAD has a more defined aetiology. AAD is an umbrella 
term for the development of diarrhoea in patients after the administration of 
antibiotics (Bartlett, 2002). However, I will focus on AAD associated with C. 
difficile infection, which occurs in 10-20% of cases of AAD (Bartlett, 2002). 
Severe infection by C. difficile is characterised by repeated episodes of 
diarrhoea, which can contain blood, as well as the formation of 
pseudomembranes on the colonic epithelium, which develop after the use of 
antibiotic therapy for an unrelated condition (Bartlett, 2002). The specific 
reason behind the onset of C. difficile-induced AAD is thought to be due to the 
unintentional removal of the microbiota by antibiotic treatment, which removes 
the natural colonisation resistance that the microbiota provides (Borriello & 
Barclay, 1986; Young & Schmidt, 2004). Disruption of the microbiota has been 
confirmed in patients with recurrent C. difficile diarrhoea, which demonstrated 
a reduction in microbial diversity compared to patients with either a single 
incidence of C. difficile-induced diarrhoea or those who were not infected 
(Chang et al., 2008). The lack of bacterial competition allows C. difficile, which 
may naturally be present in the microflora, to establish a persistent infection 
and induce diarrhoea, despite further antibiotic therapy (Bartlett, 2002). Thus, 
restoration of the gut microbiota via faecal microbial transplant has been 
explored as a potential therapeutic avenue. Systematic reviews of studies 
reporting on the effectiveness of faecal microbial transplants on C. difficile 
infection have demonstrated that this therapy has considerable potential, with 
cure rates of approximately 90% in patients with recurrent infection (Gough et 
al., 2011; Kassam et al., 2013; Li et al., 2016). Although both randomised 
controlled trials and long term safety studies are required to support the use 
of faecal microbial transplant, this treatment demonstrates the important role 
of the gut microbiota in reducing the impact of infection. 
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1.2.3. The Lactobacillus genus 
The Lactobacillus genus consists of over 200 recorded species of lactobacilli 
(http://www.ncbi.nlm.nih.gov/taxonomy), isolated from a range of locations 
including faeces, breast milk, animals, and plants (Walter, 2008). Lactobacilli 
are Gram-positive, non-spore forming facultative anaerobes of the Firmicute 
phylum which produce lactic acid and have been traditionally used in the 
development of numerous products including yoghurt, cheese, and other 
fermented foods (Claesson et al., 2007). In addition to their use in food 
fermentation, lactobacilli are also a normal resident of the human microbiota; 
with isolates identified in the oral cavity, the GIT, and the vagina of mammals, 
including humans (Walter, 2008). It is important to note that the overall 
numbers of lactobacilli in the distal GIT is low relative to other bacterial 
species, representing 0.01% of the total adult faecal microbiota (~106 CFU/ g) 
(Harmsen et al., 2002). In the proximal GIT, the number of Lactobacillus 
species increases to approximately 1% of the total microbial population 
(Walter, 2008). In the adult stomach and small intestine however, the 
proportion of lactobacilli which are transient relative to autochthonous isolates 
remains to be determined (Walter, 2008). In contrast to findings in adults, 
lactobacilli were detected in 45% of infants at 108-109 CFU/ g of faeces over 
the first 6 months from birth (Ahrné et al., 2005; Grönlund et al., 2000). This 
difference in adult and infant microbial ecology is primarily due to differences 
in diet, as lactobacilli are acquired from the mother’s breast milk and are 
amongst the pioneer colonisers of the infant GIT (Karlsson et al., 2011; Martín 
et al., 2003; Solís et al., 2010). Additionally, Lactobacillus spp. from the 
mother’s vagina have been shown to temporarily colonise approximately 1 in 
4 infants after birth (Matsumiya et al., 2002). These studies demonstrate that 
the mother is a reservoir of lactobacilli for infants and as such, the loss of 
exposure to these species, through both Caesarean section and formula-
feeding, may have an impact on the development of the newborn microbiota 
(see section 1.1.2). 
The role of Lactobacillus in the GIT is varied, due to the heterogeneous 
characteristics of this genus; however, certain strains have been identified with 
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probiotic features which can improve host intestinal function, such as aiding 
the resolution of diarrhoea. 
 
1.2.4. Use of Lactobacillus in the treatment of diarrhoea 
Numerous meta-analyses have investigated the impact of Lactobacillus spp. 
on diarrhoea, with positive outcomes reported in the prevention of AAD (21-
64% reduction) (Kale‐Pradhan et al., 2010; McFarland, 2006, 2015; Pattani et 
al., 2013; Szajewska et al., 2006) as well as a reduction in the duration of acute 
infectious diarrhoea by between 16.8 – 26.4 hours (Allen et al., 2010; Huang 
et al., 2002; Szajewska et al., 2013; Urbańska et al., 2016; Van Niel et al., 
2002). It is important to note that while meta-analyses provide a powerful 
technique to evaluate the efficacy of a particular therapeutic regimen by 
pooling data from multiple studies, probiotic characteristics are strain-specific 
and thus, effects observed at the genus and species level may not be 
applicable to every strain of a particular species. Thus, while these meta-
analyses are useful in the general assessment of probiotics on GI disorders, 
differences in the probiotic strains used as well as variation in study 
methodology (such as length of treatment, follow up period, and the selection 
of inpatients versus outpatients) should be appreciated when considering 
these findings. However, two systematic reviews of L. rhamnosus GG have 
shown that treatment with this strain reduces the incidence of AAD by 30% 
(McFarland, 2006; Szajewska et al., 2006). Additionally, both L. rhamnosus 
GG and L. reuteri DSM 17938 decrease the duration of acute infectious 
diarrhoea by 26.4 hours and 24.82 hours, respectively (Szajewska et al., 2013; 
Urbańska et al., 2016). These studies demonstrate that specific Lactobacillus 
strains can improve diarrhoeal conditions. Potential mechanisms behind these 
probiotic characteristics will be discussed. 
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1.2.4.1. Mechanisms of probiotic action 
In vitro studies investigating the probiotic effects of lactobacilli have aimed to 
identify the specific mechanisms behind probiotic action, which can be broadly 
classified as microbe-host and microbe-microbe interactions. Microbe-host 
mechanisms include modulation of the host immune response, epithelial 
barrier integrity, and mucin production (Mack et al., 2003; Resta-Lenert & 
Barrett, 2003; Vizoso Pinto et al., 2009). Microbe-microbe inhibitory actions 
include the production of antimicrobial compounds as well as competition for 
nutrients and binding sites (Lebeer et al., 2008). These protective actions can 
be widespread amongst probiotic Lactobacillus or specific at either the species 
or strain level (Figure 1.8) (Hill et al., 2014). 
 
 
Figure 1.8: Distribution of potential protective characteristics amongst 
probiotics 
Beneficial characteristics can be widespread amongst probiotics or specific to 
certain species or strains. Image taken from Hill et al. (2014). 
 
55 
 
Adhesion to the host is a frequently investigated probiotic characteristic, as 
intestinal colonisation, even if transient, is thought to be necessary to allow a 
probiotic to deliver its beneficial effects (Tuomola et al., 2001). Thus, the 
identification of specific proteins which enhance this process has been a topic 
of much interest (Vélez et al., 2007). Bacterial adhesins are generally 
classified according to their binding target (e.g. mucus-binding protein), the 
location on the bacterial cell (e.g. surface layer protein), or the mode of 
attachment to the bacterial surface (e.g. sortase-dependent proteins) (Vélez 
et al., 2007). The adhesive potential of probiotics is normally assessed in vitro 
using mucus-deficient intestinal epithelial cell lines, such as Caco-2, HT-29, 
and T84, and thus binding efficiencies may not be applicable to the in vivo 
situation (further discussed in 1.4).  
Interestingly, adhesion can also have anti-pathogenic effects through the 
competitive exclusion of pathogens from the intestinal epithelium. Pathogen 
exclusion is thought to be dependent on either competition for mutual binding 
sites/receptors or steric hindrance, where the probiotic cell physically blocks 
the access of a pathogen to the epithelial surface (Lebeer et al., 2008). These 
characteristics in vivo would be similar to colonisation resistance, where the 
probiotic bacteria and the host microbiota outcompete the infectious agent by 
preventing the pathogen from gaining a foothold in the intestinal milieu.  
In addition to inhibition of pathogens through “passive” mechanisms, 
Lactobacillus strains also produce a battery of antimicrobial compounds which 
can either kill or reduce the growth of competitor bacteria (Servin, 2004). The 
organic acids produced by Lactobacillus have potent antibacterial properties, 
as high lactic acid-producing strains inhibited S. Typhimurium, EHEC, and C. 
difficile infection in vitro (De Keersmaecker et al., 2006; Makras et al., 2006; 
Ogawa et al., 2001; Tejero-Sariñena et al., 2012). Similar effects have been 
reported in vivo, where production of lactic acid was associated with increased 
protective effects against the infection of chickens and mice with 
Campylobacter jejuni and S. Typhimurium, respectively (Annuk et al., 2003; 
Neal-McKinney et al., 2012). Likewise to lactic acid, the production of 
hydrogen peroxide by Lactobacillus has been associated with anti-pathogenic 
effects, although this is more common in vaginal isolates rather than intestinal 
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lactobacilli (Servin, 2004). However, hydrogen peroxide produced by intestinal 
Lactobacillus johnsonii strains NCC 533 and 933 can kill S. Typhimurium and 
so this method of inhibition may be more prevalent amongst other lactobacilli 
in the gut (Atassi & Servin, 2010; Pridmore et al., 2008).  
Lactobacillus species also produce bacteriocins, which are small heat-stable 
peptides targeted against related microbes inhabiting a similar niche (Eijsink 
et al., 2002). The mechanism of action of these peptides is generally through 
the formation of pores in the membrane of target bacteria, causing the 
intracellular contents to leak out from the cell (Eijsink et al., 2002; O’Connor et 
al., 2015). The best described bacteriocin is nisin, a class I bacteriocin 
(lantibiotic) produced by the lactic acid bacterium Lactococcus lactis, which 
has been used in the food manufacturing industry for the last 50 years due to 
its broad-spectrum inhibitory activity against Gram-positive bacteria, 
particularly the food contaminant Listeria monocytogenes (Delves-Broughton 
et al., 1996). While the inhibitory effects of these peptides are generally 
assessed in vitro, the protection of mice by Lactobacillus salivarius UCC118 
against L. monocytogenes was dependent on the production of the class II 
bacteriocin Abp118, demonstrating that these proteins are also effective in 
vivo (Corr et al., 2007). Interestingly, a small number of bacteriocins produced 
by lactobacilli can also kill Gram-negative bacteria, such as the L. salivarius 
1077 peptide L-1077 which inhibited both C. jejuni and Salmonella enterica 
serovar Enteritidis in vitro, as well as reducing the levels of these pathogens 
in the liver and spleen of infected chickens (Svetoch et al., 2011). It is important 
to note that these antimicrobials can inhibit both pathogenic and commensal 
bacteria, as the administration of Abp118-producing L. salivarius UCC118 
altered the microbiota in both murine and porcine models (Murphy et al., 2012; 
Riboulet-Bisson et al., 2012). While there were no reported changes in the 
health of animals which consumed the bacteriocin-producing lactobacilli, 
alterations to the microbiota may have unintended side effects and thus, the 
impact of these antimicrobials on the microbial community requires  
further investigation. 
In addition to antimicrobial characteristics, probiotic lactobacilli can also 
interact with the host. These interactions can have beneficial effects, such as 
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strengthening the epithelial barrier, which can be weakened during GI 
conditions such as IBD and infection (Lebeer et al., 2008). Beneficial effects 
of probiotics on epithelial barrier function have been demonstrated in vitro, as 
L. plantarum DSM 2648 and L. rhamnosus GG attenuated the decrease in 
TER associated with EPEC and EHEC infection of intestinal epithelial cells 
(Anderson et al., 2010; Johnson-Henry et al., 2008). The protection of 
epithelial barrier function has been associated with the prevention of TJ 
proteins ZO-1, claudin-1, and occludin dissociation from the lateral surfaces of 
the epithelial cells (Johnson-Henry et al., 2008; Miyauchi et al., 2009; Roselli 
et al., 2007). Similar findings have been reported in vivo, as L. rhamnosus 
OLL2838 and the mixed species probiotic product VSL#3 (containing 
Bifidobacterium longum, B. infantis, B. breve, L. acidophilus, L. casei, L. 
delbrueckii subsp. Bulgaricus, L. plantarium, and Streptococcus 
salivarius subsp. Thermophilus) inhibited TJ protein redistribution in mice with 
induced colitis (Madsen et al., 2001; Mennigen et al., 2009; Miyauchi et al., 
2009). Similar effects have also been reported in humans, as L. plantarum 
WCFS1 increased occludin localisation to TJs, relative to mock-treated 
controls (Karczewski et al., 2010). However, while these studies have 
demonstrated changes in epithelial barrier function induced by Lactobacillus 
species, the specific mechanisms for these effects, i.e. the molecules and 
associated receptors which initiate these changes, remain poorly defined 
(Lebeer et al., 2008). One protein which has shown promising effects on 
maintaining TJ integrity is the L. rhamnosus GG-derived protein p40, which 
alleviates DSS-induced colitis in mice via interaction with the epidermal growth 
factor (EGF) receptor (Yan et al., 2011). Whether similar proteins, which utilise 
the same mechanism, are present in other Lactobacillus strains requires 
further investigation.   
 
1.2.5. Lactobacillus reuteri 
The gut symbiont Lactobacillus reuteri is an autochthonous inhabitant of the 
mammalian gut, with the taxonomic classification shown in Figure 1.9 (Walter 
et al., 2011). L. reuteri isolates have been identified in numerous mammals, 
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including humans, mice, pigs, hamsters, cattle, rats, and dogs (Casas & 
Dobrogosz, 2000; Korhonen et al., 2007; Reuter, 2001; Salzman et al., 2002). 
In the porcine gut, L. reuteri is one of the most numerous Lactobacillus species 
isolated from the ileum, where biofilms of lactobacilli and other commensals 
bind directly to the intestinal surface (Walter, 2008). In human adults, L. reuteri 
has been detected throughout the GIT and in faeces, and has been noted as 
a predominant species in the small intestine, although this is controversial as 
other studies have suggested that only 4% of the population has an indigenous 
L. reuteri population (Dal Bello et al., 2003; Hayashi et al., 2005; Reuter, 2001; 
Valeur et al., 2004). In addition to the GIT, L. reuteri has also been isolated 
from both the vagina and breast milk, and strains sequestered from these 
environments have been widely associated with probiotic health benefits, 
including the synthesis of vitamins such as B12 and folate, as well as the 
prevention and treatment of infectious diarrhoea (Abrahamsson et al., 2009; 
Saulnier et al., 2011; Shornikova et al., 1997a; Shornikova et al., 1997b; 
Urbańska et al., 2016).  
 
 
Figure 1.9: Taxonomic classification of L. reuteri 
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1.2.5.1. Interaction of L. reuteri with the host 
Phylogenetic analysis of L. reuteri strains isolated from numerous 
backgrounds (human, mouse, rat, pig, chicken, and turkey) has determined 
that L. reuteri demonstrates host specificity (Oh et al., 2010). These findings 
have been confirmed experimentally, as L. reuteri strains sequestered from 
rodents (mouse and rat) outcompeted isolates from others backgrounds in 
germ-free mice (Oh et al., 2010). Additionally, murine L. reuteri strains lacking 
host-specific genes demonstrated reduced levels of colonisation of the murine 
foregut, further demonstrating that certain genes enhance ecological fitness in 
L. reuteri (Frese et al., 2013). These genes have numerous roles in the host, 
such as survival of gastric acid and encoding adhesins, which enhance binding 
to the mucosa, such as Mucus binding protein (MUB) and Cell and mucus 
binding protein (CmbA), produced by L. reuteri ATCC 53608 and ATCC PTA 
6475, respectively (Table 1.2). The evolution of these host-specific adhesins 
demonstrates the symbiotic relationship that mammals and birds have with L. 
reuteri, as the development of these evolutionary lineages is thought to span 
millions of years (Oh et al., 2010). The identification of these adhesins offers 
a method for the evaluation of potential probiotics for both human and animal 
consumption, as the presence of adhesins may enhance L. reuteri persistence 
in the host. 
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(Frese et al., 
2013; 
Heinemann et 
al., 2000; 
MacKenzie et 
al., 2010; Roos 
et al., 1996; 
Roos & 
Jonsson, 2002; 
Walter et al., 
2005; Walter et 
al., 2008) 
 
 
 
 
 
 
 
 
 
Table 1.2: L. reuteri proteins associated with adhesion to the mucosa 
Alternative strain names; 11063, 2MM4-1a, 3JCM112, 4MM2-3, 5FJ1. 
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1.2.5.2. Probiotic characteristics of L. reuteri 
The application of L. reuteri as a probiotic has increased in recent years, as 
numerous studies have identified beneficial effects on the host, including the 
attenuation of diarrhoea and immunomodulation (summarised in Table 1.3). In 
addition to these host effects, L. reuteri can also inhibit other microbes, as 
certain strains produce 3-hydroxypropionaldehyde, a potent antimicrobial 
commonly referred to as reuterin (Talarico et al., 1988). Reuterin is produced 
as an intermediate compound during the fermentation of glycerol into 1, 3-
propanediol, which is used to reoxidise NAD+ from NADH (pathway shown in 
Figure 1.10) (Lüthi-Peng et al., 2002; Schaefer et al., 2010). While L. reuteri 
has a high resistance to reuterin, this anti-microbial has broad inhibitory activity 
against Gram-positive and Gram-negative bacteria, as well as yeast, fungi, 
and protozoa (Axelsson et al., 1989; Casas & Dobrogosz, 2000; Chung et al., 
1989). Interestingly, L. reuteri actively secretes reuterin into its local 
environment when other bacteria are present, indicating that this mechanism 
may be used to gain a competitive advantage in the GIT milieu (Schaefer et 
al., 2010). As the production of reuterin has been demonstrated by L. reuteri 
JCM 1112 in the murine intestine in vivo, this further supports this mode of 
action (Morita et al., 2008). Due to reuterin’s broad inhibitory effects on 
microbial pathogens, this compound has numerous potential applications, 
such as a food preservative and as a pharmaceutical product (Vollenweider & 
Lacroix, 2004).  
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Table 1.3: Summarised probiotic characteristics of three L. reuteri 
strains 
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Figure 1.10: Reuterin synthesis pathway 
Reuterin is produced by L. reuteri as an intermediate compound during the 
production of 1, 3- Propanediol from glycerol. Reuterin is composed of an 
equilibrium mixture of hydrated monomeric, monomeric, and cyclic dimeric 
forms of 3-hydroxypropionaldehyde. Image taken from Casas and Dobrogosz 
(2000). 
 
In addition to reuterin, some L. reuteri strains (such as LTH2584) produce 
reutericyclin, a broad-spectrum antibiotic that alters the electrochemical 
gradient of the Gram-positive bacterial cell membrane (Gänzle et al., 2000). 
Reutericyclin has demonstrated inhibitory effects against numerous important 
pathogens, including Staphylococcus aureus, Bacillus subtilis, and C. difficile 
(Gänzle et al., 2000; Gänzle & Vogel, 2003; Hurdle et al., 2011). While this 
antibiotic shows promising effects, it still remains to be determined whether it 
is produced in vivo, as only L. reuteri isolates from sourdough have currently 
been shown to produce this compound (Gänzle & Vogel, 2003). 
While numerous L. reuteri strains synthesise the anti-microbial reuterin, other 
effects are strain-specific. Thus, we will discuss the demonstrated probiotic 
characteristics of two of the most commonly used human L. reuteri isolates, 
ATCC PTA 6475 and ATCC 55730. 
64 
 
1.2.5.2.1. L. reuteri ATCC PTA 6475 
L. reuteri ATCC PTA 6475, also known as MM4-1a, were originally isolated 
from the breast milk of a healthy Finnish woman, and is currently used in 
formulations by the probiotic company Biogaia (Stockholm, Sweden) (Liu et 
al., 2010). Investigations into the probiotic characteristics of ATCC PTA 6475 
have revealed that this strain can alleviate the effects of gastritis in vivo when 
used in combination with L. reuteri DSM 17938, as two randomised controlled 
trials in humans have identified a reduction in Helicobacter pylori symptoms, 
including diarrhoea (Emara et al., 2013; Francavilla et al., 2014). ATCC PTA 
6475 monoculture has also demonstrated anti-diarrhoeal effects, as probiotic 
supplementation reduced the production of diarrhoea by 1 day in rota-virus-
infected mice (Preidis et al., 2012). Additionally, germ-free mice pre-treated 
with ATCC PTA 6475 prior to EHEC infection shed decreased numbers of 
EHEC as well as maintained body weight, relative to non-treated littermates 
(Eaton et al., 2011). The mechanism behind the reduction of diarrhoea is 
unknown however, ATCC PTA 6475 is a reuterin producer and this strain has 
been linked to the inhibition of numerous enteric pathogens in vitro, including 
EHEC, ETEC, and S. enterica, which may partially explain these probiotic 
effects (Spinler et al., 2008). An alternative mechanism may be associated 
with the modulation of the host inflammatory state, as ATCC PTA 6475 has 
demonstrated potent anti-inflammatory effects, both in vitro and in vivo (Jones 
& Versalovic, 2009; Lin et al., 2008; Preidis et al., 2012). The anti-inflammatory 
characteristics of ATCC PTA 6475 have also been associated with an 
increased bone density in both male and oestrogen-deficient female mice 
(Britton et al., 2014; Collins et al., 2016; McCabe et al., 2013). A potential 
mechanism behind the immunomodulatory effects of ATCC PTA 6475 is the 
production of histamine from dietary L-histidine, which suppresses protein 
kinase A signalling, subsequently reducing the production of inflammatory 
cytokines (Gao et al., 2015; Thomas et al., 2012). Inhibition of the inflammatory 
response through the production of histamine by L. reuteri has been 
demonstrated both in vitro and in vivo, further supporting this mechanism (Gao 
et al., 2015; Thomas et al., 2012).  
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Interestingly, a recent study by Buffington et al. (2016) has identified that 
supplementation of ATCC PTA 6475 into mice with social disorders, induced 
via maternal high fat diet, improved sociability. While the authors linked this 
effect to the neuropeptide oxytocin, which can be induced by ATCC PTA 6475 
(Poutahidis et al., 2013), the immunomodulatory characteristics of this strain 
may also have an effect, as inflammation has also been associated with 
altered brain development (Bolton & Bilbo, 2014). The implications of these 
findings, both ethically and scientifically, remain to be determined as these 
data suggest that specific probiotics may impact the host in ways which have 
not previously been appreciated. As such, further study is required to fully 
understand the effects of ATCC PTA 6475 on the host. 
 
1.2.5.2.2. L. reuteri ATCC 55730 
L. reuteri ATCC 55730 were first isolated from the breast milk of a Peruvian 
mother who lived in the Andes, and have previously been used in probiotic 
products by Biogaia (Liu et al., 2010). As ATCC 55730 contained a plasmid 
with antibiotic resistance, this strain has now been superseded by the plasmid-
cured daughter strain DSM 17938, which has maintained the probiotic 
characteristics of ATCC 55730 (Liu et al., 2010; Rosander et al., 2008).  
Similarly to ATCC PTA 6475, the impact of ATCC 55730/ DSM 17938 on 
diarrhoea has been an area of investigation in numerous studies. These 
findings have implied that the administration of either ATCC 55730 or DSM 
17938 can reduce both the occurrence and symptoms of acute diarrhoea in 
children (Dinleyici et al., 2014; Francavilla et al., 2012; Gutierrez-Castrellon et 
al., 2014; Shornikova et al., 1997a; Urbańska et al., 2016). However, one study 
did not identify any beneficial effects of DSM 17938 against nosocomial 
diarrhoea in children, although the reason behind this contrast with the other 
studies is unknown (Wanke & Szajewska, 2012). Interestingly, DSM 17938 
specifically reduced the incidence of both EPEC- and rotavirus-associated 
diarrhoea in infants (Savino et al., 2015; Shornikova et al., 1997b). Similar 
findings have also been reported in adults, as the incidence of GI and 
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respiratory illness decreased by 60% in volunteers consuming ATCC 55730, 
relative to those in the placebo group (Tubelius et al., 2005). These probiotic 
strains were well tolerated with no side effects in either healthy or 
immunocompromised individuals and thus, represent a potential option to treat 
diarrhoea (Mangalat et al., 2012; Wolf et al., 1998).  
In contrast to ATCC PTA 6475, ATCC 55730 has often been described as an 
immunostimulatory probiotic (Liu et al., 2010). In healthy human volunteers, 
ATCC 55730 increased the number of B lymphocytes in the duodenum and 
CD4+ T-lymphocytes in the ileum (Valeur et al., 2004). Immune stimulation has 
also been observed in vitro, as ATCC 55730 secreted products stimulated the 
production of TNF-α by the monocyte cell line THP-1 (Lin et al., 2008). 
However, in children with active rectal UC, the direct administration of ATCC 
55730 by enema to the inflamed area reduced mucosal inflammation, as well 
as increasing the levels of the anti-inflammatory cytokine interleukin-10 (IL-10) 
at the site of inflammation (Oliva et al., 2012). Similar findings have also been 
reported in patients with active gingivitis, as volunteers using chewing gums 
containing L. reuteri ATCC 55730 and ATCC PTA 5289 demonstrated 
decreased levels of pro-inflammatory IL-8 and tumour necrosis factor-α (TNF-
α) (Twetman et al., 2009). Thus, these findings suggest that ATCC 55730 and 
DSM 17938 have immunomodulatory features, rather than only stimulating the 
immune response. This is supported by recent findings in a mouse model of 
necrotising enterocolitis (NEC), as DSM 17938 decreased numbers of T-
effector cells and increased T-regulatory cells in the inflamed tissue, as well 
as decreasing mortality and disease severity (Liu et al., 2014). Similar findings 
have been reported in high-risk human neonates, as prophylactic treatment 
with DSM 17938 significantly reduced the risk of NEC (Hunter et al., 2012). 
Infantile colic is defined as excessive crying with no apparent cause and is a 
common condition in infants up to 6 months (Sung et al., 2012). A recent meta-
analysis of 444 infants identified that treatment with ATCC 55730 and DSM 
17938 decreased crying 2.3-fold, relative to infants given either placebo or 
standard therapy (simethicone) (Bird et al., 2016). Importantly, there were no 
apparent side effects associated with L. reuteri supplementation, indicating 
that this therapy would be safe for future usage (Bird et al., 2016).  
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1.3. Innate mechanisms of host defence 
The intestinal epithelium, which provides the first line of defence against 
foreign antigens and bacteria, is composed of a single layer of enterocytes, 
Paneth cells, enteroendocrine cells, and goblet cells, which work in unison to 
regulate the movement of nutrients and water out of the lumen, while 
preventing microbial access across the epithelium. Homeostasis in the GIT is 
maintained by the epithelial cells through multiple mechanisms, such as the 
production of the mucus layer and the innate immune response (Johansson & 
Hansson, 2011c; McGuckin et al., 2011). The failure of these barriers is a basis 
for dysbiosis in the gut, as well as the development of IBD (Neuman & Nanau, 
2012). Whilst the mucus layer and the innate immune response inhibit 
bacterial access, these defences can be modified through microbial 
interaction, including both EPEC and Lactobacillus, and thus the role of 
bacteria on these systems remains an important area of research. 
 
1.3.1. Mucus 
1.3.1.1. Intestinal mucus production 
The lining of the GIT encompasses the largest surface area of any part of the 
human body, totalling approximately 400 m2 in adults, and is covered by a 
thick layer of mucus (Mowat & Viney, 1997). The mucus layer is a biochemical 
coating which protects the intestinal epithelium by lubricating the mucosal 
surface, preventing mechanical damage from food passing through the 
intestines. The mucus layer also acts as a barrier and a habitat for microbes, 
preventing bacterial access to the epithelium while also providing a glycan-rich 
environment for commensal bacteria to inhabit.  
The thickness and structure of the mucus layer is dependent on the location 
in the GIT, which corresponds with the role of each section in digestion as well 
as the bacterial burden (Johansson et al., 2011b). The current understanding 
of mucus thickness is based on findings in rodents, although a more recent 
study with human colonic biopsies was in agreement with these observations 
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(Figure 1.11) (Atuma et al., 2001; Gustafsson et al., 2012). In the stomach, a 
thick mucus layer is required to protect the epithelium from the harsh acidic 
conditions which could damage the epithelial surface (Ermund et al., 2013). 
The mucus structure changes in the small intestine, as the mucus thickness 
decreases and becomes loose and penetrable (Ermund et al., 2013). This 
change in the mucus facilitates the absorption of nutrients by villi while also 
protecting the epithelial surface, as the rapid transit time of digested food, the 
efficient capture of bacteria by the mucus as well as the production of 
antimicrobial compounds, inhibits microbial access to the epithelium (Ermund 
et al., 2013). In the distal small intestine and the large bowel (ileum and colon, 
respectively), the mucus thickness increases drastically, as the bacterial load 
reaches its peak in the colon (Ermund et al., 2013). As the transit time of food 
in the colon is reduced, the thick outer mucus layer provides a habitat for the 
large microbial population, which extract inaccessible nutrients from digested 
material in the lumen (Bäckhed et al., 2005). These changes in mucus 
thickness represent a dynamic response to the specific challenges that the 
regions of the GIT encounter.  
 
 
Figure 1.11: Mucus thickness throughout the rat GIT 
The thickness of the inner and outer mucus layers change dependent on the 
location in the GIT. Image adapted from Juge (2012). 
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In addition to variable mucus thickness, the structure of the mucus layer also 
differs between GI locations (Atuma et al., 2001). In the rat colon, the mucus 
forms an inner (~150 µm) and an outer (~550 µm) layer, the former excluding 
bacterial access to the epithelium whereas the latter facilitates bacterial 
colonisation (Figure 1.12A) (Johansson et al., 2011a). These layers 
demonstrate different physical properties, as the outer mucus layer can be 
easily removed via aspiration, while the inner layer remains adherent (Atuma 
et al., 2001; Gustafsson et al., 2012). The outer mucus layer is formed from 
the inner layer via the cleavage of cysteine residues in the mucin proteins, 
which initiates a four-fold expansion of the mucin glycoprotein while 
maintaining the structural integrity of the mucus layer (Figure 1.12B) 
(Johansson et al., 2011a; Johansson et al., 2008). 
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Figure 1.12: The inner and outer mucus layers of the colon 
(A) The inner stratified (S) and outer mucus layer (green) where the former is 
devoid of bacteria (red) whereas the latter demonstrates distinct bacterial 
colonisation. Scale bar = 20 µm. Image taken from Johansson et al. (2008). 
(B) Cleavage of cysteine residues in the MUC2 mucin initiates a four-fold 
expansion of the glycoprotein. Images taken from Johansson et al. (2011a). 
 
In contrast to the colon, the mucus layer of the small intestine is comprised of 
a single layer of loose mucus, which can be aspirated to reveal the villous 
surface (Atuma et al., 2001; Ermund et al., 2013). However, microbial access 
to the small intestinal epithelium is rarely observed, as bacteria are inhibited 
by antibacterial compounds such as defensins and RegIII lectins, which are 
released by Paneth cells and enterocytes (Figure 1.13) (Bevins, 2006; 
Vaishnava et al., 2011).  
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Figure 1.13: Mucus structure in the small and large intestine 
Bacterial access to the small intestinal epithelium is inhibited through the 
production and secretion of anti-microbial compounds into the loose mucus 
layer (A). In the large intestine, the dense inner mucus layer inhibits bacterial 
movement to the epithelium (B). Image adapted from Johansson and Hansson 
(2011c). 
 
Mucus has an essential role in inhibiting the access of biological and chemical 
insults to the epithelial surface. This has been demonstrated in mice deficient 
in Muc2, the primary secreted mucin in the murine small and large intestine, 
which spontaneously develop a severe colitis, characterised by the production 
of bloody stools as well as reduced weight gain (Van der Sluis et al., 2006). 
The induction of colitis is partly due to the microbiota contacting the gut 
epithelium. Mice deficient in O-glycan formation, and hence demonstrated 
altered mucus properties, showed reduced colitis when treated with broad-
spectrum antibiotics, which depleted aerobic and anaerobic bacteria (Fu et al., 
2011). Furthermore, when Muc2-deficient mice were exposed to A/E pathogen 
C. rodentium, the symptoms of infection were amplified, as these mice rapidly 
lost weight and demonstrated a 90% mortality rate, whereas wildtype mice 
recovered from infection after one week (Bergstrom et al., 2010). These 
studies demonstrate the importance of mucus in maintaining a healthy GIT. 
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1.3.1.2. Mucin structure and production 
The mucus layer is produced by secretion of mucin glycoproteins from 
epithelial goblet cells. Up to date, 17 mucins have been identified in humans, 
with 10 of these produced in the GIT (Arike & Hansson, 2016). Mucins can be 
divided into two groups, secreted gel-forming mucins (MUC2, -5AC, -5B, and 
-6) and membrane-bound mucins (MUC1, -3, -4, -12, -13, and -17) (Arike & 
Hansson, 2016). All mucin glycoproteins share a common core structure, a 
protein domain which is rich in proline, threonine, and serine residues (called 
the PTS domain), and can be over 2000 amino acids long (Arike & Hansson, 
2016). The serine and threonine residues of the PTS domain are heavily 
glycosylated, forming a distinct “bottle brush” structure, contributing up to 70% 
of the mucin mass (Figure 1.14) (Arike & Hansson, 2016; Johansson et al., 
2011b; Juge, 2012; Lindén et al., 2008a).  
 
 
Figure 1.14: Structure of gel-forming and transmembrane mucins 
Mucin glycoprotein structure with the protein core (red) and oligosaccharides 
decorations (green). Image taken from (Johansson et al., 2011b) 
 
Bacterial access to the epithelium throughout the GIT is inhibited by the 
adhesion of bacteria to mucins which mimic cell surface receptors, trapping 
microbes away from the epithelium (Lindén et al., 2008a). Trapped bacteria 
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are subsequently removed during the turnover of mucus through sheer 
mechanical force, which is generated from the movement of digested food 
through the intestines (Kerss et al., 1982). In the small and large intestine, 
MUC2 is the predominant secreted mucin, which forms a net-like structure 
upon release from the goblet cell, acting as a filter to prevent microbial 
passage to the epithelium (Johansson et al., 2011a). The formation of the 
MUC2 mucin in the goblet cell has been relatively well defined. Briefly, the 
MUC2 protein dimerises at the C-terminus in the endoplasmic reticulum before 
transportation to the Golgi body (Figure 1.15A) (Ambort et al., 2012a; 
Johansson et al., 2011b). In the Golgi body, the PTS domains of the apomucin 
are glycosylated and N-terminal oligomerisation occurs, before the mucin 
molecules are packed into vesicles (Ambort et al., 2012a; Johansson et al., 
2011b). Upon release from the goblet cell, the mucin molecules expand and 
combine to form the net-like structure, linked by covalent and non-covalent 
bonds (Figure 1.15B) (Ambort et al., 2012b; Johansson et al., 2011b).  
 
 
Figure 1.15: Formation of the MUC2 mucin structure 
(A) C-terminal dimerisation of MUC2 apomucin (indicated by the arrow), (B) 
MUC2 polymeric net-like structure. Image adapted from Johansson et al. 
(2011b). 
 
One of the key roles of glycan decorations of MUC2 are to protect the mucin 
from degradation by host digestive enzymes (Arike & Hansson, 2016). The 
glycans of the MUC2 mucin are themselves resistant to proteases and further 
prevent the access of these enzymes to the vulnerable mucin protein core 
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(Lidell et al., 2006). Additionally, glycans also play an important role in the 
selection of the host microbiota, as O-glycans act as adhesion sites and 
nutrient sources for commensal bacteria (Juge, 2012; Koropatkin et al., 2012; 
Tailford et al., 2015b). 
 
1.3.1.3. Mucus as a habitat for the microbiota 
The mucus layer facilitates the colonisation of a diverse range of microbes, as 
mucin O-glycans have a diverse structure which offer numerous binding sites 
for different bacteria (Derrien et al., 2010; Juge, 2012). Bacterial localisation 
in the GIT is influenced by mucin glycan structures, as these carbohydrates 
differ across the GIT, which may be a host mechanism to encourage the 
growth of certain bacteria in specific areas of the gut (Donaldson et al., 2016). 
In mice, differences in glycan structures have been identified across the GIT, 
as the levels of sulfation, fucosylation, and sialyation of mucins was dependent 
on the location in the small and large intestine (Larsson et al., 2013). The 
importance of glycosylation in bacterial binding to mucins has been 
demonstrated in animal models, as mice deficient in the production of O-
glycans with a core-1 structure demonstrated an altered gut microbiota, with 
increased abundance of Bacteroidetes relative to Firmicutes, whereas 
wildtype mice were the inverse (Sommer et al., 2014). Bacterial adhesion to 
mucins is mediated by a variety of surface receptors, such as the MUB protein 
of L. reuteri ATCC 53608, which binds to terminally sialyated glycans (Etzold 
et al., 2014a; MacKenzie et al., 2010). The MUB protein contains multiple 
repeats constituted of Ig- and mucus binding domains with homology to the 
MucBP domain of L. monocytogenes (Boekhorst et al., 2006; Etzold et al., 
2014a; Juge, 2012; MacKenzie et al., 2009). While MUB is unique to ATCC 
53608, surface proteins containing the MucBP domain are located throughout 
all sequenced L. reuteri genomes such as the CmbA adhesin from human L. 
reuteri isolates (Etzold et al., 2014b; Jensen et al., 2014; MacKenzie et al., 
2010). Other Lactobacillus species also produce surface proteins with mucus-
binding domains, including L. rhamnosus GG (mucus-binding factor protein) 
and L. plantarum strains WCFS1 and 299v (mannose-specific adhesin) 
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(Pretzer et al., 2005; von Ossowski et al., 2011). The prevalence of adhesins 
containing mucus-binding characteristics indicates the importance of these 
proteins in Lactobacillus colonisation/survival in the host. Besides specific 
mucus binding proteins, bacterial extracellular appendages also interact with 
intestinal mucins, such as the L. rhamnosus GG SpaCBA pilin and the 
probiotic E.coli Nissle 1917 flagella (Juge, 2012; Kankainen et al., 2009; 
Lebeer et al., 2012; Nishiyama et al., 2015; Troge et al., 2012). 
In addition to providing binding sites for the microbiota, the mucus layer also 
acts as a food source, as glycans from mucins can be utilised by bacterial 
species that produce mucin-degrading enzymes (Koropatkin et al., 2012; 
Tailford et al., 2015a). Ruminococcus, Bifidobacterium, Bacteroides, and 
Akkermansia species have all been identified as mucin degraders however, 
these effects, as well as the specific glycans targeted, are strain specific (Crost 
et al., 2013; Crost et al., 2016; Derrien et al., 2004; Ruas-Madiedo et al., 2008; 
Sonnenburg et al., 2005).  For example, A. muciniphilia demonstrates a narrow 
glycan range whereas Bacteroides thetaiotaomicron targets both dietary- and 
host-derived glycans (Derrien et al., 2004; Sonnenburg et al., 2005). 
As a consequence of mucin degradation, mucinolytic bacteria produce a range 
of metabolites, including short chain fatty acids (SCFA), particularly butyrate, 
which aid in the maintenance of epithelial homeostasis and provide an energy 
source for colonocytes (Hamer et al., 2008). Butyrate can also increase the 
production of mucus by IEC’s (Barcelo et al., 2000; Finnie et al., 1995; 
Hatayama et al., 2007; Tazoe et al., 2009). The exact mechanism remains 
unknown but the ERK signalling cascade has been implicated (Tazoe et al., 
2009). It is important to note that the majority of studies have investigated the 
impact of butyrate on the colon rather than the small intestine. However, 
butyrate, as well as the SCFAs acetate and propionate, are detected in 
ileostomy effluent, which indicates that SCFAs are present in the small 
intestine and thus may have similar beneficial effects (Zoetendal et al., 2012). 
In addition to effects on the host, butyrate also influences bacterial virulence 
and reduces the expression of the key S. enterica pathogenicity island SPI1, 
which is necessary for epithelial colonisation (Gantois et al., 2006). The health 
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benefits of SCFAs on maintaining host homeostasis remains an area of active 
research. 
 
1.3.1.4. Pathogen subversion of the mucus layer 
In order to initiate infection in the healthy GIT, pathogens must either infiltrate 
or degrade the mucus layer (Figure 1.16) (reviewed in McGuckin et al. (2011)). 
The flagellum is a key bacterial appendage which facilitates movement 
through mucus as well as enhancing microbial persistence by binding to 
mucins, as demonstrated for EPEC, EHEC, and C. difficile (Erdem et al., 2007; 
Tasteyre et al., 2001). Interestingly, the EPEC flagellum is not essential for the 
colonisation of human duodenal biopsies with an intact mucus layer, as a fliC-
deficient mutant demonstrated enhanced binding relative to the wildtype 
(Schüller et al., 2009). This implies that the interaction between flagella and 
the mucus may inhibit epithelial infection (Schüller et al., 2009). However, 
components of the C. difficile flagella specifically bind to mucus from the 
mouse caecum but not the porcine stomach, which could indicate either host 
or GIT location selection by C. difficile (Tasteyre et al., 2001). 
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Figure 1.16: Pathogenic mechanisms to subvert the mucus layer 
Pathogens can either (A) degrade the mucus layer with extracellular 
mucinases, (B) target microfold (M) cells which sample the gut microbiota and 
are not covered by a thick mucus layer, or (C) secrete toxins which diffuse 
through the mucus and disrupt TJs and inhibit mucus production. Image 
adapted from McGuckin et al. (2011). 
 
Some GI pathogens produce enzymes which degrade mucus (Figure 1.16A) 
(McGuckin et al., 2011). Mucinase production has been identified in numerous 
pathogens including EAEC (Pic), EHEC (StcE), and Vibrio cholerae (TagA) 
(Dutta et al., 2002; Grys et al., 2005; Szabady et al., 2011). The EHEC 
metalloprotease StcE cleaves the protein core of the mucin glycoprotein, 
degrading the mucus coating and revealing the epithelial surface for 
colonisation (Angel et al., 2012; Grys et al., 2005). Additionally, the 
degradation of the mucus layer creates a nutrient-poor environment for 
commensal bacteria, which reduces colonisation resistance by the host 
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microbiota against EHEC infection (Bäumler & Sperandio, 2016). Alternatively, 
H. pylori modifies the local environment to reduce mucus viscoelasticity, 
without degrading the mucus layer (Celli et al., 2009). The stomach mucus 
forms an effective barrier at a low pH however, H. pylori releases a urease 
which hydrolyses urea and elevates the pH of the mucus from 4 to 6 (Celli et 
al., 2009). By altering the rheological properties of the mucus, H. pylori can 
move freely toward the epithelium, to escape from the harsh acidic 
environment of the stomach lumen (Celli et al., 2009; Montecucco & Rappuoli, 
2001).  
In the small intestine, microfold (M) cells, present in the dome epithelium of 
Peyer’s patches, sample antigens from the lumen and transport them to 
underlying immune cells (Wang et al., 2014b). The sampling of the microbiota 
is an essential component of the localised immune system in the gut, which 
allows the host to prepare an antigen-specific IgA response against potential 
insults, without inducing an inflammatory response (Neutra et al., 2001). For 
effective sampling in the lumen, M cells have minimal mucus coverage, due to 
a lack of goblet cells in the Peyer’s patch, and thus offer a preferential site for 
infection in the small intestine (Figure 1.16B) (McGuckin et al., 2011; Wang et 
al., 2014b). Infection of M cells has been demonstrated by numerous invasive 
GI pathogens, including S. Typhimurium, S. flexineri, and L. monocytogenes 
(Jensen et al., 1998; Jepson & Clark, 2001; Jones et al., 1994; Sansonetti et 
al., 1996).  
Some GI pathogens produce toxins which travel through the functional mucus 
layer and access the epithelium (Figure 1.16C) (McGuckin et al., 2011). These 
toxins can alter the mucus in various ways, such as H. pylori-secreted 
cytotoxins CagA and VacA, which directly inhibit mucin synthesis and 
secretion (Beil et al., 2000; Byrd et al., 2000). Alternatively, toxins can modify 
the mucus layer indirectly, such as those produced by V. cholerae, which 
impact on the normal functioning of the cell and further induce apoptosis or 
weaken TJs in the epithelial barrier (Arce et al., 2005; Fasano et al., 1997; 
Lucas, 2010).  Through interaction with the epithelium, cholera toxin induces 
the secretion of water into the lumen which disrupts the mucus layer and 
induces diarrhoea, providing an opportunity for V. cholerae to both establish 
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infection in the host and disseminate into the external environment (Lucas, 
2010).  
The current understanding of the interaction between EPEC and the mucus is 
limited however, the infection of mice with the related A/E pathogen C. 
rodentium induced the depletion of Muc2 from goblet cells, mediated by the 
host immune response, indicating that the detection of A/E bacteria induced 
changes in the mucus layer (Bergstrom et al., 2008). Additionally, EPEC 
produces SslE (secreted and surface-associated lipoprotein from E. coli; also 
produced by ETEC and ExPEC), a secreted enzyme which has mucinolytic 
properties in vitro and in vivo (Luo et al., 2014; Nesta et al., 2014; Valeri et al., 
2015). While this enzyme offers a mechanism behind EPEC access to the 
epithelium, the impact of this mucinase during human infection still remains to 
be determined.   
 
1.3.2. Innate immune response 
1.3.2.1. Innate immune response to pathogens 
If a pathogen subverts the mucus layer and gains access to the epithelium, 
the host then initiates innate immune defence mechanisms against the 
invading microbe (Figure 1.17). This response detects ubiquitous microbial 
molecules, referred to as microbe-associated molecular patterns (MAMPs), 
which are detected by pattern recognition receptors (PRRs). PRRs are 
comprised of Toll-like receptors (TLRs), receptors that detect MAMPs at the 
host cell surface or in endosomes, and nucleotide-binding oligomerization 
domain (NOD)-like receptors (NLRs), which detect intracellular MAMPs 
(Figure 1.18) (Chen et al., 2009). Due to the constant evolution of pathogens 
which can quickly adapt to avoid host defences, PRRs have evolved to identify 
a limited range of highly conserved motifs which are not produced by higher 
eukaryotes, such as peptidoglycan, lipopolysaccharide (LPS) , and flagellin, 
detected by TLR2, TLR4, and TLR5, respectively (Aderem & Ulevitch, 2000). 
The detection of a MAMP initiates a cascade via the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein 
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kinase (MAPK) signalling pathways, which activate the pro-inflammatory 
transcription factors NF-κB and activator protein-1 (AP-1), respectively 
(Aderem & Ulevitch, 2000; Chen et al., 2009; de Grado et al., 2001). The target 
genes of NF-κB include the cytokines interleukin (IL)-1β, IL-6, IL-8, TNF-α, and 
interferon-γ (IFN-γ), which are secreted from the host cell and induce the 
chemotactic migration of macrophages, phagocytes, neutrophils, and dendritic 
cells to the site of infection (Tak & Firestein, 2001). These immune cells attack 
pathogens with DNA-damaging free-radicals (such as H2O2 and NO) as well 
as engulfing and phagocytosing microbes (Knight, 2000).  
 
Figure 1.17: Innate immune response in the GIT 
The innate immune response is initiated upon detection of MAMPs by PRRs 
(either TLRs or NLRs). The PRRs initiate the NF-κB signalling cascade, 
upregulating the expression of pro-inflammatory genes, which encode 
secreted antimicrobial proteins (AMP) and inflammatory cytokines. The 
secretion of cytokines recruits phagocytes to the site of infection, inducing 
transepithelial migration to the apical surface. These immune cells release 
free-radicals (such as NO and H2O2) and phagocytose invading microbes.  
 
Furthermore, the detection of pathogens by the intestinal epithelium (through 
TLRs and NLRs) can induce the production and secretion of antimicrobial 
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peptides, such as defensins, REGIII lectins, and cathelicidins, which integrate 
into the bacterial cell wall and/or membrane and form pores, resulting in 
osmotic leakage and cell death (Mukherjee & Hooper, 2015). These small 
peptides are produced by Paneth cells, enterocytes and goblet cells and are 
specifically targeted against bacteria, as these antimicrobials have net positive 
charges, whereas the bacterial cell wall has a net negative charge, allowing 
electrostatic interactions between the peptide and the bacterial cell (Dürr et 
al., 2006; Fujii et al., 1993; Mukherjee et al., 2014). In contrast, only the 
cytoplasmic surface of the eukaryotic cell membrane is negatively charged, 
thus the controlled secretion of these cationic peptides outside the membrane, 
prevents interaction with the host cell (Mukherjee & Hooper, 2015).  
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Figure 1.18: Inflammatory signalling pathway activation by PRRs upon 
detection of MAMPs 
(A) TLR-mediated and (B) NLR-mediated signalling pathways. Image adapted 
from Chen et al. (2009). 
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1.3.2.2. Innate immune response against EPEC infection 
The innate immune response raised against EPEC infection has been well 
investigated and has been associated with neutrophil infiltration at the site of 
infection (Moon et al., 1983). The migration of neutrophils across the epithelial 
surface is mediated by the chemoattractant IL-8, a cytokine which is 
significantly increased during EPEC infection (Khan et al., 2008; Nadler et al., 
2010; Pearson et al., 2011; Ruchaud-Sparagano et al., 2007; Savkovic et al., 
1997; Schüller et al., 2009; Sharma et al., 2006; Zhou et al., 2003). Flagellin, 
the principle component of the EPEC flagellum, has been implicated as the 
primary immunostimulatory factor, as flagellin induced the production of IL-8 
in both in vitro (HT-29 and T84) and ex vivo (duodenal biopsies) models (Khan 
et al., 2008; Schüller et al., 2009; Sharma et al., 2006; Zhou et al., 2003). 
Whilst flagellin has been identified as a key inducer of the IL-8 response, it is 
important to note that the loss of fliC does not completely abrogate the 
production of IL-8, implying that other immunostimulatory factors are involved 
(Khan et al., 2008; Schüller et al., 2009; Sharma et al., 2006). While EPEC 
LPS, DNA, and EspC do not induce an IL-8 response in vitro, the additional 
immunogenic factor(s) remain unknown (Sharma et al., 2006).  
Interestingly, the innate immune response against EPEC infection is thought 
to contribute to the onset of diarrhoea, as migrating neutrophils initiate the 
release of chloride ions by the epithelium, which induces fluid secretion from 
epithelial cells into the lumen (Crane et al., 2002; Crane et al., 2007; 
Viswanathan et al., 2009). However, EPEC counteracts the host immune 
response via the secretion of effector proteins into the host cell.  
 
1.3.3. The effect of EPEC on innate defences 
The innate immune response raised against EPEC perturbs the normal 
intestinal milieu, creating a hostile environment, which aids in the clearance of 
the pathogen from the host. However, the EPEC genome encodes a vast 
repertoire of effector proteins that dampen the host response to infection 
(Kaper et al., 2004). These effectors target the NF-κB and the MAPK signalling 
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pathways and effectively inhibit the immune response through the 
mechanisms described below. 
The NF-κB transcription factor is a key mediator in the propagation of the 
innate immune response against EPEC infection. NF-κB is comprised of two 
subunits, p50 and p65, which are dimerised at the Rel homology domain on 
the N-terminus of each subunit (Pearson et al., 2011). In the non-inflamed cell, 
NF-κB is located in the cytoplasm in an inactive form bound to IκB however, 
upon initiation of the pro-inflammatory cascade, IκB is phosphorylated by IκB 
kinase (IKK), which induces IκB ubiquitination (Tak & Firestein, 2001). The 
removal of IκB subsequently activates NF-κB, which translocates to the 
nucleus and initiates the transcription of genes containing a κB enhancer 
element, such as IL-8 (Figure 1.17A) (Kunsch & Rosen, 1993; Tak & Firestein, 
2001). The EPEC effector protein NleE prevents NF-κB activation by inhibiting 
phosphorylation of IKK and subsequent degradation of IκB (Figure 1.19) 
(Nadler et al., 2010; Newton et al., 2010; Vossenkämper et al., 2010; Yen et 
al., 2010). NleB has a similar, though less pronounced, effect on IKK (Gao et 
al., 2013; Li et al., 2013; Nadler et al., 2010; Pearson et al., 2011). In addition, 
NleB reduces the GAPDH-mediated degradation of TNF receptor associated 
factor-2 (TRAF2), which is activated during the TNF-α-induced inflammatory 
response, which further inhibits NF-κB activation (Gao et al., 2013; Li et al., 
2013). In contrast to NleE and NleB, NleC directly targets the NF-κB 
heterodimer by cleaving the p65 subunit at the N-terminus, degrading NF-κB 
(Figure 1.19) (Baruch et al., 2011; Mühlen et al., 2011; Pearson et al., 2011; 
Yen et al., 2010). The effector proteins NleH1 and NleH2 also target the NF-
κB complex, specifically the non-Rel component human ribosomal protein S3 
(RPS3), which inhibits the localisation of NF-κB to κB enhancer sites (Gao et 
al., 2009; Pham et al., 2012; Wan et al., 2007). However, despite substantial 
homology between these proteins, these effectors induce different effects on 
RPS3, as NleH1 and NleH2 inhibit and activate RPS3, respectively (Gao et 
al., 2009; Pham et al., 2012). Interestingly, despite NleH1 reducing RPS3 
translocation to the nucleus, an EHEC ΔnleH1 mutant strain induced a more 
severe disease in infected pigs, which was associated with an enhanced 
inflammatory response, even though little diarrhoea was produced (Gao et al., 
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2009). As both NleH1 and NleH2 can interact and bind to each other, this 
suggests that these proteins modulate the innate immune response in unison 
however, the mechanism behind this effect remains unknown (Pham et al., 
2012). Finally, the EPEC Tir protein also inhibits the NF-κB pathway through 
the recruitment of Src homology region 2 domain-containing phosphatase-1 
(SH-1), which subsequently binds to and inhibits TRAF6 phosphorylation, 
preventing the activation of TGF-β activated kinase-1 and further downstream 
processes (Figure 1.19) (Ruchaud-Sparagano et al., 2011; Yan et al., 2012).  
 
 
Figure 1.19: Inhibition of the NF-κB inflammatory pathway by EPEC 
effector proteins 
EPEC effector proteins (blue) target both inflammatory cascade proteins (red) 
and helper proteins (brown) which initiate the innate immune response. Image 
adapted from Raymond et al. (2013). 
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While the NF-κB pathway is the predominant mechanism responsible for the 
innate immune response against EPEC infection, the MAPK pathway also 
contributes to inflammation through the induction of AP-1 (Figure 1.20). 
However, activation of the MAPK pathway is inhibited by EPEC effector 
proteins such as NleD, which cleaves JNK and p38, subsequently preventing 
the nuclear translocation of AP-1 (Marchés et al., 2005). Interestingly, the loss 
of nleD does not reduce IL-8 protein production (Baruch et al., 2011; Marchés 
et al., 2005). Similarly to NleD, NleC also targets and cleaves p38, 
demonstrating the multifunctional activity of this protein, which also targets the 
p65 subunit of NF-κB (discussed above) (Sham et al., 2011). In contrast to 
other EPEC effector proteins, NleH2 stimulates an increase in AP-1 activity 
however, the mechanism behind this effect remains to be determined (Gao et 
al., 2009).  
 
 
Figure 1.20: Inhibition of the MAPK signalling pathway by EPEC effector 
proteins 
EPEC effector proteins NleD and NleC cleave signalling molecules in the 
MAPK signalling pathway. Image based on Morrison (2012). 
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1.3.4. The effect of Lactobacillus on innate defences 
As the mucus layer is the primary colonisation site for lactobacilli in the GIT, 
as well as the initial barrier to infection, microbial modulation of this surface is 
an area of ongoing investigation (Juge, 2012; Walter, 2008). Upregulation of 
MUC3 gene and protein expression has been demonstrated by the probiotic 
strain L. plantarum 299v when incubated on HT-29 cells (Mack et al., 2003; 
Mack et al., 1999). Furthermore, changes in MUC3 expression in HT-29 cells 
were associated with a decrease in EPEC binding (Mack et al., 2003; Mack et 
al., 1999). Lactobacillus also modulate the production of secreted mucins, as 
MUC2 protein levels in LS174T cells and mice were increased by the L. 
rhamnosus GG secreted protein p40, which interacted with the EGF receptor 
(Wang et al., 2014a). Furthermore, L. reuteri ATCC PTA 4659 and R2LC 
increased the mucus thickness in mice with DSS-induced colitis and in healthy 
controls (Ahl et al., 2016).  
In addition to enhancing the mucus layer, some Lactobacillus strains also have 
potent immunomodulatory characteristics, which can aid in the maintenance/ 
restoration of gut homeostasis during inflammatory events. Moreover, the 
influence of probiotics on ailments with persistent GI inflammation, such as 
IBD, has shown some promising outcomes, although further randomised 
controlled trials are required to ensure clinical efficacy (Ghouri et al., 2014). 
The effects of probiotics on the innate immune response have generally been 
determined by measuring changes in pro-inflammatory cytokine production, 
using both in vitro and in vivo model systems. Lactobacillus strains are usually 
classified as either anti-inflammatory or immunostimulatory, such as L. reuteri 
ATCC PTA 6475 and L. reuteri ATCC 55730, respectively (previously 
discussed in 1.2.4.1.1 and 1.2.4.1.2). Importantly, immunomodulatory effects 
can be dependent on either the model system used or the immune stimulus, 
as L. rhamnosus GG decreased the production of IL-8 in Caco-2 cells treated 
with flagellin, yet induced IL-8 production in HT-29 cells infected with S. 
Typhimurium (Lopez et al., 2008; Pinto et al., 2009). Furthermore, mice with 
DSS-induced colitis presented with an increased disease severity when 
treated with L. rhamnosus GG relative to mice which did not receive the 
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probiotic, demonstrating that probiotic choice can influence clinical outcome in 
vivo (Mileti et al., 2009).  
The exact mechanisms responsible for the immunomodulatory characteristics 
of Lactobacillus strains are often poorly defined however, inhibition of IκB 
degradation has been suggested in multiple studies (Ko et al., 2007; Lopez et 
al., 2008; Ma et al., 2004; Petrof et al., 2009; Tien et al., 2006). Alternatively, 
some Lactobacillus strains increase the production of anti-inflammatory 
cytokines by dendritic cells, such as IL-10 (Christensen et al., 2002; Drakes et 
al., 2004; Fernandez et al., 2011; O'Hara et al., 2006). Additionally, secreted 
products produced by lactobacilli have been associated with decreased 
expression of inflammatory cytokines (Coconnier et al., 2000; Nemeth et al., 
2006). In a small number of studies, the decrease in inflammation has been 
directly associated with specific compounds, such as the anti-oxidant 
glutathione and histamine, which are produced by L. fermentum 5716 and L. 
reuteri ATCC PTA 6475, respectively (Peran et al., 2006; Thomas et al., 2012). 
Whether the production of these compounds is widespread amongst anti-
inflammatory lactobacilli remains to be determined and is an area of ongoing 
research. 
 
1.4. Model systems for studying bacterial interaction with the 
intestinal mucosa 
1.4.1. Cultured epithelial cell lines 
The most frequently used model for the assessment of both Lactobacillus and 
EPEC interactions with the intestinal epithelium are cultured epithelial cell 
lines. Generally, either HeLa cells, derived from a cervical carcinoma, or colon 
carcinoma cells have been used to determine the effects of lactobacilli and 
EPEC on microbial binding, the innate immune response, and mucin 
regulation (Law et al., 2013). As the intestinal epithelium exhibits distinct 
polarity, cell-based models have been adapted to resemble this structure, with 
polarised Caco-2 and T84 cells frequently being used to determine the impact 
of bacterial interaction with the epithelia. However, the interactions between 
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microbes and cancer cell lines is known to differ from those which occur at the 
intestinal epithelium, which is due to a number of reasons (Law et al., 2013). 
Firstly, the intestinal epithelium consists of four main cell types (enterocytes, 
goblet cell, enteroendocrine cells, and Paneth cells), whereas cultured 
epithelial cells represent a single cell type. Thus, the interaction and cross-
communication between the various cell types in the epithelium is not 
observed in cultured cell line based models. Furthermore, the most frequently 
used IECs (HT-29, Caco-2, and T84) are enterocyte-like cells, which do not 
secrete mucins and are thus not protected by a mucus layer. As the mucus 
protects the epithelium in vivo, the absence of this layer removes an essential 
component of intestinal defence against microbes in the healthy intestinal 
environment (Johansson et al., 2011b; Johansson et al., 2011a; Johansson et 
al., 2008). Thus, the use of non-mucus producing IECs to evaluate probiotic 
binding is more representative of ailments with a perturbed mucus barrier, 
such as IBD, rather than the healthy GIT. Finally, immortal cancer cell lines 
have undergone substantial genomic mutations which enable these cells to 
continuously propagate, whereas non-malignant cells enter senescence. This 
presents a key problem, as these mutations can alter the basic cell physiology 
and the function of the cell.  
However, cancer cell lines enable the researcher to dissect the gut epithelium 
from the complex environment of the GIT, which can assist in the identification 
of novel bacterial features. Nonetheless, it is crucial to complement results 
from cell-based assays with more physiologically relevant models, to ensure 
that these findings are representative of the in vivo situation (Law et al., 2013). 
 
1.4.2. In vivo model systems 
The identification of relevant in vivo models for EPEC infection remains an 
active area of investigation, as experiments on infants would be highly 
unethical (Goosney et al., 2000; Law et al., 2013). A small number of studies 
have been performed on adult volunteers to assess EPEC virulence 
(Donnenberg et al., 1993b; Levine & Edelman, 1984; Levine et al., 1985; 
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Tacket et al., 2000; Vallance & Finlay, 2000). It is important to note that 
stomach acid neutralisation and a large EPEC dose were required to induce 
diarrhoea in adults, which does not represent the conditions required for 
natural infection (Nataro & Kaper, 1998). 
Investigators have used gnotobiotic piglets as an in vivo infection model for 
human EPEC infection and identified EPEC colonisation in the porcine 
midileum (Moon et al., 1983; Tzipori et al., 1985). However, the required 
maintenance costs for larger animals and maintaining germ-free status, as well 
as few genetically modified lines, encourages the use of alternative model 
systems. Mice have also been utilised to investigate EPEC infection of the 
GIT, with Savkovic et al. (2005) identifying mucosal colonisation and neutrophil 
migration to the epithelium. However, these data are conflicting with other 
reports, which show minimal colonisation of the mouse GIT by EPEC 
(Klapproth et al., 2005; Mundy et al., 2006). In contrast, streptomycin-treated 
and neonatal mice supported EPEC adhesion when treated with a high 
bacterial dose, suggesting colonisation resistance by the intestinal microbiota 
as a cause for absent EPEC binding in conventional mouse models (Dupont 
et al., 2016; Royan et al., 2010). Although EPEC-infected germfree and 
neonatal mice demonstrated A/E lesion formation at the epithelial surface, 
these mice do not develop watery diarrhoea after infection (Dupont et al., 
2016; Meador et al., 2014; Vallance & Finlay, 2000). Thus, no murine model 
to date presents with the complete repertoire of clinical symptoms associated 
with EPEC infection of human infants (Law et al., 2013; Vallance et al., 2002).  
The natural murine pathogen C. rodentium has often been used as a proxy for 
EPEC to examine intestinal infection by A/E pathogens, as the Citrobacter 
genome contains a LEE PAI which shares 41 open reading frames with the 
EPEC LEE PAI (Deng et al., 2001). However, 32% of the C. rodentium 
genome is not shared with EPEC, which includes at least seven putative T3S 
effector proteins (Petty et al., 2010). Further differences from EPEC infection 
include location of intestinal colonisation, as C. rodentium adhere to the murine 
cecum and colon, and different pathologies, as C. rodentium infection does 
not induce profuse, watery diarrhoea in the host (Law et al., 2013). 
Additionally, C. rodentium infection is not limited to infant mice (Law et al., 
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2013). In contrast, infection of weaned rabbits with rabbit EPEC demonstrated 
a similar phenotype to human EPEC colonisation, as the infection was age 
restricted and induced a similar tissue pathology, alongside potentially lethal 
diarrhoea (Law et al., 2013; Moon et al., 1983; Robins-Browne et al., 1994). 
However, the severity of diarrhoea in infant rabbits inhibits the investigation 
into moderate changes in disease phenotype (Law et al., 2013). Furthermore, 
there are few genetically modified rabbit lines, which limits the evaluation of 
the host response to EPEC infection (Law et al., 2013).  
In contrast to EPEC infection studies, clinical studies investigating probiotic 
characteristics are more prevalent, as Lactobacillus species are generally 
regarded as safe (GRAS) and can thus be consumed without risk of harm to 
the participant, which reduces ethical and safety concerns (Salminen et al., 
1998). Furthermore, L. reuteri strain ATCC 55730 was not detrimental in 
immunocompromised patients, further supporting the GRAS status of these 
microbes (Wolf et al., 1998). In addition to human volunteer studies, animals 
have been used to investigate probiotic characteristics including mice, rats, 
chickens, and pigs. However, as L. reuteri strains demonstrate ecological 
adaption to their original host species, this limits the use of animals when 
investigating the probiotic characteristics of human-derived strains, as findings 
in one species may not be applicable to another (Walter, 2008).  
 
1.4.3. Ex vivo model systems 
To overcome the lack of relevant in vivo models for EPEC infection studies, 
Knutton and colleagues developed an in vitro organ culture (IVOC) system, 
which used intestinal mucosal biopsy samples to investigate the interaction of 
A/E E. coli with the intestinal epithelium (Knutton et al., 1987). IVOC has 
numerous advantages over traditional cell culture, including the presence of 
all major epithelial cell types and the protective mucus layer (Fang et al., 
2013). A limitation of IVOC is that EPEC infection is not restricted to the 
mucosal surface. However, a polarised system (pIVOC) has been developed, 
which confines bacterial access to the epithelial biopsy surface, enabling the 
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investigation of the innate immune response against EPEC infection (Schüller 
et al., 2009). 
IVOC is a valuable model for the study of microbe-host interactions at the 
intestinal mucosa however, there are a number of limitations which prevent 
the routine use of this system. Firstly, IVOC studies require ethical approval, 
as samples are acquired from patients in addition to any biopsies which are 
taken for diagnostic use. Secondly, access to human tissue can be 
unpredictable due to the need for patient consent. Thirdly, different host 
backgrounds can result in considerable variation between experiments. 
Finally, IVOC experiments are limited to approximately eight hours, as tissue 
survival is reduced in the absence of blood supply. While there are limitations 
to the IVOC method, this system is currently regarded as the gold standard for 
the investigation of pathogenic E. coli interaction with the intestinal mucosa 
(Girard et al., 2007; Phillips & Frankel, 2000; Schüller et al., 2009).  
Human intestinal tissue has also been used in the investigation of probiotic 
Lactobacillus characteristics, such as samples from patients with IBD to 
determine the impact of probiotic strains on inflammation (Tsilingiri et al., 
2012). The interaction between lactobacilli and GI pathogens has also been 
explored with intestinal tissue from the porcine gut (Bogovič Matijašić et al., 
2006; Collins et al., 2010). Nonetheless, the use of intestinal tissue for 
probiotic research remains a niche area.  
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1.5. Aims and objectives 
The overarching aim of this PhD project was to determine the influence of 
probiotic L. reuteri on EPEC infection of the human intestinal epithelium, with 
particular focus on 1) EPEC binding, 2) mucus production, and 3) pro-
inflammatory host response. Both in vitro and ex vivo human intestinal 
epithelial cell models were used in this study. 
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2.1. Bacterial strains and growth conditions 
2.1.1. Bacterial strains 
The bacterial strains used in this study are listed in Table 2.1. All experiments 
using EPEC were performed in a containment level 2 facility. 
 
Strain Description Reference 
L. reuteri   
ATCC PTA 6475 Human isolate Oh et al. (2010) 
ATCC PTA 6475 CmbA- Human isolate Etzold et al. (2014b) 
DSM 20016 Human isolate Oh et al. (2010) 
LMS11-3 Human isolate Oh et al. (2010) 
ATCC 55730 Human isolate Oh et al. (2010) 
ATCC 53608 Pig isolate Oh et al. (2010) 
ATCC 53608 MUB- Pig isolate MacKenzie et al. (2010) 
100-23C Rat isolate Oh et al. (2010) 
LB54 Chicken isolate Oh et al. (2010) 
   
EPEC   
E2348/69 EPEC wildtype (O127:H6) Levine et al. (1978) 
CVD452 EPEC escN mutant Jarvis et al. (1995) 
AGT01 EPEC fliC mutant Girón et al. (2002) 
UMD864 EPEC espB mutant Donnenberg et al. (1993a) 
   
Table 2.1: Bacterial strains used in this study 
 
2.1.2. Culture methods 
L. reuteri were routinely cultured in de Man, Rogosa and Sharpe (MRS) culture 
medium (Oxoid), which is selective for Lactobacillus by low pH (6.2 ± 0.2). L. 
reuteri broth cultures were inoculated from frozen glycerol stocks and grown 
standing in an anaerobic cabinet (5% CO2, 10% H2 and 85% N2, Don Whitley 
Scientific) at 37 °C overnight. L. reuteri colonies were cultured at 37 °C on 
MRS agar (1.5% w/v agar, Formedium) plates overnight under anaerobic 
conditions. 
EPEC were routinely cultured in Lennox Lysogeny Broth (LB) (Formedium) 
and grown standing in aerobic conditions at 37 °C overnight. EPEC colonies 
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were cultured at 37 °C on LB agar (1.5% w/v agar) plates overnight under 
aerobic conditions. 
EPEC cultures were stored as streaks on LB plates for up to one month at 4 
°C before re-streaking. EPEC deletion mutants were selected with the 
appropriate antibiotic at the following concentrations: kanamycin (50 µg/ mL) 
and chloramphenicol (25 µg/ mL).  
  
2.1.3. Cryopreservation and thawing of strains 
Stock cultures of L. reuteri and EPEC were preserved in 15% (v/v) glycerol 
solution. A 50% glycerol solution was prepared in deionised distilled H2O 
(ddH2O) and sterilized by autoclaving. 300 µL 50% glycerol solution was mixed 
with 700 µL fresh overnight culture in a sterile ampoule by pipetting and snap 
frozen on dry ice before long term storage at -70 °C. 
 
2.2. Cell culture 
All cell lines were routinely cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 4500 mg/ L glucose and 3700 mg/ L sodium bicarbonate 
(Sigma). DMEM medium was supplemented with 4 mM L-glutamine (Sigma) 
and 10% foetal bovine serum (FBS, Sigma). Cells were maintained at 37 °C 
in a 5% CO2 atmosphere. Media used during routine cell culture were warmed 
to 37 °C prior to use. Cells were grown in 25 cm2 culture flasks (Sarstedt and 
Greiner Bio-One) and passaged at full confluency. 
HT-29 (ECACC 91072201) and LS174T cells (ECACC 87060401), originally 
isolated from human colon adenocarcinoma, were used between passages 5 
to 20 and 7 to 27, respectively. 
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2.2.1. Trypsinisation and passaging of cell lines 
At confluency, the cell culture media were removed and cells were washed 
twice with 4 mL PBS (Sigma) to remove residual FBS, which can deactivate 
trypsin. Cells were washed once with 0.5 mL 0.25% trypsin- 0.02% 
ethylenediaminetetraacetic acid (EDTA) solution (T/E, Sigma) before 0.5 mL 
T/E were applied. Cells were incubated at 37 °C until cell detachment from the 
flask (approximately 5 min). Trypsin was deactivated by resuspending the cells 
in 4.5 mL supplemented DMEM, and cells were split at dilution ratios of 1:10 
into a new 25 cm2 culture flask. Cells were split approximately every 7 days 
and the cell culture media were replaced every 2 days, to prevent acidification. 
 
2.2.2. Determination of cell concentration and cell seeding 
After trypsinisation, 10 µL of cell suspension was mixed with 10 µL trypan blue 
(Sigma) to identify nonviable cells. Trypan blue is unable to permeate the cell 
membrane of live cells, and only dead cells are stained blue. Viable cells were 
counted using an improved Neubauer haemocytometer (Hawksley; depth 0.1 
mm) and an inverted light microscope (Zeiss Invertoskop ID03). Two fields (1 
x 10-4 mL/ field) (Figure 2.1) were counted and multiplied by 104 to determine 
the cell concentration. The volume of cell suspension required for seeding (x) 
was determined by the following formula; 
x = (y * w) / z 
y is the desired number of cells/ well, w is the number of wells to be seeded, 
and z is the cell concentration.  
Cells were seeded into 24 well plates at 1 x 105 cells/ well (HT-29) or 1.5 x 105 
cells/ well (LS174T). Cells were seeded onto sterile coverslips (CS), for 
microscopy analysis, or directly onto wells for all other experiments. Cells were 
grown to confluence (7 days) and, prior to infection, cell culture media were 
replaced with plain DMEM. 
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Figure 2.1: Neubauer cell counting chamber 
Red boxes indicate the cell counting area with a defined volume of 0.1mm3, 
equivalent to 10-4 mL. 
 
2.2.3. Cryopreservation and resurrection of cell lines 
2.2.3.1. Cryopreservation of cell lines 
Cells were grown in 75 cm2 culture flasks until confluence. Cells were 
trypsinised and resuspended in 5 mL supplemented DMEM, and the cell count 
was determined as described in 2.2.2. Cell concentration was adjusted to 2-4 
x 106 cells/ mL, and 950 µL cell suspension was added to a freezing vial. 50 
µL dimethyl sulfoxide (DMSO) (5% final concentration, Sigma) was added, and 
vials were placed in a freezing container (Mr Frosty, Nalgene), containing 
isopropanol (Sigma), and cooled to -80 °C overnight at a cooling rate of 1 °C/ 
min to reduce ice crystal formation. Frozen vials were transferred to liquid 
nitrogen storage (vapour phase; -190 °C) for long term preservation.  
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2.2.3.2. Resurrection of cell lines 
Frozen vials were removed from liquid nitrogen storage and warmed quickly 
to room temperature (RT). The cell suspension was transferred into 5 mL 
supplemented DMEM, resuspended and centrifuged for 7 min at 188 x g to 
remove DMSO. The supernatant was discarded, and the cell pellet was 
resuspended in 7 mL supplemented DMEM. The cell suspension was 
transferred into a 25 cm2 culture flask and cultured as previously described. 
 
2.3. Infection assay 
2.3.1. Adhesion assay 
Prior to inoculation, L. reuteri and EPEC were spun down at 18,000 x g for 5 
min and resuspended in DMEM. Approximately 5 x 107 bacteria (Multiplicity of 
infection (MOI) of 50 bacteria/ cell) were incubated with the cell monolayers at 
37 °C in a 5% CO2 atmosphere for 1 h. The cell monolayers were washed with 
PBS (3x) to remove non-adherent bacteria, and processed according to further 
applications. 
 
2.3.2. Protection assay 
2.3.2.1. Short-term protection assay  
For short-term protection assays, 5 x 108 L. reuteri (MOI 500) were pre-
incubated with cell monolayers for 1 h. Subsequently, 5 x 106 EPEC (MOI 5) 
were added for 1 h. At the end of the experiment, cell monolayers were 
washed with PBS (3x), and processed according to further applications.  
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2.3.2.2. Long-term protection assay 
Cells were pre-incubated with 5 x 108 L. reuteri for 4 h, and the cell culture 
media were tested with pH indicator strips (ThermoFisher, pH range 4.5-10.0 
at 0.5 intervals) after the incubation to determine potential acidification. 
Non-adherent lactobacilli were removed by washing with DMEM for 5 min on 
a rocking platform (30 rotation/ min), and cells were incubated with 5 x 106 
EPEC for 1 or 3 h. At the end of the experiment, cells were washed with PBS 
(3x) and processed for further applications.  
 
2.3.3. Contact killing assay 
To assess the impact of L. reuteri on EPEC viability, 5 x 108 L. reuteri were 
pre-incubated for 1 h in 1 mL DMEM medium at 37 °C in 5% CO2 atmosphere, 
and 5 x 106 EPEC were added and further incubated for 1 h. As 1% Triton X-
100 (TX-100, Sigma) was used in protection assay experiments to release 
adherent bacteria (see 2.3.5), 1% TX-100 was added to the co-culture for 10 
min after the EPEC incubation. EPEC survival was assessed by plating out 
serial dilutions of the co-culture on LB agar plates and viable EPEC were 
determined relative to the initial inoculum by plate counting. 
 
2.3.4. Co-culture assay 
To determine the effect of L. reuteri and EPEC on mucus production and the 
inflammatory response, 5 x 107 L. reuteri were incubated with 5 x 107 EPEC 
on cell monolayers at 37 °C in 5% CO2 atmosphere for 6 h. Cell culture media 
were spun down at 18,000 x g for 5 min and the supernatant frozen at – 80 °C 
until processing. Cells were washed with PBS (3x) and processed for further 
applications. 
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2.3.5. Quantification of bacterial colonisation 
Cells were lysed with 1% TX-100 in PBS for 10 min at RT to release adherent 
bacteria. The lysate was serially diluted in PBS, plated out and incubated 
overnight at 37 °C. Bacterial colonies were counted, and adherence was 
determined according to the following formula; 
% adherence = (adherent bacteria/ mL/ inoculated bacteria/ mL) * 100 
 
2.4. In vitro organ culture (IVOC) of human intestinal biopsy 
tissue 
2.4.1. Ethical approval and collection of biopsy samples 
This study was performed with ethical approval from the University of East 
Anglia Faculty of Medicine and Health ethics committee (ref 2010/11-030). All 
biopsies were collected through the Norwich Biorepository, which has National 
Research Ethics Service approval (ref 08/h0304/85+5). Samples were 
provided by the Gastroenterology Department at the Norwich and Norfolk 
University Hospital. 
Up to six biopsies from the second part of the duodenum were obtained with 
informed consent from 87 adults (24-87 years; average age 64.7; 42 male and 
45 female) undergoing routine upper endoscopy for investigation of GI 
symptoms (see Appendix 1 for a copy of the Norwich Biorepository information 
sheet and consent form for adult patients). Patients were not included in the 
study if they met any of the following criteria; 
Previous infection of Human Immunodeficiency Virus or Hepatitis B. 
The patient suffered from any conditions of the small bowel. 
For studies investigating the immune response, patients were also excluded if 
they had used immunosuppressive medication within the past month. 
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Biopsies were taken from macroscopically normal areas, transported to the 
laboratory in IVOC medium and processed for experimentation within the next 
hour. 
 
2.4.2. Culture of biopsy samples  
Biopsies were maintained in IVOC medium (0.94 g NCTC 135 medium 
(Sigma), 0.22 g sodium bicarbonate (Sigma), and 1 g D-(+)-mannose (Sigma), 
to prevent bacterial adhesion by type I fimbriae, dissolved in 90 mL ddH2O). 
The solution was filter sterilized with a 0.45 µm syringe filter (Sartorius Stedim), 
and combined with 90 mL DMEM and 20 mL newborn calf serum (Sigma). The 
medium was stored at 4 °C. 
IVOC was performed as described previously (Knutton et al., 1987). Briefly, 
biopsies were cut with a disposable scalpel to a diameter of 2-3 mm and 
orientated with the mucosal side upwards on a foam support (Simport) in a 12 
well plate in 1 mL IVOC medium. IVOC medium in the well was adjusted to 
allow a thin film of medium to cover the biopsy. Biopsies were infected with 25 
µL standing overnight culture (2.5 x 107 bacteria) and incubated on a seesaw 
rocker with 12 revolutions/ min in air with 5% CO2 at 37 °C for up to 8 h. 
Medium was changed at 4 h and 6 h to maintain pH and prevent bacterial 
overgrowth. At the end of the experiment, biopsies were transferred to glass 
screw cap tubes and washed twice with PBS by vigorous shaking to remove 
mucus and non-adhering bacteria. Alternatively, biopsies were processed 
without washing to allow assessment of the mucus layer. 
 
2.4.2.1. Polarised IVOC 
The polarised IVOC technique was pioneered by Schüller et al. (2009), and is 
an adaption of IVOC which restricts bacterial access to the mucosal surface. 
For this, the biopsy was sandwiched between two Perspex disks (12 mm 
diameter, Faculty of Science Mechanical Workshop, University of East Anglia) 
with a central aperture (2 mm diameter), as demonstrated in Figure 2.2.  
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For mounting of the biopsy, a cellulose nitrate membrane filter (3 µm pore size, 
Whatman) was soaked in IVOC medium and placed onto the basal disk. The 
biopsy was placed centrally on the membrane and orientated with the mucosal 
side facing upwards under a dissection microscope. To prevent bacterial 
leakage, the apical disk was sealed to the mucosal biopsy surface with 
Histoacryl tissue glue (Braun Medical). The biopsy-containing unit was 
mounted into a Snapwell support (polycarbonate membrane, Corning) and 
placed into a 6 well plate with 3 mL IVOC medium in the basolateral chamber. 
For adherence assays, biopsies were submerged in 180 µL IVOC medium and 
infected with 20 µL standing overnight bacterial culture (2 x 107 CFU). The 
biopsies were incubated on a seesaw rocker at 37 °C in a 5% CO2 atmosphere 
for up to 6 h. Apical medium was removed after 2 h, and biopsies were washed 
with 200 µL IVOC medium. Biopsies were further incubated under slightly 
submerged conditions (~50 µl of medium) to reduce epithelial shedding. For 
protection assays, biopsies were pre-incubated with 109 L. reuteri in 300 µL 
IVOC medium for 2 h. Biopsies were washed with IVOC medium to remove 
non-adherent L. reuteri and biopsies were incubated with 2 x 107 EPEC for 4 
h. At the end of the experiment, specimens were removed from the support, 
washed, and processed according to further applications.  
 
 
Figure 2.2: pIVOC system 
Biopsies were mounted between two Perspex disks with a central aperture to 
limit bacterial access to the mucosal biopsy surface. Adapted from 
Schüller et al. (2009). 
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2.4.3. Scanning electron microscopy 
Biopsies were fixed in 2.5% glutaraldehyde (Agar Scientific) in PBS overnight 
and stored at 4 °C until processing. All subsequent incubation steps were 
performed on a rocker. Samples were washed twice with PBS and once with 
ddH2O for 10 min. The biopsies were dehydrated by subsequent incubation in 
30%, 50%, 70%, and 90% acetone in ddH2O for 15 min followed by two 15 
min incubations in 100% acetone. The specimens were dried by incubation in 
tetramethylsilane (Sigma) for 10 min and air-dried for at least 10 min. Samples 
were orientated under a dissecting  microscope and mounted with the mucosal 
surface facing upwards on aluminium stubs (TAAB Laboratory Equipment 
Ltd.) using silver paint (Agar Scientific). The biopsies were sputter-coated with 
gold (Polaron SC7640 sputter coater, Quorum Technologies), and viewed with 
a JEOL JSM 4900 LV scanning electron microscope (School of Environmental 
Sciences, UEA). 
 
2.4.4. Biopsy cryosections 
Biopsies with preserved mucus layers were embedded in optimal cutting 
temperature compound (Sakura) in a cryotube, snap-frozen in an ethanol/dry 
ice bath and stored at -80 °C. Serial sections of 7 µm were cut with a Microm 
HM550 cryostat (Thermo Scientific), picked up on poly L-lysine-coated slides 
(Agar Scientific) and air-dried for at least 30 min. Slides were stored at -80 °C 
until processing. 
 
2.4.5. Quantification of bacterial colonisation of biopsies 
Biopsies were transferred to microcentrifuge tubes and lysed in 1 mL 1% TX-
100 for 15 min at RT. The specimens were homogenised with a sterile pestle 
(Sigma), and vortexed. Serial dilutions of the lysate were plated on LB agar, 
and adherent bacteria were quantified by plate counting. 
 
105 
 
2.4.6. Preparation of biopsy lysates for cytokine analysis 
Biopsies were transferred to microcentrifuge tubes containing 250 µL ice cold 
lysis buffer (1% TX-100 and 0.5% protease inhibitor cocktail (Sigma) in PBS). 
Samples were incubated on ice for 5 min and homogenised with a sterile 
pestle. The lysate was centrifuged at 18,000 x g for 15 min at 4 °C to pellet 
insoluble proteins. The supernatant was removed and stored at -80 °C until 
further processing. 
 
2.5. Fluorescence staining 
2.5.1. Antibodies and dilutions 
The antibodies used in this study are listed in Table 2.2. 
 
Antigen Host species Dilution Source 
CmbA Rabbit 1:250 D. MacKenzie 
MUB Rabbit 1:250 D. MacKenzie 
Srr Rabbit 1:250 D. MacKenzie 
E. coli Goat 1:500 abcam 
NF-κB Rabbit 1:200 Santa Cruz 
MUC2 Mouse 1:250 Santa Cruz 
MUC5AC Rabbit 1:250 Santa Cruz 
    
Table 2.2: Primary antibodies used in this study 
 
All incubations with antibodies were performed at RT. 
 
2.5.2. Staining of adherent cell lines and tissue cryosections 
Slides containing cryosections were equilibrated to RT for 10 min, and sections 
were encircled with a PAP pen (Sigma) to prevent antibody crossover between 
sections. For mucus preservation, coverslips and cryosections were fixed with 
ice-cold methanol/ acetone (1:1; MeOH/ acetone) for 4 min on ice, and washed 
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once with PBS. For all other applications, fixation was performed in 3.7% 
formaldehyde in PBS (formalin) for 15 min at RT. All samples were stored at 
4 °C in PBS until further processing.  
Samples were incubated in 0.5% bovine serum albumin (BSA; Sigma), and 
0.1% TX-100 (formalin-fixed samples only) in PBS for 20 min to block non-
specific binding sites and permeabilise the cell membrane. All reagents were 
diluted in 0.5% BSA in PBS, as detailed in Table 2.2. Samples were washed 
once with PBS and incubated with the first primary antibody for 60 min at RT. 
Unbound antibody was removed by washing with PBS on a rocking platform 
for 10 min, and specimens were incubated with the secondary antibody for 30 
min in the dark. Secondary antibodies were either Alexa Fluor-488 or Alexa 
Fluor-568 (IgG; Life Technologies) and were used at a 1:400 dilution. Unbound 
antibody was removed by washing, and incubations in primary/ secondary 
antibodies were repeated with the remaining antibodies. If required, samples 
were counterstained with 4', 6-diamidino-2-phenylindole (DAPI; 1:5000; 
Roche) to label cell nuclei and/or fluorescein isothiocyanate (FITC)-
conjugated phalloidin (1:200; Sigma) to visualise filamentous actin and actin 
pedestals. Samples were washed for 40 min with a single PBS change, air-
dried for 5 min, and mounted in Vectashield (Vector Laboratories). Samples 
were stored at 4 °C in the dark until evaluation with a fluorescence microscope 
(Axiovert 200M or Axioimager M2, Zeiss). 
 
2.5.3. Analysis of fluorescence microscopy images 
To quantify EPEC actin pedestal and microcolony formation, images were 
taken from ten random fields of view at a set exposure time. EPEC were 
counted and each bacterium was classified on whether they were associated 
with an actin pedestal and whether they were contained in a microcolony (five 
or more bacteria grouped together). 
To quantify mucin protein in LS174T cells, images were taken at set exposure 
times and analysed using ImageJ, a public domain imaging software (Wayne 
Rasband, NIH). Protein levels were determined by measuring fluorescence 
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intensity by analysis of integrated density. To reduce background, 
fluorescence intensity was limited to a minimum threshold for inclusion in the 
analysis which was kept constant for all images within an experiment.  
 
2.6. Gene expression analysis using quantitative real time 
PCR (qPCR) 
2.6.1. RNA extraction 
Eukaryotic RNA from LS174T cells was extracted using the RNeasy Mini kit 
(Qiagen) with RNase-free tubes, tips, and reagents. Confluent LS174T cells 
were lysed with 350 µL RLT buffer, supplemented with 3.5 µL β-
mercaptoethanol (Sigma) to inhibit intrinsic RNases. Cells were detached by 
scraping with a pipette tip. The lysate was homogenised by vortexing for 10 
sec and stored at -80 °C until further processing. RNA extraction was 
performed according to the manufacturer’s protocol for “RNA extraction from 
animal cells using spin technology”. Genomic DNA was removed by “on-
column” digestion with DNase I as described in the manufacturer’s protocol. 
RNA was eluted in 30 µL RNase-free water and stored at -20 °C  
until further processing. 
 
2.6.2. Assessment of RNA quality by agarose gel 
electrophoresis and spectrophotometry 
RNA integrity was determined by agarose gel electrophoresis in 
Tris/Borate/EDTA (TBE) buffer (10x TBE:108 g Tris (Sigma), 55 g boric acid, 
and 40 mL 0.5 M EDTA, pH 8.0 (Sigma) in 1 L ddH2O). RNA samples were 
labelled with DNA nontox dye (PanReac AppliChem) separated in a 1% (w/v) 
agarose (Sigma) gel at 250 mA and 90 V for 30 min (Consort E863), and 
visualised using a U:Genius ultra violet gel imager (Syngene). RNA integrity 
was confirmed by identification of the 28S and the 18S ribosomal RNA 
subunits (Figure 2.3).  
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RNA quantity and purity was assessed with a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific). Protein contamination was evaluated 
by the ratio of absorbance at 260 nm and 280 nm with a value between 1.8 
and 2.0 considered acceptable. The ratio of absorbance at 230 nm and 260 
nm was used as a secondary measure to assess salt contamination, with a 
value between 1.5 and 2 considered acceptable. RNA quantity was 
determined by absorbance at 260 nm, and RNA concentrations were 
presented as ng/ µL. 
 
Figure 2.3: Representative image of intact RNA 
RNA degradation was assessed by agarose gel electrophoresis. Each lane 
represents an individual sample. 
 
2.6.3. cDNA synthesis 
Complementary DNA (cDNA) was synthesised from 1 µg RNA using the 
qScript cDNA supermix (Quanta Biosciences), according to the 
manufacturer’s instructions, and a thermal cycler (Biometra Professional Trio). 
A reverse transcriptase-negative (RT-) control, with no added cDNA supermix, 
was run alongside the cDNA synthesis to assess DNA contamination during 
qPCR analysis. cDNA was diluted at a ratio of 1:3 with sterile nanopure H2O 
and stored at 4 °C for up to 1 week or at -20 °C for long-term storage. 
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2.6.4. Primers used in this study 
 
Target 
gene Primer sequence 
Product 
size (bp) Reference 
MUC1 F 5’CGACGTGGAGACACAGTTCA 3’ 165 This Study 
R 5’AGAACACAGACCAGCACCAG 3’   
MUC2 F 5’ACTGCACATTCTTCAGCTGC 3’ 233 This Study 
R 5’ATTCATGAGGACGGTCTTGG 3’   
MUC3A F 5’ACCACCCTTACATCACGCAG 3’ 121 This Study 
R 5’AAGCACACTGTCCCTGTTCC 3’   
MUC5AC F 5’CTGGGGTCCTCATTCAGCAG 3’ 212 This Study 
R 5’CCCGAATTCCATGGGTGTCA 3’   
MUC6 F 5’GCTTCGTATTCGACGGCAAC 3’ 256 This Study 
R 5’ATGTCCACGACAAGGCTCAG 3’   
MUC12 
F 5’TGAAGGGCGACAATCTTCCTC 3’ 104 
(F) Moal et al. (2005) 
(R) This Study 
R 5’AGTGTAGTCTGCCTCCAGGAT 3’   
MUC13 F 5’TGTAAACACAGCCACCAACCA 3’ 158 This Study 
R 5’AAGTAGCTGTTGGGAAAGGTGT 3’   
MUC17 F 5’GTTTCAACACCACTGGCACC 3’ 122 This Study 
R 5’CTGGTCCCGGTACTCCACTA 3’   
IL-8 F 5'TTGAGAGTGGACCACACTGC 3' 98 Ou et al. (2009) 
R 5'TGCACCCAGTTTTCCTTGG 3'   
YWHAZ F 5'ACTTTTGGTACATTGTGGCTTCAA 3' 94 Jacob et al. (2013) 
R 5'CCGCCAGGACAAACCAGTAT 3'   
POLR2A F 5'GATGGGCAAAAGAGTGGACTT 3' 180 Schüller et al. (2009) 
R 5' GGGTACTGACTGTTCCCCCT 3'   
    
Table 2.3: Primers used in this study 
 
2.6.5. Primer design 
All primers selected for this study were based on publically available human 
gene sequences (http://www.ensembl.org/index.html) and supplied by Sigma 
Genosys. Primers were designed using the PrimerBLAST software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) with the following 
parameters: 
 Primer length: 15-25 base pairs (bp) 
 Melting temperature (Tm): 58 – 63 °C 
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 GC content: 20-80% 
 Self-complementarity: <8 
In addition, forward and reverse primers for a specific gene were designed 
to have a melting temperature within 2 °C of each other. When possible, 
the following additional parameters were employed:  
 Amplicon length: 80 – 250 bp 
 Amplicon GC content: <60% 
 Spanning of exon-intron boundaries 
Primers were evaluated for the formation of secondary structures and primer 
dimers using the Sigma design tool. Lyophilised oligonucleotides were 
resuspended in RNase-free water to a final concentration of 100 µM and 
stored at -20 °C. 
 
2.6.6. qPCR 
qPCR experiments were performed using SYBR® Green JumpStart™ Taq 
ReadyMix™ (SYBR) (Sigma). Each experiment was performed in a 96 well 
PCR plate (Sarstedt), with each well containing 5 µL SYBR Readymix, 1 µL 
primer solution (containing 10 µM forward and reverse primer), 0.1 µL internal 
reference dye, 1 µL cDNA, and 3 µL nanopure H2O. The plate was kept on ice 
during pipetting to prevent amplification before the start of the cycling protocol. 
Samples were run in duplicate for each gene tested. Corresponding RT- and 
non-template controls (without cDNA) controls were included for each primer 
pair to assess DNA contamination of RNA preparations and reagents, 
respectively. The plate was sealed with transparent sealing film (Sarstedt) and 
spun down using a swing-rotor centrifuge at 2000 x g for 1 min, to gather 
reagents at the base of the wells. The qPCR reaction was performed using an 
ABI7500 Taqman real-time PCR system (Applied Biosystems) with the 
following cycling parameters: 
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Stage 1 – 1 cycle 
 95 °C for 2 min – Initial denaturation 
Stage 2 – 40 cycles 
 95 °C for 30 sec – Denaturation 
 60 °C for 30 sec – Annealing 
 72 °C for 35 sec – Elongation 
Stage 3 – 1 cycle 
 72 °C for 5 min – Final elongation (for gel electrophoresis) 
Stage 4 – 1 cycle – Dissociation curve analysis 
 95 °C for 15 sec 
 65 °C for 60 sec 
 95 °C for 15 sec 
 60 °C for 15 sec 
Amplification and dissociation curves were analysed using Taqman SDS 
software. 
 
2.6.7. Primer validation 
Primer specificity was assessed by dissociation curve analysis (single peak) 
and agarose gel electrophoresis to determine product size. Primer efficiency 
was determined by amplifying two-fold serial dilutions (1:2 to 1:32) of template 
cDNA. Cycle threshold (CT) values were log transformed and plotted against 
dilutions, and the slope of the regression line was determined. Slopes of -3.0 
to -3.6 were considered acceptable, indicating 85 to 115% amplification 
efficiency according to the formula;  
Amplification efficiency = (10^(-1/slope-1)) *100. 
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2.6.8. Relative quantification of gene expression (ΔΔCT) 
The ΔΔCT method determines relative changes in gene expression between 
treated and non-treated samples (Livak & Schmittgen, 2001). CT values for the 
gene of interest (GOI) were normalised by subtraction of the geometric mean 
of the reference genes (YWHAZ and POLR2A), the normalised value referred 
to as ΔCT. To determine the relative change in gene expression (ΔΔCT) of the 
GOI, the non-treated ΔCT was subtracted from the ΔCT of the treated sample. 
Fold expression values were determined as follows: 
Fold-expression = 2–ΔΔCT 
 
2.7. Quantification of IL-8 expression by ELISA 
IL-8 production was quantified using the human IL-8 enzyme-linked 
immunosorbent assay (ELISA) development kit (Peprotech) according to the 
manufacturer’s instructions. Reactions were performed in Nunc Maxisorb 
immunoassay 96 well plates (Fisher Scientific), and colour development was 
quantified using a Benchmark Plus Microplate Spectrophotometer plate reader 
and Microplate Manager 5.2.1 software (Bio-Rad). IL-8 production in biopsy 
lysates was normalised against total protein content, determined using the DC 
protein colorimetric assay (Bio-Rad) according to the manufacturer’s protocol 
for microtitre plates. The standard curve was prepared with 0.1 – 0.5 µg/ mL 
BSA in lysis buffer and 10 µL of sample/standard were used for analysis.  
 
2.8. Statistical analysis 
All data are shown as means ± standard errors of the mean (SE). Statistical 
analysis was performed using GraphPad Prism software (version 5). Student’s 
T-test was used to determine differences between two groups. One-way 
ANOVA with Tukey’s multiple comparisons test was used to determine 
differences between multiple groups. Non-parametric Kruskal-Wallis with 
Dunn’s post hoc test was used for quantification of IL-8 production in biopsies. 
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All gene expression data were log10 transformed before statistical analysis. A 
P value of <0.05 was considered significant with degrees of statistical 
significance presented as follows: *=P<0.05, **=P<0.01, ***=P<0.001. 
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The work contained in this chapter was the basis of the following 
publication: 
 
Walsham, A. D., MacKenzie, D. A., Cook, V., Wemyss-Holden, S., Hews, C. 
L., Juge, N., & Schüller, S. (2016). Lactobacillus reuteri Inhibition of 
Enteropathogenic Escherichia coli Adherence to Human Intestinal 
Epithelium. Frontiers in microbiology, 7. 
(See Appendix 2) 
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3.1. Introduction and objectives of study 
Adhesion to the host is an important step in EPEC pathogenesis (Knutton et 
al., 1987). EPEC adhere to the epithelium by forming A/E lesions, which have 
been observed in both human in vitro and ex vivo models (Knutton et al., 1989; 
Knutton et al., 1987). A/E lesions are characterised by intimate attachment of 
EPEC to the host cell, effacement of underlying microvilli and the 
polymerisation of actin beneath the bacterium (Knutton et al., 1989; Moon et 
al., 1983). Formation of the A/E lesion reduces the absorptive surface and, 
alongside the effects of other T3S effector proteins, contributes to the onset of 
diarrhoea (Moon et al., 1983; Viswanathan et al., 2009). Therefore, inhibition 
of EPEC binding to the host provides an attractive target for prevention and 
treatment strategies. 
Probiotics offer a solution to inhibit pathogen binding, with those which 
persevere within the host being particularly valuable (Juge, 2012; 
Kleerebezem et al., 2010). Probiotic persistence in the GIT is seen as 
beneficial as this increases the interaction time between the host and the 
probiotic to deliver beneficial effects, such as competing with pathogens to 
reduce infection (Lebeer et al., 2008). To investigate probiotic-pathogen 
interaction, in vitro models have been developed which typically use three 
intervention protocols: pre-incubation of the probiotic before infection 
(protection), inoculation of pathogen and probiotic together (competition), and 
probiotic administration after infection (displacement). Protection assays 
simulate the use of probiotics as a preventative measure before infection, 
whereas displacement assays investigate the effect of probiotics after 
infection, resembling therapeutic intervention. Previous studies investigating 
the impact of lactobacilli on EPEC adherence to epithelial cell lines have 
demonstrated that pre- or co-incubation of live Lactobacillus spp. reduced 
EPEC binding (Bernet et al., 1994; Coconnier et al., 1993a; Forestier et al., 
2001; Sherman et al., 2005). In addition, non-viable lactobacilli have also 
shown antagonistic effects against diarrhoeagenic E. coli adhesion to 
intestinal cell lines (Chauvière et al., 1992b; Coconnier et al., 1993a; 
Coconnier et al., 1993b). Competitive exclusion has been suggested as one 
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mechanism responsible for the reduction in pathogen binding by probiotics, 
through both physical inhibition (steric hindrance) and competition for mutual 
binding sites (Chan et al., 1985). While the specific host receptors are 
generally undefined, carbohydrate-containing receptors have previously been 
linked to adhesion of lactobacilli and enteric pathogens to host cells 
(Adlerberth et al., 1996; Lee & Puong, 2002; Neeser et al., 2000). Interestingly, 
cell-surface adhesins isolated from L. crispatus and L. helveticus reduced S. 
Typhimurium, EIEC, EHEC, and EPEC binding to epithelial cells and 
extracellular matrix proteins, suggesting mutual receptors (Chen et al., 2007; 
Horie et al., 2002; Johnson-Henry et al., 2007).  
However, the accessibility of cell-surface receptors to probiotic bacteria in a 
healthy individual is uncertain, as the epithelium is covered by a thick layer of 
mucus (Atuma et al., 2001; Juge, 2012). The mucus layer of the GIT is the 
primary colonisation site for commensal bacteria, facilitating host-microbe and 
microbe-microbe interactions (Johansson et al., 2011a). Yet, most studies 
investigating adherence of probiotic bacteria and their interaction with 
pathogens have generally used non-mucus producing IECs, such as Caco-2, 
HT-29, and T84 cells (Navabi et al., 2013a; van Klinken et al., 1996). As these 
cell lines lack a functional mucus layer, the observed interactions may better 
represent a diseased state such as IBD, in which the mucus layer has been 
compromised, rather than the healthy mucosa prior to infection (Sheng et al., 
2012).  
In this study, we sought to determine the effects of L. reuteri on EPEC binding 
to the intestinal epithelium in the absence and presence of a mucus layer. For 
this, we selected the colon adenocarcinoma cell lines HT-29 and LS174T, as 
these cell lines represent the two interfaces for L. reuteri to exert an effect 
against EPEC binding; at the epithelial surface (HT-29) and in the mucus layer 
(LS174T). HT-29 cells resemble the enterocytes of the small intestine and 
produce MUC3, a membrane-bound mucin which is present in the small and 
large intestine (Mack et al., 2003), and have been used in a number of studies 
investigating inhibition of pathogen colonisation by lactobacilli (Candela et al., 
2008; Mack et al., 1999; Rousset, 1986; Zhang et al., 2010b). In contrast, 
LS174T cells are goblet cell-like and produce MUC2 and MUC5AC, the major 
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secreted mucins of the intestines and stomach, respectively (Kuan et al., 1987; 
van Klinken et al., 1996). In addition to cancer cell lines, the IVOC model was 
utilised with human duodenal biopsies. IVOC demonstrates greater 
physiological relevance to the GIT, as biopsies demonstrated the native gut 
structure and were covered by a representative mucus layer. While IVOC is 
considered the gold standard for the investigation into EPEC interaction with 
the intestinal epithelium, few studies have utilised this model for probiotic 
research (Collins et al., 2010). 
 
3.2. Results 
3.2.1. L. reuteri adhesion to HT-29 cells is strain specific 
To select adhering L. reuteri strains for further protection assays, several L. 
reuteri isolates, from human, pig, chicken, and rat (Table 2.1), were incubated 
with HT-29 cells for 1 h. Bacterial adhesion was initially evaluated by 
fluorescence microscopy using antibodies specific to L. reuteri adhesins. As 
shown in Figure 3.1A, adhesion varied between L. reuteri strains with the rat 
isolate 100-23C demonstrating minimal adhesion, with few bacteria attached 
to HT-29 cells, while the human strain ATCC PTA 6475 and the pig isolate 
ATCC 53608 displayed greater adhesion, with bacteria localised across the 
monolayer. We also observed that ATCC 53608 demonstrated 
aggregative properties.  
Bacterial binding to HT-29 cells was further quantified by plating out serial 
dilutions of cell lysates and counting colony forming units (CFU). Whereas 
ATCC 53608 demonstrated the highest adherence to HT-29 cells, the human 
strains ATCC PTA 6475 and DSM 20016 exhibited similar adhesion as EPEC 
and isolates ATCC 55730 and LB54, from human and chicken respectively, 
exhibited the lowest binding potential (Figure 3.1B). As the strains with the 
greatest binding, we selected ATCC PTA 6475 and ATCC 53608 for further 
analysis. Additionally, these L. reuteri isolates showed distinct binding 
patterns, as aggregates of ATCC 53608 were bound to individual HT-29 cells. 
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In contrast, fewer ATCC PTA 6475 were bound to individual cells, but these 
bacteria were more dispersed across the epithelial surface.  
 
 
Figure 3.1: L. reuteri adhesion to HT-29 cells is strain specific 
HT-29 cells were incubated with various L. reuteri strains and EPEC for 1 h. 
Adherent bacteria were observed by immunofluorescence staining (A) and 
quantified by plate counting (B). (A) ATCC PTA 6475, ATCC 53608 and 100-
23C were stained with antisera specific to the adhesins CmbA, MUB, and SRR 
respectively (red) while cell nuclei were labelled with DAPI (blue). Images are 
representative of three independent experiments performed in duplicate. 
Scale bars = 10 µm. (B) Bacterial adhesion is expressed as a percentage 
relative to the inoculated dose. Data are shown as means ± standard error of 
the mean (SE) of three independent experiments performed in duplicate.  
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3.2.2. Mucus binding proteins increase L. reuteri adhesion to 
HT-29 and LS174T cells 
The role of L. reuteri adhesins, such as CmbA (ATCC PTA 6475) and MUB 
(ATCC 53608), has previously been investigated, and binding to mucus 
(CmbA and MUB) and Caco-2 cells (CmbA) has been demonstrated (Jensen 
et al., 2014; MacKenzie et al., 2010). We aimed to identify the importance of 
the adhesins CmbA and MUB in binding to mucus-producing LS174T and 
mucus-deficient HT-29 cells. The presence of MUC2 was investigated in both 
cell lines by immunofluorescence staining, which demonstrated that MUC2 
was only expressed in LS174T cells (Figure 3.2A). 
To investigate the role of CmbA and MUB in L. reuteri adhesion to mucus and 
the epithelium, LS174T and HT-29 cells were incubated with ATCC PTA 6475, 
ATCC 53608, and isogenic adhesin deletion mutants (ATCC PTA 6475 CmbA- 
and ATCC 53608 MUB-) for 1 h. Quantification of adhered bacteria revealed 
that the absence of MUB significantly reduced adherence to HT-29 and 
LS174T cells (Figure 3.2B). We also observed a reduction in the binding of the 
CmbA- mutant relative to the wildtype strain, but this did not reach significance. 
Furthermore, the adhesion of all strains to LS174T cells was significantly 
higher than HT-29 cells. 
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Figure 3.2: Mucus binding proteins enhance L. reuteri adhesion to HT-29 
and LS174T cells 
(A) Immunofluorescence staining confirmed production of MUC2 (green) in 
LS174T but not HT-29 cells. Cell nuclei were stained with DAPI (blue). Images 
are representative of three independent experiments performed in duplicate. 
Scale bar = 10 µm. 
(B) EPEC, L. reuteri ATCC PTA 6475, ATCC 53608, or isogenic adhesin 
mutants (ATCC PTA 6475 CmbA- and ATCC 53608 MUB-) were incubated 
with HT-29 and LS174T cells for 1 h. Adhesion of bacteria is expressed as a 
percentage relative to the inoculated dose. Data are shown as means ± SE of 
three independent experiments performed in duplicate.  ** = P <0.01. 
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3.2.3. L. reuteri inhibits EPEC adhesion to HT-29, but not 
LS174T cells 
To investigate the effect of L. reuteri on EPEC adhesion, we pre-incubated 
HT-29 and LS174T cells with L. reuteri before EPEC infection. To determine 
the pre-treatment period for further experiments, HT-29 cells were pre-
incubated with a 100x excess of L. reuteri for 1 or 3 h before addition of EPEC 
for 1 h. EPEC adhesion was assessed by plate counting. As shown in Figure 
3.3A, pre-treatment of HT-29 cells with L. reuteri ATCC PTA 6475 and ATCC 
53608 for 1 and 3 h significantly inhibited EPEC adhesion. As the protective 
effect did not significantly change between the 1 and 3 h pre-treatment, we 
used a 1 h pre-incubation for further experiments. We then determined the 
minimal dose required to inhibit EPEC binding by pre-incubating HT-29 cells 
with a 100x, 10x or 1x (equivalent numbers) excess of L. reuteri, relative to the 
EPEC inoculum, before infecting with EPEC for 1 h. While 100x excess of 
ATCC PTA 6475 or ATCC 53608 significantly inhibited EPEC adhesion, no 
effect was observed with a 10x or 1x excess of L. reuteri (Figure 3.3B). In 
contrast to HT-29 cells, pre-treatment with a 100x L. reuteri excess did not 
significantly reduce EPEC binding to LS174T cells (Figure 3.3C).  
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Figure 3.3: L. reuteri pre-incubation inhibits EPEC adhesion to HT-29, but 
not LS174T cells 
(A) HT-29 cells were pre-incubated with a 100x excess of L. reuteri ATCC PTA 
6475, ATCC 53608, or left untreated (-) for 1 h or 3 h before EPEC was added 
for 1 h. Cell-associated EPEC were quantified by plate counting and adhesion 
was expressed as a percentage relative to the EPEC inoculum. Data are 
shown as means ± SE of three independent experiments performed in 
duplicate.  * = P <0.05; ** = P <0.01. 
(B) HT-29 cells were pre-incubated with a 100x, 10x or 1x (equivalent 
numbers) excess of L. reuteri ATCC PTA 6475, ATCC 53608 or left untreated 
(-) for 1 h before the addition of EPEC for 1 h. Cell-associated EPEC were 
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quantified by plate counting, and adhesion was expressed relative to 
inoculated EPEC. Data are shown as means ± SE of three independent 
experiments performed in duplicate.  * = P <0.05. 
(C) LS174T cells were pre-incubated with a 100x excess of L. reuteri ATCC 
PTA 6475, ATCC 53608, or left untreated (-) for 1 h before the addition of 
EPEC for 1 h. Cell-associated EPEC were quantified by plate counting, and 
adhesion was expressed relative to inoculated EPEC. Data are shown as 
means ± SE of three independent experiments performed in duplicate. 
 
To determine whether inhibition of EPEC adhesion to HT-29 cells by L. reuteri 
was dependent on L. reuteri adhesion to the epithelium, HT-29 cells were 
incubated with a 100x excess of L. reuteri for 2 h (total incubation time of L. 
reuteri and HT-29 cells in previous experiments) and washed to remove 
unbound bacteria before the addition of EPEC for 1 h. In addition, the effect of 
L. reuteri secreted products on EPEC adherence was investigated by 
incubating HT-29 cells with L. reuteri-conditioned cell culture medium (DMEM 
pre-incubated with L. reuteri for 2 h) before infection with EPEC for 1 h. As 
shown in Figure 3.4, EPEC binding was not significantly reduced by adherent 
L. reuteri or conditioned medium.  
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Figure 3.4: Inhibition of EPEC adhesion is independent of adherent L. 
reuteri and secreted anti-microbial compounds 
HT-29 cells were exposed to the following treatments before incubation with 
EPEC for 1 h: L. reuteri for 1 h (total LR), L. reuteri for 2 h and subsequent 
removal of non-adherent bacteria (adherent LR), L. reuteri-conditioned 
medium for 2 h (supernatant), or non-treated (-). Cell-associated EPEC were 
quantified by CFU and adhesion was expressed as a percentage relative to 
inoculated EPEC. Data are shown as means ± SE of three independent 
experiments performed in duplicate.  * = P <0.05. 
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3.2.4. L. reuteri ATCC 53608 decreases EPEC viability  
in co-culture 
While secreted products from L. reuteri did not affect EPEC adherence, we 
further investigated whether L. reuteri or its secreted products reduced EPEC 
viability. A 100x excess of L. reuteri or L. reuteri-conditioned cell culture 
medium was pre-incubated for 1 h in cell-free wells before the addition of 
EPEC for 1 h. While incubation with ATCC PTA 6475 or conditioned media did 
not affect the number of EPEC recovered, incubation with ATCC 53608 
demonstrated a reduction in recovered EPEC, although this did not reach 
significance (Figure 3.5A).  
As described in previous studies (MacKenzie et al., 2010) and demonstrated 
in Figure 3.1A, ATCC 53608 forms autoaggregates mediated by the adhesin 
MUB. This property may have caused the reduced EPEC CFU counts 
observed in the previous assay by “trapping” EPEC bacteria within bacterial 
clusters. To investigate this hypothesis, co-culture experiments were repeated 
with ATCC 53608 MUB-, which does not aggregate (Figure 3.5B). In addition, 
some co-cultures were treated with TX-100, the detergent we used to lyse the 
HT-29 and LS174T cell monolayers, at the end of the experiment to determine 
whether TX-100 affected aggregate formation or EPEC recovery. As shown in 
Figure 3.5C, co-incubation with ATCC 53608 or the MUB-deficient mutant 
significantly decreased the recovery of EPEC. In addition, TX-100 treatment 
did not impact on EPEC growth or ATCC 53608-mediated reduction of EPEC 
retrieval. 
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Figure 3.5: Co-incubation with L. reuteri ATCC 53608 reduces EPEC 
recovery independent of aggregate formation 
(A) L. reuteri ATCC PTA 6475, ATCC 53608 (100x excess), conditioned 
medium, or untreated medium was pre-incubated for 1 h before the addition 
of EPEC for 1 h. Recovered EPEC were quantified by plate counting and 
expressed as a percentage relative to the number of inoculated bacteria. Data 
are shown as means ± SE of three independent experiments performed in 
duplicate.  
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(B) Phase contrast images of L. reuteri ATCC 53608 wildtype and ATCC 
53608 MUB-. Images are representative of three independent experiments 
performed in duplicate. Scale bars = 10 µm. 
(C) L. reuteri ATCC 53608 wildtype or a MUB-deficient mutant (53608 MUB-) 
were pre-incubated for 1 h before the addition of EPEC for 1 h. At the end of 
the experiment, some co-cultures were treated with TX-100, and EPEC were 
quantified by plate counting. Recovered EPEC are expressed as a percentage 
relative to the number of inoculated EPEC. Data are shown as means ± SE of 
three independent experiments performed in duplicate. Asterisks denote a 
significant difference from EPEC only control.  ** = P <0.01; *** = P <0.001 
 
3.2.5. Adherent L. reuteri ATCC PTA 6475 inhibit EPEC 
adhesion to HT-29 but not LS174T cells 
In our previous experiments, we did not observe inhibition of EPEC binding to 
HT-29 cells by adherent L. reuteri after 2 h incubation (Figure 3.4). However, 
after a 1 h incubation, few L. reuteri were bound to HT-29 cells (Figure 3.1A). 
To increase L. reuteri adhesion, incubations were extended to 4 and 6 h, and 
adhesion was assessed by immunofluorescence. Whereas binding of L. 
reuteri was similar after 4 or 6 h incubation (data not shown), detachment of 
HT-29 and LS174T cell monolayers increased with longer incubations. 
Therefore, a 4 h pre-incubation period was selected for further studies. 
As shown in Figure 3.6A, L. reuteri ATCC PTA 6475 and ATCC 53608 
extensively adhered to LS174T cells, while binding to HT-29 cells was less 
pronounced. In addition, aggregate formation of ATCC 53608 was evident on 
HT-29 cells, as previously observed (Figures 3.6A). Having established 
efficient L. reuteri adherence, the protection assay was modified. Cells were 
pre-incubated with L. reuteri (100x excess) for 4 h, non-adherent L. reuteri 
were removed, and EPEC were added for 1 h. Results demonstrated in Figure 
3.6B showed that adherent ATCC PTA 6475, but not ATCC 53608, 
significantly inhibited EPEC adherence to HT-29 cells. In contrast, no effect 
was observed in LS174T cells (Figure 3.6B).  
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Figure 3.6: Adherent L. reuteri ATCC PTA 6475 inhibit EPEC binding to 
HT-29 but not LS174T cells 
(A) Confluent HT-29 and LS174T cells were incubated with ATCC PTA 6475 
or ATCC 53608 for 4 h. Adherent L. reuteri (green) were visualised by 
immunofluorescence microscopy. Cell nuclei were counterstained with DAPI 
(blue). Colour channels are merged for HT-29 whereas only the green channel 
is shown on LS174T cells, to improve clarity of L. reuteri. Images are 
representative of three independent experiments performed in duplicate. 
Scale bars = 10 µm. 
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(B) HT-29 and LS174T cells were pre-incubated with ATCC PTA 6475, ATCC 
53608 (100x excess), or left untreated (-) for 4 h. Non-adherent bacteria were 
removed and EPEC were added for 1 h. Cell-bound EPEC were quantified by 
plate counting, and adhesion was expressed as a percentage relative to 
inoculated EPEC. Data are shown as means ± SE of three independent 
experiments performed in duplicate.  * = P <0.05. 
 
3.2.6. Pre-incubation with L. reuteri ATCC PTA 6475 increases 
the formation of EPEC microcolonies on LS174T cells 
As LS174T cells produce mucus, CFU counts in cell lysates may not provide 
an accurate measure of EPEC adherence to the epithelial surface. To 
differentiate between mucus- and cell surface-bound bacteria, we utilised the 
fluorescent actin staining test to identify actin pedestal formation, a 
characteristic of A/E lesion formation (Figure 3.7A). EPEC were incubated with 
LS174T cells for 3 h to enable pedestal formation, and total EPEC and EPEC 
associated with pedestals were quantified by immunofluorescence microscopy 
and counting. While pre-treatment with L. reuteri did not influence EPEC A/E 
lesion formation (Figure 3.7B), more prominent clusters of EPEC were 
observed in LS174T cells pre-incubated with ATCC PTA 6475 (Figure 3.7C). 
Quantification of EPEC contained within these microcolonies confirmed that 
significantly more EPEC were located in microcolonies after pre-incubation 
with ATCC PTA 6475 compared to ATCC 53608- and non-treated  
cells (Figure 3.7D). 
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Figure 3.7: Adherent ATCC PTA 6475 enhance EPEC microcolony 
formation in LS174T cells 
(A) LS174T cells were incubated with EPEC (red) for 3 h. Actin pedestal 
formation was visualised by immunofluorescence staining for filamentous actin 
(green) and E. coli (red). Image representative of four independent 
experiments performed in duplicate. Scale bar = 10 µm. 
(B) Quantification of EPEC associated with actin pedestals. LS174T cells were 
pre-incubated with ATCC PTA 6475, ATCC 53608 or left untreated (-) for 4 h, 
and EPEC were added for 3 h. Pedestal formation was expressed as a 
percentage relative to the total number of adherent EPEC. Data are shown as 
means ± SE of four independent experiments performed in duplicate. 
(C) Pre-incubation of LS174T cells with ATCC PTA 6475 increased EPEC 
microcolony formation compared to untreated cells (-). EPEC were visualised 
by immunofluorescence staining and are shown in black and white to increase 
clarity. Image is representative of four independent experiments performed in 
duplicate. Scale bars = 10 µm.  
(D) Quantification of EPEC microcolony formation (five or more bacteria). 
EPEC contained within microcolonies were expressed as a percentage 
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relative to the total number of adherent EPEC observed. Data are shown as 
means ± SE of four independent experiments performed in duplicate.  *** = P 
<0.001 
 
3.2.7. L. reuteri is localised in the mucus layer of human 
duodenal biopsies 
While cultured cells are a useful tool in the assessment of host-microbe 
interactions, these cell lines lack the complex epithelial structure formed from 
multiple cell types (Law et al., 2013). Thus, findings using cultured cells require 
further validation in more physiologically relevant model systems, such as 
IVOC. Therefore, to further investigate bacterial binding to the human intestinal 
mucosa, duodenal biopsies were inoculated with L. reuteri ATCC PTA 6475, 
ATCC 53608, or EPEC for 8 hours, and colonisation was assessed by 
scanning electron microscopy (SEM). To distinguish between bacterial 
localisation in the mucus layer and at the epithelial surface, biopsies were fixed 
with either the mucus layer present or removed to reveal the epithelium. We 
identified that EPEC were localised in the mucus layer and at the epithelial 
surface of the biopsy, with prominent A/E lesion formation and microvillous 
elongation across the villous surface (Figure 3.8A). In contrast, both L. reuteri 
strains were located exclusively in the mucus layer, with no apparent binding 
to the epithelium (Figure 3.8A, images shown for ATCC PTA 6475 only). This 
was confirmed by immunofluorescence staining of cryosections, which 
demonstrated that L. reuteri were restricted to the mucus layer (Figure 3.8B). 
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Figure 3.8: L. reuteri localise to the mucus layer of human duodenal 
biopsies 
(A) SEM of duodenal biopsies incubated with L. reuteri ATCC PTA 6475 or 
EPEC for 8 h. Biopsies were fixed with the mucus layer present (mucus) or 
washed to allow visualisation of the epithelium (epithelium). Images are 
representative of three independent experiments performed in duplicate. 
(B) Fluorescence microscopy of duodenal biopsies incubated with L. reuteri 
ATCC PTA 6475 for 8 h. Cryosections were stained for MUC2 (green), ATCC 
PTA 6475 (red) and cell nuclei (blue). Images are representative of three 
independent experiments performed in duplicate. Scale bars = 10 µm. 
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3.2.8. Pre-incubation with L. reuteri inhibits EPEC colonisation 
of the intestinal epithelium by polarised IVOC 
To quantify EPEC adherence to the duodenal biopsy epithelium, a polarised 
IVOC (pIVOC) model restricting bacterial access to a defined mucosal surface 
area was used (Schüller et al., 2009). The time period of EPEC infection was 
optimised to enable sufficient colonisation of the epithelium without epithelial 
shedding. Biopsies were infected for 6 to 8 h, and EPEC colonisation and 
epithelial integrity were assessed by SEM. While no epithelial shedding was 
observed on non-infected controls (8 h incubation), substantial shedding of the 
epithelium occurred after 7 and 8 hours of EPEC infection (Figure 3.9). In 
contrast, epithelial integrity was maintained after 6 h of infection (Figure 3.9), 
and this period was chosen for further pIVOC experiments. 
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Figure 3.9: EPEC colonisation of human duodenal biopsy epithelium in 
pIVOC 
Biopsies were infected with EPEC or left non-infected for 6 to 8 h and 
examined by SEM. The epithelium was preserved on both uninfected (8 h) and 
biopsies incubated with EPEC for 6 h, demonstrated by the discernible brush 
border. However, shedding of the biopsy epithelium and exposure of the 
basement membrane was observed after 7 and 8 h of EPEC infection. Images 
are representative of eight independent experiments performed in duplicate. 
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3.2.9. L. reuteri reduces EPEC colonisation of human 
duodenal biopsy epithelium 
To investigate the influence of L. reuteri on EPEC colonisation ex vivo, 
duodenal biopsies were pre-incubated with 50x excess of ATCC PTA 6475, 
ATCC 53608, or left untreated (-) for 2 h. After removal of non-adherent L. 
reuteri, biopsies were infected with EPEC for 4 h. At the end of the experiment, 
the mucus layer was removed by washing and EPEC colonisation of the 
epithelium was quantified by plating out biopsy lysate and determining CFUs. 
Our data revealed a significant reduction in EPEC colonisation by L. reuteri 
compared to non-treated biopsies (Figure 3.10). 
 
Figure 3.10: L. reuteri ATCC PTA 6475 and ATCC 53608 significantly 
inhibit EPEC colonisation of duodenal biopsy epithelium 
Duodenal biopsies were pre-incubated with ATCC PTA 6475, ATCC 53608, 
or left untreated (-) for 2 h, non-adherent bacteria were removed, and EPEC 
were added for 4 h. Cell-bound EPEC were quantified by plate counting and 
adhesion is presented as EPEC CFU/ biopsy. Data are shown as means ± SE 
of four independent experiments performed in duplicate. * = P <0.05; ** = P 
<0.01. 
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3.3. Discussion 
The colonisation efficacy of probiotic bacteria is often assessed using 
epithelial cancer cell lines (Joint FAO/WHO Working Report, 2002; Vélez et 
al., 2007). However, most of these cell lines lack a functional mucus layer 
which is likely to impact on bacterial binding, as the mucus layer is the primary 
habitat for commensal bacteria (Johansson et al., 2008; Navabi et al., 2013a). 
In this study, we examined the effects of L. reuteri on EPEC colonisation of the 
human intestinal epithelium using enterocyte- and goblet cell-like cell lines as 
well as human duodenal biopsies as models of human infection. Through this 
investigation, we aimed to develop our understanding of probiotic-pathogen 
interaction and evaluate the probiotic potential of L. reuteri.  
 
3.3.1. Influence of L. reuteri strain selection on epithelial 
adhesion 
In this study, we demonstrated that L. reuteri binding to HT-29 cells is strain-
dependent. This is consistent with previous findings, which have emphasised 
the importance of strain specificity when investigating Lactobacillus adhesion 
to IECs (Chauviere et al., 1992a; Tuomola & Salminen, 1998). One study 
identified variable adhesion efficacy between a selection of Lactobacillus 
species to HT-29 cells, with strain-specific cell surface molecules aiding L. 
reuteri adhesion (Wang et al., 2008). These cell surface molecules may have 
evolved due to adaptation of lactobacilli to their local environment (Frese et 
al., 2011). Niche adaptation has previously been documented in L. reuteri, as 
genomic clades which contain adhesins that enhance adhesion to the host 
organism have been identified in strains isolated from humans, rodents, and 
pigs (Oh et al., 2010; Wegmann et al., 2015). Supporting previous studies, 
deletion of host-specific adhesin genes in the rodent strain L. reuteri 100-23 
diminished colonisation of Lactobacillus-free mice (Frese et al., 2011). 
Therefore, the presence of specific adhesins in L. reuteri provides a rationale 
for the selection of candidate probiotics. However, adhesion studies are 
required to confirm binding efficacy.  
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Interestingly, ATCC 53608, a porcine isolate, demonstrated the highest 
adherence of the L. reuteri strains examined. Similarities between the porcine 
and human GIT (Heinritz et al., 2013) may account for this characteristic, and 
thus the porcine gut may provide an additional avenue for the isolation of novel 
probiotic strains. It is important to note the ecological variation within the 
porcine and human GIT however, with numerous Lactobacillus species 
forming biofilm layers directly contacting the squamous epithelium of the pig 
stomach (Fuller et al., 1978). Within humans, no such niche has been 
identified and relatively few Lactobacillus species are thought to be persistent 
in the GIT (Walter, 2008). Efficient adhesion of ATCC 53608 to human IECs 
may be linked to the formation of aggregates mediated by the MUB protein, 
as ATCC 53608 MUB- did not aggregate and showed diminished adherence 
to IEC’s (MacKenzie et al., 2010; Wadstroum et al., 1987).  
L. reuteri strains ATCC PTA 6475, DSM 20016, and LMS11-3, originally 
isolated from human hosts, demonstrated comparable binding to HT-29 cells, 
whereas human strain ATCC 55730 showed reduced adhesion. These 
findings are supported by previous studies, which demonstrated high 
adherence of ATCC PTA 6475 (referred to as MM4-1a) and DSM 20016 to 
HT-29, Caco-2, and LS174T cells, whereas the ATCC 55730-derived strain 
DSM 17938 showed reduced binding (Jensen et al., 2012). Interestingly, 
ATCC 55730 is currently marketed as a dietary supplement, and previous 
studies have demonstrated colonisation of the stomach and duodenum of 
human volunteers, suppression of Helicobacter pylori infection, and reduction 
of diarrhoeal episodes in children (Francavilla et al., 2008; Valeur et al., 2004; 
Weizman et al., 2005). Therefore, the lack of correlation between in vitro and 
in vivo data suggests that probiotic screening with cell line models requires 
further validation with more physiologically relevant model systems. 
Mucus binding proteins (MBPs) facilitate adhesion of lactobacilli to the host 
(reviewed in Juge (2012); Lebeer et al. (2008); Van Tassell and Miller (2011); 
Vélez et al. (2007)) and have been identified within a range of Lactobacillus 
species, such as the L. rhamnosus GG SpaCBA pillin (Kankainen et al., 2009) 
and the L. reuteri 104R surface protein MapA (Miyoshi et al., 2006; Rojas et 
al., 2002). MBPs typically consist of a sorting peptide, an LPxTG motif in the 
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C-terminus (anchoring the MBP to the bacterial cell wall), and multiple repeats 
of the mucus binding domain mub, which shares homology with the bacterial 
mucin binding protein domain Pfam-MucBP, a sequence located in a number 
of L. monocytogenes proteins (Boekhorst et al., 2006; Juge, 2012). The MUB 
protein of ATCC 53608 and the CmbA protein of ATCC PTA 6475 have been 
characterised as MBPs which mediate adhesion to mucus and the epithelium 
in vitro (Etzold et al., 2014a; Jensen et al., 2014; Roos & Jonsson, 2002). In 
our study, we identified that MUB and CmbA enhanced L. reuteri binding to 
both mucus-secreting LS174T cells and mucus-deficient HT-29 cells. As HT-
29 cells have been shown to express cell-bound MUC3 when stimulated by L. 
rhamnosus GG and L. plantarum 299v, this may suggest a potential receptor 
for L. reuteri binding (Mack et al., 2003).  
While CmbA and MUB enhance L. reuteri adhesion, ATCC PTA 6475 CmbA- 
and ATCC 53608 MUB- still partially bound to LS174T cells. This finding 
suggests that additional cell surface proteins may contribute to the adhesion 
of these L. reuteri strains to mucus. One study identified three L. acidophilus 
NCFM cell surface proteins, FbpA, Mub, and SlpA, which contributed to 
adhesion to Caco-2 cells (Buck et al., 2005). Furthermore, these binding 
proteins may be multifactorial in purpose, with additional roles to cellular 
adhesion. The elongation factor Tu protein of L. johnsonii La1, a guanosine 
nucleotide protein which assists protein synthesis in the cytoplasm, has been 
identified as an adhesin-like molecule on the bacterial cell surface (Granato et 
al., 2004). While our findings are supported by these studies, the presence of 
additional adhesins on L. reuteri ATCC PTA 6475 requires  
further investigation.  
We further observed increased adhesion of L. reuteri and EPEC to LS174T 
compared to HT-29 cells, suggesting that mucus enhanced microbial binding. 
This is in agreement with our data on duodenal biopsies, which demonstrated 
L. reuteri localisation to the mucus. Previous studies have demonstrated 
increased binding of L. rhamnosus GG, L. johnsonii La1, and L. bulgaricus 
ATCC 11842 human intestinal mucus compared to resected human colonic 
tissue (Ouwehand et al., 2002). Put together with our data, these findings 
suggest preferential lactobacilli binding to mucus, potentially due to MBPs 
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such as MUB and CmbA. While further investigation is required to confirm that 
enhanced L. reuteri binding to LS174T cells is mediated by the adhesion of 
MBPs to mucins, these findings support the use of mucus-producing models 
when investigating probiotic adhesion 
 
3.3.2. Influence of L. reuteri on EPEC adherence in vitro 
In this study, we report that L. reuteri ATCC PTA 6475 and ATCC 53608 
significantly inhibit EPEC adhesion to HT-29 cells. One mechanism of 
pathogen inhibition is competitive exclusion, where probiotics compete with a 
pathogen to access binding sites on the epithelial surface. Previous reports 
investigating competitive exclusion have suggested that either pre-incubation 
of the probiotic or co-incubation with the pathogen is required, as pathogen 
displacement is uncommon (Lebeer et al., 2008). One study investigating pre-
incubation, co-incubation, and displacement of DAEC and ETEC binding by L. 
acidophilus La1 demonstrated that inhibition of E. coli binding to Caco-2 cells 
was only achieved during protection and co-incubation studies (Bernet et al., 
1994). A similar study investigating the effect of L. salivarius and L. plantarum 
on S. aureus adhesion to Caco-2 cells identified that only pre-incubation and 
competition assays inhibit S. aureus binding (Ren et al., 2012). As previous 
reports have demonstrated successful inhibition of pathogenic E. coli adhesion 
by pre-incubation with Lactobacillus species (Bernet et al., 1994; Coconnier et 
al., 1993a), we selected this intervention protocol for our study. 
We initially investigated the influence of L. reuteri pre-incubation time on EPEC 
binding. We determined that 1 and 3 hour pre-incubation of L. reuteri inhibited 
EPEC adhesion to HT-29 cells. A previous study identified that 1 hour pre-
incubation of L. acidophilus ATCC 4356 and S. thermophilus ATCC 19258 
significantly inhibited EIEC adhesion to Caco-2 cells (Resta-Lenert & Barrett, 
2003). Longer pre-incubation periods have also been reported, with 6 hour 
pre-incubation of either L. acidophilus R0052 or L. rhamnosus R0011 inhibiting 
both EPEC and EHEC adhesion to polarised T84 cells (Sherman et al., 2005). 
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Previous studies investigating the protective effects of lactobacilli on EPEC 
adhesion to non-mucus producing IECs have found different dosage 
requirements with equivalent numbers of L. acidophilus La1 inhibiting EPEC 
adherence to Caco-2 cells (Bernet et al., 1994; Coconnier et al., 1993a). 
Interestingly, the study by Coconnier et al. (1993a) also found that pre-
incubation with heat-killed L. acidophilus decreased EPEC binding too Caco-
2 cells, although a 10-fold excess was required for this effect. Similarly, EPEC 
binding to polarised T84 cells was reduced by L. acidophilus and L. rhamnosus 
when pre-incubated at 10x and 1,000x excess, respectively (Sherman et al., 
2005). Furthermore, L. rhamnosus and a selection of L. acidophilus strains 
inhibited EHEC adherence to HT-29 cells when incubated at 1,000x excess 
(Kim et al., 2008). Thus, our findings that a 100-fold excess of L. reuteri 
reduced EPEC binding agree with other studies investigating the protective 
characteristics of Lactobacillus. 
It has been demonstrated that lactobacilli produce anti-microbial compounds 
(Servin, 2004). Some L. reuteri strains, including ATCC PTA 6475 and ATCC 
53608, produce the antimicrobial compound reuterin from glycerol, which 
inhibits a broad spectrum of bacterial species, including E. coli (Spinler et al., 
2008; Talarico et al., 1988). Furthermore, lactic acid produced by L. casei 
Shirota and L. acidophilus YIT 0070 has bacteriostatic and bactericidal effects 
on EHEC (Ogawa et al., 2001). However in our study, EPEC adherence was 
not affected by L. reuteri-conditioned medium, which suggests that neither 
lactic acid nor reuterin are responsible for the suppression of EPEC binding. 
We further investigated the interaction between L. reuteri and EPEC in the 
absence of HT-29 cells, to determine the effect of L. reuteri on EPEC viability. 
We observed that co-incubation with ATCC 53608 wildtype and a MUB-
deficient mutant decreased EPEC viability independently of secreted products. 
With these initial experiments, we were unable to identify a specific 
mechanism behind this reduction in EPEC viability. However, further studies 
could investigate whether this effect is dependent on live bacteria and whether 
this effect is constitutive or a specific response to competitor bacteria. 
Competitive binding of probiotics to pathogen cell surface receptors has also 
been suggested as an inhibitory mechanism. One study found that EPEC 
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adherence to HT-29 cells was inhibited by L. plantarum 299v, but not by an L. 
plantarum 299v mutant deficient in a mannose-specific adhesin (Mack et al., 
2003). The loss of this adhesin may have prevented the competitive exclusion 
of EPEC from shared receptors, as EPEC produces mannose-sensitive type I 
fimbriae (Adlerberth et al., 1996; Knutton et al., 1987). However, it should be 
noted that the role of type I fimbriae in EPEC host cell binding is currently 
undefined (Elliott & Kaper, 1997). In contrast to these previous findings, during 
our short-term protection assays, L. reuteri bound to the epithelium were 
unable to reduce EPEC adherence. As we only observed a protective effect 
when non-adherent L. reuteri were maintained, these findings suggest that L. 
reuteri exclude EPEC by steric hindrance, where L. reuteri cells impede EPEC 
access to the epithelial surface, during short-term pre-incubations (Chan et al., 
1985). 
In contrast to HT-29 cells, L. reuteri did not affect EPEC adhesion to LS174T 
cells during short-term protection assays. Previous studies on pathogen-
probiotic interaction within mucus have shown that a 1 hour pre-incubation of 
L. casei Shirota and L. johnsonii LJ1 reduced S. Typhimurium adhesion to 
immobilised human mucus (Tuomola et al., 1999). This effect appeared to be 
species-specific as a selection of L. rhamnosus strains had either no effect or 
significantly increased S. Typhimurium adhesion (Tuomola et al., 1999). 
Similarly, the probiotic E. coli Nissle 1917 reduced EHEC binding when co-
cultured for 2 hours with LS174T cells (Rund et al., 2013). This difference to 
our observations is likely due to alternative experimental conditions, such as 
the probiotic species investigated and the models used. It is currently not 
known why L. reuteri did not inhibit EPEC access to LS174T cells although the 
presence of additional binding sites in the secreted mucus is one potential 
explanation.  
As we observed low levels of L. reuteri binding to the epithelium during short-
term protection assays, we modified the cell culture model to investigate the 
impact of adherent L. reuteri on EPEC binding by increasing the pre-incubation 
period to 4 hours, and removing non-bound L. reuteri. Interestingly, we 
observed a reduction in EPEC adherence to HT-29 cells after pre-incubation 
with ATCC PTA 6475, but not ATCC 53608. This difference may be associated 
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with the strain-specific adherence characteristics. While ATCC PTA 6475 
binding was uniformly distributed across the epithelial surface, aggregates of 
ATCC 53608 were associated with fewer cells thus potentially blocking fewer 
EPEC binding sites. 
Surprisingly, neither L. reuteri strain inhibited EPEC binding to LS174T cells 
when pre-incubated for 4 h, despite higher adherence to this cell line. As 
LS174T cells produce mucus, EPEC may access additional binding sites 
within the mucus layer, and the EPEC flagellum has previously been shown to 
increase binding to bovine mucus (Erdem et al., 2007). To differentiate 
between EPEC binding to mucus and the cell surface epithelium, we adapted 
the infection protocol to enable actin pedestal formation, a marker of epithelial 
adhesion, which can be detected by fluorescence microscopy (Moon et al., 
1983; Viswanathan et al., 2009). However, we found no significant difference 
in the number of cell-bound EPEC on LS174T cells pre-treated with either L. 
reuteri strain compared to non-treated controls. These findings suggest that 
ATCC PTA 6475 and ATCC 53608 do not reduce EPEC binding to the LS174T 
cell surface. This could be associated with the secreted mucus layer, as MUC2 
may reduce L. reuteri access to epithelial receptors which are shared with 
EPEC, reducing competition for mutual binding sites. 
Interestingly, we observed a significant increase in the number of EPEC 
contained in microcolonies on LS174T cells pre-incubated with ATCC PTA 
6475 compared to both ATCC 53608-treated and non-treated controls, which 
may be associated with different L. reuteri binding characteristics. Although 
the adhesion of both L. reuteri strains to LS174T cells appeared similar, we 
were unable to differentiate between mucus and cell-bound L. reuteri. As such, 
adherence to the LS174T cell surface may differ between L. reuteri strains, as 
we observed on HT-29 cells. Thus, the adhesion of ATCC PTA 6475 to 
LS174T cells may inhibit the cell-cell spread of EPEC, resulting in microcolony 
formation. Further investigation with CmbA-deficient ATCC PTA 6475 as well 
as removal of the LS174T mucus layer (through inhibition of mucus synthesis 
or mucus degradation) could be utilised to investigate ATCC PTA 6475 binding 
to LS174T cells. 
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3.3.3. Influence of L. reuteri on EPEC colonisation ex vivo 
Investigations into probiotic-pathogen interactions have generally used cell-
line based models to identify potential beneficial outcomes. However, cancer 
cell lines consist of clonal cell populations whereas in vivo, the intestinal 
epithelium is comprised of a mixture of different cell types (including 
enterocytes and goblet cells) with a defined mucus layer and host microbiota 
(Johansson & Hansson, 2011c; Noah et al., 2011). To address this difference 
between the in vitro and in vivo situation, we further investigated the interaction 
of L. reuteri and EPEC by IVOC of human duodenal biopsies. IVOC is 
regarded as the current gold standard for investigating interactions of EPEC 
with the human intestinal mucosa (Fang et al., 2013; Knutton et al., 1987). Yet, 
IVOC has not been used to investigate probiotic effects against pathogens at 
the human epithelial surface. However, a previous study has shown that pre-
incubation with L. plantarum JC1 did not reduce S. Typhimurium adhesion to 
porcine jejunal and colonic intestinal tissue (Collins et al., 2010). In contrast, 
pre-incubation with L. reuteri LM1 and L. salivarius LM2 inhibited Brachyspira 
pilosicoli colonisation of chicken caecal tissue (Mappley et al., 2011).  
In this study, we showed that L. reuteri ATCC PTA 6475 and ATCC 53608 
were localised in the mucus layer and were unable to access the epithelium of 
human duodenal biopsies. Previous studies have identified epithelial binding 
of lactobacilli to human and porcine intestinal tissue samples, in the absence 
of the mucus layer (Bogovič Matijašić et al., 2006; Tsilingiri et al., 2012). Our 
findings, alongside these previous studies, suggest that lactobacilli do not 
access the epithelium when the mucus layer is intact. Thus, investigations into 
the effects of probiotics on mucus-free models may only represent conditions 
where the mucus layer is either absent or non-functional, such as IBD (Sheng 
et al., 2012). Furthermore, the exclusion of L. reuteri from the duodenal 
epithelium may also be due to anti-microbial products secreted by enterocytes 
and Paneth cells into the mucus layer (Ouellette, 1997). The mouse 
antimicrobial lectin RegIIIγ (a homologue of human Hepatocarcinoma-
intestine-pancreas/pancreatic associated protein (HIP/PAP)) has previously 
been identified as an inhibitor of Gram-positive bacteria which is secreted by 
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villous by enterocytes (Cash et al., 2006; Vaishnava et al., 2011). The 
secretion of RegIIIγ, as well as other antimicrobials such as β-defensins, is 
thought to maintain an exclusion zone between the small intestinal epithelium 
and the microbiota (McGuckin et al., 2011; Ouellette, 2004; Porter et al., 1997). 
Thus, it is probable that the production of antimicrobial products and the 
secretion of the mucus layer exclude L. reuteri from the duodenal epithelium.  
Interestingly, pre-incubation with L. reuteri significantly reduced EPEC binding 
to the epithelium of duodenal biopsies. As L. reuteri were restricted to the 
mucus layer, inhibition of EPEC binding to the epithelium must occur at the 
mucus interface, e.g. by steric inhibition of EPEC penetration of the mucus 
layer. These data contrast with our observations in mucus-producing LS174T 
cells where L. reuteri did not reduce EPEC adhesion. This could be due to 
differences in mucus composition, as the secreted mucus layer of the 
duodenum is mainly comprised of MUC2, whereas LS174T cells produce 
MUC2, MUC5AC (usually expressed in the stomach), and gallbladder mucin 
(Atuma et al., 2001; van Klinken et al., 1996). Therefore, future studies should 
utilise physiologically relevant model systems, such as IVOC, to assess 
probiotic characteristics. 
 
3.4. Summary 
In this study, we have demonstrated strain-specific protective effects of L. 
reuteri against EPEC adhesion to intestinal cell lines and duodenal biopsies. 
These protective mechanisms include competitive exclusion, both within the 
mucus layer and at the epithelial surface, as well as potential inhibition of 
EPEC dispersion across the epithelium. Furthermore, we observed that 
inhibition was dependent on the model system used. Therefore, these findings 
emphasise the importance of model and strain selection when investigating 
probiotic characteristics. 
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4.1. Introduction and objectives of study 
The mucus layer is the first line of defence against invading pathogens of the 
GIT. Mucus is structurally composed of mucins, heavily glycosylated proteins 
with tandem repeats of PTS residues, which form a mesh-like structure 
enabling colonisation by commensal bacteria and impeding microbial access 
to the epithelium (Johansson et al., 2011b; Juge, 2012). The mucus of the 
colon forms two layers, the outer loose layer which facilitates microbial 
colonisation and the inner adherent layer which excludes the microbiota from 
the epithelium (Johansson et al., 2008). In contrast, the mucus of the small 
intestine forms a single loose layer, which is colonised by microbes, to facilitate 
nutrient absorption (Johansson et al., 2011b). The colonic and small intestinal 
mucus layers are composed of MUC2, the major secreted mucin in the human 
intestine (Johansson et al., 2011b). In addition to the secreted mucus layer, 
intestinal epithelial cells are covered by the glycocalyx, which is composed of 
the cell-bound mucin MUC3 (Kim & Ho, 2010). The glycocalyx and secreted 
mucus impede bacterial movement, as flagella of EPEC and EHEC bind to 
mucin O-glycans (Erdem et al., 2007; Ye et al., 2015). Furthermore, mucins 
act as decoy receptors for pathogen adhesion, as the binding of H. pylori and 
EPEC to cell-bound mucins MUC1 and MUC3 inhibits pathogen access to the 
epithelial cell surface (Lindén et al., 2009; Mack et al., 2003). In addition to the 
physical mucus barrier, bacterial access to the intestinal epithelium is inhibited 
by the secretion of antimicrobial compounds, such as defensins and lectins, 
by intestinal epithelial cells into the mucus layer (Johansson & Hansson, 
2011c; Vaishnava et al., 2011).  
Pathogens have evolved multiple strategies to circumvent the host mucus 
layer. The stomach pathogen H. pylori secretes cytotoxins CagA and VacA, 
which reduce mucin synthesis by inhibiting intracellular processing of 
glycoproteins (Beil et al., 2000; Byrd et al., 2000). Alternatively, pathogenic E. 
coli produce mucin-degrading enzymes such as StcE (EHEC, Grys et al. 
(2005)), SslE (secreted and surface-associated lipoprotein from E. coli; EPEC, 
ETEC, and ExPEC, Luo et al. (2014), Nesta et al. (2014)), and Pic (Dutta et 
al., 2002), which reduce the viscosity of the mucus layer and facilitate 
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penetration to the epithelial surface. Therefore, enhancing the mucus layer 
could inhibit EPEC colonisation and probiotics offer a potential mechanism, as 
previous studies have identified modulation of host mucin expression by 
Lactobacillus isolates. While production of cell-associated MUC3 is enhanced 
by L. rhamnosus GG and L. plantarum 299v in HT-29 cells, secreted L. 
rhamnosus GG protein p40 has been associated with an increase in MUC2 
expression in LS174T cells and murine intestinal models (Caballero-Franco et 
al., 2007; Mack et al., 2003; Wang et al., 2014a). Thus, stimulation of host 
mucin production by probiotics may offer a therapeutic strategy to reduce 
pathogen binding to the epithelium.  
In this study, we aimed to investigate the effect of EPEC and L. reuteri strains 
ATCC PTA 6475 and ATCC 53608 on mucin dynamics in mucus-secreting 
LS174T cells and human duodenal biopsies.  
 
4.2. Results 
4.2.1. MUC5AC expression in LS174T cells is significantly 
increased by L. reuteri ATCC 53608 and EPEC 
To investigate the effects of L. reuteri and EPEC on mucin gene expression, 
LS174T cells were incubated with L. reuteri or EPEC for different time periods, 
and expression of intestinal mucins MUC1, MUC2, MUC3A, MUC5AC, MUC6, 
MUC12, MUC13, and MUC17 was determined by relative qPCR analysis, 
using the ΔΔCt method (Livak & Schmittgen, 2001). Prior to gene expression 
studies, specificity and amplification efficiency of all primers was determined 
by Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and qPCR 
(Figure 4.1). Specificity of each primer set was determined by the presence of 
a single peak in the dissociation curve (Figure 4.1A) and the presence of a 
single band at the predicted size on an agarose gel (Figure 4.1B). The 
formation of a primer dimer was noted during MUC13 amplification, as a single 
peak was identified on the dissociation curve, but two bands were observed 
by gel electrophoresis (Figure 4.1A and B). We excluded MUC3A from further 
analysis as only one in three MUC3A primer sets demonstrated amplification 
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of a single product. Furthermore, when the amplicon was examined by gel 
electrophoresis, only a faint band was observed (Figure 4.1B). 
 
Figure 4.1: Validation of primer specificity and amplification efficiency 
(A) Dissociation curves were generated for each primer pair. The presence of 
a single peak indicated primer specificity to a single target. (B) Agarose gel 
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electrophoresis analysis of qPCR products to determine amplicon product 
size. Representative image from two experiments (C) Amplification efficiency 
of primer pairs. Primers were tested in a qPCR assay with cDNA which had 
been serially diluted two-fold. Ct values of each dilution were plotted on a 
scatter graph and the slope was used to determine the primer efficiency of 
each primer set. Data are representative of four independent experiments. 
 
To normalise our qPCR data, we selected the housekeeper genes tyrosine 3-
monooxygenase/ tryptophan 5-monooxygenase activation protein, zeta 
polypeptide (YWHAZ, Jacob et al. (2013)) and RNA polymerase II (POLR2A, 
Schüller et al. (2009)), as the expression of these genes did not change during 
treatment with either ATCC PTA 6475 (Figure 4.2A) or EPEC (Figure 4.2B) 
and non-treated cells.  
 
 
Figure 4.2: Housekeeper genes YWHAZ and POLR2A demonstrate stable 
expression under treated and non-treated conditions 
LS174T cells were treated with L. reuteri ATCC PTA 6475 (A), EPEC (B) or 
left non-treated (NT) for 6 h and expression of YWHAZ and POL2RA was 
determined by qPCR. Data are shown as means of Ct ± SE of three 
experiments performed in duplicate. 
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Subsequent qPCR analysis demonstrated that incubation with L. reuteri ATCC 
53608 significantly increased MUC5AC and MUC1 gene expression at 1-4 h 
and 1 h, respectively (Figure 4.3). In contrast, expression of MUC6, MUC12, 
MUC13 and MUC17 did not significantly change after 1 to 6 h incubation with 
either EPEC or L. reuteri (Figures 4.3–4.5). 
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Figure 4.3: Incubation with L. reuteri ATCC 53608 significantly increases 
MUC5AC and MUC1 gene expression in LS174T cells 
LS174T cells were incubated with ATCC 53608 for 1, 3, 4, and 6 h or left non-
treated for 6 h. (A) Expression of mucin genes which did not significantly 
change, or were only significantly increased at one time point, relative to NT 
controls. (B) Fold change in MUC5AC gene expression at 1, 3, 4, and 6 h, 
relative to non-treated control. Data are shown as means ± SE of three 
independent experiments performed in duplicate.  * = P <0.05; ** = P <0.01; 
*** = P <0.001. 
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In contrast to L. reuteri ATCC 53608, incubation of LS174T cells with ATCC 
PTA 6475 did not significantly change mucin gene expression at any time point 
(Figure 4.4).  
 
 
Figure 4.4: ATCC PTA 6475 does not significantly induce mucin gene 
expression in LS174T cells 
LS174T cells were incubated with ATCC PTA 6475 for 1, 3, 4, and 6 h or left 
non-treated for 6 h, and expression of mucin genes was determined relative 
to non-treated controls. Data are shown as means ± SE of three independent 
experiments performed in duplicate. 
 
Interestingly, infection of LS174T cells with EPEC significantly upregulated 
expression of MUC5AC at 1-6 h and MUC2 at 1 and 6 h post-infection (Figure 
4.5B and C). 
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Figure 4.5: EPEC significantly induces MUC2 and MUC5AC gene 
expression in LS174T cells 
LS174T cells were incubated with EPEC for 1, 3, 4, and 6 h or left untreated 
for 6 h. (A) Expression of mucin genes which did not significantly change 
relative to non-treated controls.  (B) Fold change in MUC2 gene expression at 
1, 3, 4, and 6 h, relative to non-treated controls. (C) Fold change in MUC5AC 
gene expression at 1, 3, 4, and 6 h, relative to non-treated controls. Data are 
shown as means ± SE of three independent experiments performed in 
duplicate.  * = P <0.05; ** = P <0.01; *** = P <0.001. 
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4.2.2. MUC2 protein levels in LS174T cells are significantly 
altered by L. reuteri ATCC PTA 6475 and EPEC 
As we observed an increase in MUC2 gene expression by EPEC as well as 
an upregulation of MUC5AC by both ATCC 53608 and EPEC, we sought to 
confirm these findings at the protein level. Therefore, LS174T cells were 
incubated with EPEC, ATCC 53608, ATCC PTA 6475, or left untreated for 6 h 
and MUC2 and MUC5AC protein expression was investigated by 
immunofluorescence staining. Fluorescence was subsequently quantified by 
integrated density using ImageJ software (Wayne Rasband, NIH).  
MUC5AC immunofluorescence staining of non-treated cells demonstrated 
mucin localisation on distinct cells (Figure 4.6A). In contrast to our qPCR 
findings, neither L. reuteri nor EPEC significantly affected the total amount of 
MUC5AC protein relative to NT controls (Figure 4.6B-D).  
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Figure 4.6: MUC5AC protein content in LS174T cells was not altered by 
incubation with EPEC or L. reuteri 
(A) MUC5AC immunofluorescence staining in LS174T cells. Image is 
representative of three independent experiments. Scale bar = 10 µm. (B-D) 
Integrated density quantification of MUC5AC immunofluorescence staining in 
LS174T cells incubated with (B) ATCC 53608, (C) ATCC PTA 6475, or (D) 
EPEC for 6 h. Data were compared to the NT control and are shown as means 
± SE of three independent experiments performed in duplicate. 
 
Immunofluorescence staining of MUC2 in non-treated LS174T cells 
demonstrated a distinct cellular localisation on the majority of cells (Figure 
4.7A). Whereas incubation of LS174T cells with ATCC 53608 did not 
significantly change MUC2 protein expression (Figure 4.7B), treatment with 
ATCC PTA 6475 significantly increased MUC2 protein levels relative to NT 
controls (Figure 4.7C). In contrast, infection with EPEC significantly decreased 
the MUC2 fluorescence density in LS174T cells (Figure 4.7D).  
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To determine whether incubation with L. reuteri could restore MUC2 levels in 
EPEC-infected LS174T cells, equivalent numbers of ATCC PTA 6475 and 
EPEC were added to LS174T cells for 6 h. As shown in Figure 4.7E, co-
incubation of ATCC PTA 6475 with EPEC restored MUC2 protein in LS174T 
cells to non-treated levels. 
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Figure 4.7: MUC2 protein levels in LS174T cells are modulated by ATCC 
PTA 6475 and EPEC 
(A) Immunofluorescence staining of MUC2 protein in LS174T cells. Image is 
representative of five independent experiments. Scale bar = 10 µm. (B-E) 
Integrated density quantification of MUC2 immunofluorescence staining in 
LS174T cells incubated with (B) ATCC 53608, (C) ATCC PTA 6475, (D) 
EPEC, or (E) ATCC PTA 6475 and EPEC for 6 h. Data are shown as means 
± SE of either three (A-D) or five (E) independent experiments performed in 
duplicate.  * = P <0.05; ** = P <0.01; *** = P <0.001 versus NT controls.  
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4.2.3. Mucus analysis in duodenal biopsies 
As we observed differences between mucin gene and protein expression in 
LS174T cells, we investigated mucus protein levels in duodenal biopsies. This 
represented a substantial technical challenge, as the mucus layer collapses if 
the sample becomes dehydrated, due to the high water content which supports 
the mucus structure (Johansson & Hansson, 2012; Johansson et al., 2008). 
To optimise mucus preservation in human duodenal biopsies, cryosections 
were fixed with MeOH/ acetone (1:1) or processed without fixation and stained 
for MUC2 and cell nuclei. Cryosections fixed with MeOH/ acetone 
demonstrated discernible MUC2 staining in goblet cells, but not staining of the 
mucus layer, whereas an external mucus layer was observed in non-fixed 
samples (Figure 4.8A). Therefore, further experiments were performed on 
non-fixed samples. 
To investigate whether L. reuteri or EPEC altered mucus production by human 
tissue, as observed in LS174T cells, duodenal biopsies were incubated with 
L. reuteri or EPEC for 8 h. Cryosections were stained for MUC2 and cell nuclei, 
and L. reuteri and EPEC were detected by using antisera specific to CmbA, 
MUB, or E. coli. Mucus thickness was examined at numerous points along the 
villous. However, mucus preservation was inconsistent along the biopsy 
surface, ranging from the presence of an intact mucus layer (Figure 3.8B) to 
small patches of mucus covering the epithelium (Figure 3.8C). Therefore, this 
method was unsuitable for assessing changes in mucus thickness due to L. 
reuteri and EPEC. 
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Figure 4.8: Preservation of MUC2 protein in biopsy cryosections 
(A) MUC2 staining (green) of cryosections of duodenal biopsies without 
fixation or fixed in MeOH/ acetone. Cell nuclei were labelled in blue. White 
arrows indicate goblet cells, M indicates the external mucus layer. Images are 
representative of two independent experiments performed in duplicate. Scale 
bar = 10 µm. (B-C) MUC2 fluorescence staining of cryosections showing a 
well-preserved mucus layer overlaying the villus epithelium (B) or mucus 
detachment (C). Mucus and villous tips are indicated by M and V, respectively. 
Images are representative of three independent experiments performed in 
duplicate. Scale bars = 50 µm (B) and 100 µm (C). 
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4.3. Discussion 
The mucus layer is a dynamic environment which acts as a habitat and food 
source to commensal bacteria, as well as providing a barrier to infection. 
Disruption of the mucus layer to gain access to the epithelium is a key process 
during GI infection by a number of pathogens thus, restoration of the mucus 
layer through probiotics may offer therapeutic solution to inhibit infection. 
In this study, we have analysed the modulatory effects of L. reuteri and EPEC 
on mucus production using the MUC2-producing LS174T cell line. Our results 
suggest that EPEC reduces MUC2 protein levels and that this effect can be 
mitigated through co-incubation with L. reuteri ATCC PTA 6475. 
 
4.3.1. Mucin gene expression does not directly correlate with 
protein levels  
To investigate the impact of L. reuteri and EPEC on mucin production, we 
analysed the expression of major intestinal mucin genes and MUC2 and 
MUC5AC protein levels in LS174T cells. While MUC5AC gene expression was 
significantly upregulated by ATCC 53608 and EPEC, no significant changes 
in MUC5AC protein levels were detected. In addition, incubation with EPEC 
significantly upregulated MUC2 gene expression, but resulted in a significant 
decrease in MUC2 protein levels. Ultimately, treatment with ATCC PTA 6475 
caused a significant increase in MUC2 protein levels despite absent effect on 
MUC2 gene expression. Taken together, these results show a lack of 
correlation between mucin gene expression and protein levels. This has been 
previously demonstrated in mice with cystic fibrosis, where Muc2 gene 
expression was decreased in the ileum of mice with cystic fibrosis compared 
to WT mice, but no change in mucin quantity was detected (Parmley & 
Gendler, 1998). Differences in mucin gene and protein levels have also been 
reported during C. rodentium infection of mice, where Muc1 and Muc2 gene 
expression in the distal colon was highest during the early stage of infection, 
while increased mucus thickness was only observed 10 days later (Gustafsson 
et al., 2013). These findings demonstrate that mucin gene expression is not 
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directly correlated with protein levels and suggest different stages of post-
translational regulation, as outlined below.  
As the biosynthesis of mucin is a multi-step process, there are numerous 
opportunities for pathogens to disrupt mucin protein production and secretion. 
After protein synthesis, apomucins are N-glycosylated and dimerized in the 
rough endoplasmic reticulum before being translocated into the Golgi 
apparatus, where O-glycosylation occurs (Asker et al., 1998). H. pylori LPS 
reduces mucin production in rat gastric biopsies by inhibiting sulfation and O-
glycosylation of apomucins (Liau et al., 1992). After glycosylation, mucins are 
packed into granules and secreted into the lumen. Mucin secretion can be 
initiated by secondary messengers, such as Ca2+ and cyclic AMP (Ambort et 
al., 2012a; Takahashi et al., 1999) or bacterial proteins such as the potent 
secretagogue Cholera toxin (Forstner et al., 1981; Lencer et al., 1990). In 
contrast, H. pylori reduces mucus turnover in the mouse stomach by 
increasing the time from mucin synthesis to secretion (Navabi et al., 2013b).  
 
4.3.2. Influence of L. reuteri on mucin expression 
In this study, we determined that L. reuteri ATCC PTA 6475 significantly 
increased MUC2 protein levels in LS174T cells relative to non-treated controls. 
This agrees with similar observations reported for other Lactobacillus species. 
L. rhamnosus GG secreted protein p40 increases MUC2 gene and protein 
expression in LS174T cells and mouse colonic epithelium, by activating EGF 
receptor (Wang et al., 2014a). Modulation of MUC2 gene expression by L. 
rhamnosus GG has also been demonstrated in Caco-2 cells (Mattar et al., 
2002). However, as Caco-2 cells do not secrete MUC2 protein (van Klinken et 
al., 1996), the biological relevance of these findings are questionable. In 
addition, L. rhamnosus GG and L. plantarum 299v stimulate expression of cell-
associated MUC3 protein in HT-29 cells (Mack et al., 2003). While we did not 
detect MUC3A mRNA in LS174T cells, future experiments could investigate 
the expression of MUC3A protein at the intestinal epithelium using human 
duodenal biopsies, to determine whether MUC3A is modulated by L. reuteri 
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and whether mucin expression was associated with decreased  
microbial binding. 
Mucus secretion from goblet cells into the gut lumen is a continuous process, 
excluding microbes from the epithelial surface and providing lubrication for the 
movement of digested material (Deplancke & Gaskins, 2001). This process 
can be induced by secretagogues such as carbachol or calcium ionophores, 
thereby increasing the thickness of the mucus layer and reducing pathogen 
access to the epithelium (Deplancke & Gaskins, 2001; McCool et al., 1990). 
Previous studies have shown that administration of the probiotic VSL#3, 
containing a mixture of Lactobacillus, Bifidobacterium, and Streptococcus 
spp., increased Muc1, Muc2, and Muc3 gene expression and total mucin 
secretion in the rat intestine (Caballero-Franco et al., 2007). Furthermore, 
conditioned medium of the individual VSL#3 Lactobacillus species stimulated 
mucin secretion by LS174T cells (Caballero-Franco et al., 2007). 
Unfortunately, the secretagogues were not identified in the study and thus, we 
do not know whether this effect is strain-specific or a generic feature  
of Lactobacillus. 
In our investigation, we did not determine whether the increase in MUC2 
protein levels in LS174T cells was caused by stimulation of MUC2 production 
or exocytosis. Mucin synthesis could be determined by pulse-chase 
experiments using labelled mucins (GalNAz or [3H] glucosamine) (Byrd et al., 
2000; Cole et al., 2013). Alternatively, mucin synthesis could be inhibited with 
benzyl-α-GalNAc and total MUC2 levels could be compared between non-
treated, L. reuteri-treated, and secretagogue-treated LS174T cells (Kuan et 
al., 1989; McCool et al., 1990).  
 
4.3.3. Influence of EPEC on mucin expression  
In this study, we determined that EPEC reduced MUC2 protein levels in 
LS174T cells. While previous studies have investigated the interaction of 
EPEC with mucus, these reports have mainly focused on microbial binding 
rather than the effect of EPEC on mucin protein levels. One study showed a 
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significant increase in expression of MUC2 and MUC5AC protein in HT-29 
MTX cells infected with atypical EPEC, but not EPEC E2348/69 used in our 
study (Vieira et al., 2010). This discrepancy may be due to the difference cell 
lines used as HT-29 MTX cells predominantly secrete MUC5AC, whereas 
LS174T cells primarily produce MUC2 (Hennebicq-Reig et al., 1998). 
Further studies have investigated the effect of related pathogens on mucus 
production in vivo. Infection of rabbits with a rabbit EPEC strain induced mucus 
secretion and increased the number of ileal goblet cells (Ramirez et al., 2005). 
Similarly, infection of mice with C. rodentium increased mucus secretion 
(Bergstrom et al., 2008; Lindén et al., 2008b). Interestingly, these effects were 
dependent on the adaptive immune response, as mucus secretion in 
immunocompromised mice was unaffected by C. rodentium infection 
(Bergstrom et al., 2008). In contrast, our study focussed on the localised rather 
than systemic response during the early stages of infection and in the absence 
of an adaptive immune response. While we did not determine the mechanisms 
underlying reduced MUC2 protein levels, we can suggest potential 
explanations and future experiments to test these hypotheses. Firstly, EPEC 
infection could inhibit mucin synthesis as shown for H. pylori, which 
suppresses MUC5AC and MUC1 synthesis in gastric cells and MUC1 
synthesis in the stomach of infected mice (Byrd et al., 2000; Navabi et al., 
2013b). These effects were also mediated by bacterial lysates and could be 
caused by the cytotoxins CagA and VacA, which inhibit mucin production (Beil 
et al., 2000; Byrd et al., 2000). No homologous toxins have been identified in 
EPEC, but other proteins might mediate a similar effect. To further investigate 
this hypothesis, pulse-chase experiments with labelled mucins could be 
performed as previously described (4.3.2).  
An alternative mechanism could be degradation of MUC2 protein by secreted 
enzymes. The extracellular E. coli serine protease autotransporter of the 
Enterobacteriaceae (SPATE) proteins have previously been associated with 
mucin degradation (Dutta et al., 2002). In particular, the class II SPATE Pic 
(produced by EAEC and S. flexneri) and Tsh (produced by avian pathogenic 
E. coli), but not the EPEC class I SPATE protein EspC, degrade bovine 
submaxillary mucus (Dutta et al., 2002). While class I SPATEs have not 
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previously been associated with glycoprotein degradation (Ruiz-Perez & 
Nataro, 2014), it is important to note that the impact of EspC on intestinal 
MUC2 has not been investigated thus far. Specificity of SPATEs to particular 
mucins has previously been demonstrated for the class II SPATE EatA 
produced by ETEC, which degraded MUC2, but not bovine submaxillary 
mucus (Kumar et al., 2014). In addition, the secreted serine proteases from 
the nematode Trichuris muris selectively degrade murine Muc2, but not 
Muc5ac (Hasnain et al., 2012).  
Alternative secreted enzymes produced by E. coli pathotypes have also been 
associated with mucin degradation, such as the EHEC extracellular zinc 
metalloprotease StcE, which degrades salivary MUC7 (Grys et al., 2005). StcE 
has been suggested to enhance intimate attachment to the epithelium by 
removing cell-bound mucins, as an isogenic stcE mutant formed fewer actin 
pedestals on Hep-2 cells than the wildtype strain, despite similar levels of 
adhesion (Grys et al., 2005). Surprisingly, recombinant StcE did not degrade 
intestinal MUC2 or MUC5AC in cell lysates (Grys et al., 2006). In contrast, the 
E. coli metalloprotease SslE degrades both bovine submaxillary mucus and 
human MUC2 (Luo et al., 2014; Nesta et al., 2014; Valeri et al., 2015). SslE 
(previously referred to as YghJ) is produced by ETEC, ExPEC, and EPEC and 
can be expressed on the cell surface or secreted (Baldi et al., 2012; Iguchi et 
al., 2009; Luo et al., 2014). SslE promotes rabbit EPEC infection, as an 
isogenic sslE mutant demonstrated reduced colonisation and pathogenesis 
(Baldi et al., 2012). Thus, SslE and EspC represent potential candidates and 
their role in MUC2 degradation during EPEC infection should be further 
investigated by construction of isogenic deletion mutants.  
Our study has also demonstrated that incubation with L. reuteri ATCC PTA 
6475 inhibits the reduction in MUC2 protein levels induced by EPEC. Our 
findings in Chapter 3 demonstrate that L. reuteri ATCC PTA 6475 does not 
affect EPEC viability or inhibit binding to LS174T cells. It is therefore unlikely 
that inhibition of EPEC binding would explain the effect of L. reuteri on MUC2 
levels in LS174T cells co-incubated with EPEC. As ATCC PTA 6475 enhanced 
MUC2 protein amounts when incubated with LS174T cells alone, this suggests 
that the increase in MUC2 induced by L. reuteri counteracts the decrease 
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induced by EPEC. Thus, further investigation is required to identify the 
molecular determinants responsible for EPEC and ATCC PTA 6475-mediated 
modulation of MUC2 protein levels. 
 
4.3.4. Investigating mucus production in intestinal biopsies 
In addition to the studies on LS174T cells described above, we also used 
human duodenal biopsies to investigate the effects of L. reuteri and EPEC on 
mucus production ex vivo. Unfortunately, we were unable to reliably quantify 
mucus thickness due to lack of consistent mucus preservation on biopsy 
samples. Preservation of the mucus layer has previously been described as 
problematic due to high water content, as dehydration of this layer causes the 
mucus layer to collapse (Johansson & Hansson, 2012).  
Non-fixed tissue samples have been used to assess the mucus thickness of 
the human stomach (Jordan et al., 1998) and the colon (Fyderek et al., 2009) 
using the histochemical stains Alcian Blue and Periodic Acid Schiff, which 
detect acidic and neutral mucins, respectively (Matsuo et al., 1997). 
Comparison of mucus thickness by evaluation of stained cryosections and in 
vivo measurements in the rat distal colon, has produced similar results for the 
inner adherent mucus layer, while the outer loose mucus layer was lost during 
histological processing (Strugala et al., 2003). In contrast to the stomach and 
the colon, the mucus layer of the small intestine is loose and can be easily 
removed (Atuma et al., 2001; Gustafsson et al., 2012). Thus, determining the 
thickness of the small intestinal mucus layer presents a substantial technical 
challenge. Fixation with Carnoy’s solution (60% dry ethanol, 30% chloroform, 
and 10% glacial acetic acid) and paraffin embedding has demonstrated 
excellent preservation of both the loose outer and the adherent inner mucus 
layer of the murine colon (Johansson et al., 2008; Johansson et al., 2009). 
However, this protocol required the preservation of a whole piece of murine 
colon with the faecal pellet in situ, to prevent mucus layer detachment 
(Johansson et al., 2011a). As we used human duodenal biopsies in our study, 
166 
 
it is uncertain whether comparable preservation of the small intestinal mucus 
layer would have been achieved with Carnoy’s fixation. 
Measurements of mucus layer thickness in the murine small intestine have 
previously been achieved by visualising the mucus with inactivated charcoal 
particles (Atuma et al., 2001; Gustafsson et al., 2012). Mucus thickness was 
subsequently determined in situ by measuring the mucus with a 
micromanipulator connected to a microscope (Atuma et al., 2001; Gustafsson 
et al., 2012). The advantage of this technique is the lack of additional 
processing steps as well as real-time measurements of changes in the mucus 
layer. However, specialist equipment and method adaption for human 
duodenal samples would be required. 
An alternative method to assess the impact of EPEC and L. reuteri on mucus 
production ex vivo would be to analyse de novo mucin synthesis, as previously 
described in 4.3.2. This technique has previously been used on resected 
colonic tissue and colonic biopsies from patients with ulcerative colitis and thus 
could potentially be adapted for IVOC (Finnie et al., 1995; Tytgat et al., 1996).  
 
4.4. Summary 
In this study, we identified that L. reuteri ATCC PTA 6475 and EPEC enhanced 
and reduced MUC2 protein levels in LS174T cells, respectively. Furthermore, 
when these strains were co-incubated with LS174T cells, ATCC PTA 6475 
counteracted the decrease in MUC2 protein content induced by EPEC. While 
the specific mechanisms behind these changes still remain to be investigated, 
these data suggest that both EPEC and L. reuteri ATCC PTA 6475 affect 
mucus production in the human GIT.  
As the mucus layer is the first line of defence against infection, the 
development of probiotics supporting the mucus layer may have applications 
for reducing enteric infections and alleviating diseases with a compromised 
mucus layer, such as IBD. As mucus-stimulating characteristics are strain-
specific, further research is required to identify the mechanisms behind these 
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effects as well as the bacterial strains capable of modulating mucus 
production. Furthering our understanding of these processes may contribute 
to the development of new therapies and vaccines against EPEC infection. 
  
168 
 
CHAPTER FIVE: Modulation of the innate immune response 
 
TURN WHITE 
 
CHAPTER FIVE 
 
Modulation of the  
innate immune response  
  
169 
 
5.1. Introduction and objectives of study 
EPEC infection of the intestinal mucosa is characterised by moderate 
inflammation and the recruitment of neutrophils to the site of infection 
(Savkovic et al., 1996). This response is modulated by both pro- and anti-
inflammatory signals generated by EPEC (Savkovic et al., 1996; Sharma et 
al., 2006). The initial immune response against EPEC is dependent on the 
detection of bacterial flagellin by host TLR5, which activates NF-κB and 
induces the translocation of this transcription factor into the nucleus (Khan et 
al., 2008; Ruchaud-Sparagano et al., 2007; Schüller et al., 2009; Sharma et 
al., 2006; Zhou et al., 2003). Binding of NF-κB to inflammatory genes 
subsequently initiates the production of pro-inflammatory cytokines such as 
the neutrophil chemoattractant IL-8 (Kunsch et al., 1994; Savkovic et al., 
1996). However, EPEC downregulate the immune response by T3S effector 
proteins, inhibiting NF-κB translocation into the nucleus and counteracting 
other signalling pathways, such as AP-1 (Hartland et al., 2000; Jarvis et al., 
1995; Knutton et al., 1998; Wong et al., 2011). The reduced inflammatory 
response inhibits EPEC clearance from the host (Wong et al., 2011).  
Probiotics can restore immune homeostasis to the intestinal milieu and specific 
strains exhibit anti-inflammatory or immuno-stimulatory characteristics in in 
vitro and in vivo systems (Díaz‐Ropero et al., 2007). For example, the anti-
inflammatory probiotic mixture VSL#3 induced and maintained remission in 
patients with ulcerative colitis (Bibiloni et al., 2005; Huynh et al., 2009; Miele 
et al., 2009; Sood et al., 2009; Tursi et al., 2010). Immunomodulation has also 
been demonstrated for L. reuteri as strains ATCC 55730 and ATCC PTA 5289 
reduced pro-inflammatory cytokine expression in patients with gingivitis 
(Twetman et al., 2009). Furthermore, ATCC PTA 4659 and ATCC 55730-
derived strain DSM 17938 reduced the incidence of LPS-induced necrotising 
enterocolitis by modulation of TLR4 and NF-κB signalling (Liu et al., 2012). As 
inflammation contributes to the development of diarrhoea, anti-inflammatory 
probiotics could be applied to reduce diarrhoeal symptoms (Viswanathan et 
al., 2009). A promising candidate probiotic is L. reuteri ATCC PTA 6475, which 
produces histamine that suppresses the pro-inflammatory response (Jones & 
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Versalovic, 2009; Lin et al., 2008; Liu et al., 2010; McCabe et al., 2013; Preidis 
et al., 2012; Thomas et al., 2012). In line with these studies, we investigated 
the influence of L. reuteri ATCC PTA 6475 and ATCC 53608 on IL-8 cytokine 
production during EPEC infection of intestinal cell lines and human duodenal 
biopsies. 
 
5.2. Results 
5.2.1. L. reuteri inhibits EPEC-induced IL-8 production by  
HT-29 cells 
To investigate the effects of L. reuteri on IL-8 protein production, HT-29 cells 
were incubated with L. reuteri ATCC PTA 6475, ATCC 53608, EPEC, or left 
non-treated for 6 h, and IL-8 protein levels in cell culture media were 
determined by ELISA. As shown in Figure 5.1A, IL-8 production by HT-29 cells 
was significantly induced by EPEC infection relative to non-treated controls. In 
contrast, neither L. reuteri isolate induced the production of IL-8. To determine 
whether these strains demonstrated anti-inflammatory effects against EPEC-
induced IL-8 production, HT-29 cells were co-incubated with equivalent 
numbers of EPEC and either ATCC PTA 6475 or ATCC 53608 for 6 h. We 
identified that co-incubation with L. reuteri significantly reduced IL-8 levels 
relative to HT-29 cells incubated with EPEC alone, though this did not reach 
baseline levels (Figure 5.1B).  
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Figure 5.1: Co-incubation with L. reuteri ATCC PTA 6475 and ATCC 53608 
inhibits EPEC-induced IL-8 production by HT-29 cells 
(A) HT-29 cells were incubated with L. reuteri ATCC PTA 6475, ATCC 53608, 
EPEC, or left non-treated (NT) for 6 h. (B) HT-29 cells were co-incubated with 
equivalent numbers of EPEC and ATCC PTA 6475, ATCC 35608, or EPEC 
alone for 6 h. IL-8 protein levels in cell culture media were assessed by ELISA. 
Data are shown as means ± SE of three independent experiments performed 
in duplicate. ** = P <0.01; *** = P <0.001 versus non-treated controls. £ = P 
<0.05; £££ = P <0.001 versus EPEC-infected samples.  
 
To determine the kinetics of IL-8 production in mucus-producing LS174T cells, 
incubations with L. reuteri or EPEC were performed for 3, 4 and 6 h, and IL-8 
was determined as previously described. In contrast to HT-29 cells, incubation 
with L. reuteri ATCC PTA 6475 and ATCC 53608 induced IL-8 production in 
LS174T cells, suggesting pro-inflammatory effects in this cell line (Figure 5.2), 
therefore HT-29 cells were used for further experiments. 
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Figure 5.2: L. reuteri and EPEC induce IL-8 protein production by  
LS174T cells 
LS174T cells were incubated with ATCC PTA 6475, ATCC 53608, EPEC for 
3, 4, or 6 h or left non-treated (NT) for 6 h. IL-8 levels in cell culture media 
were assessed by ELISA. Data are shown as means ± SE of three 
independent experiments performed in duplicate. ** = P<0.01; *** = P <0.001 
versus NT.  
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5.2.2. EPEC supernatant induces IL-8 production in HT-29 
cells 
Previous studies have shown that EPEC-induced IL-8 response in vitro and ex 
vivo is predominantly associated with flagellin, although other factors have 
been described (Khan et al., 2008; Schüller et al., 2009; Sharma et al., 2006; 
Zhou et al., 2003). To determine whether EPEC flagellin caused increased  
IL-8 production in HT-29 cells, 6 h incubation were performed with wildtype 
EPEC, an isogenic fliC mutant (AGT01), or filter sterilised supernatant from 
EPEC overnight cultures (SN). As shown in Figure 5.3, incubation with 
wildtype EPEC and EPEC SN significantly increased IL-8 production relative 
to HT-29 cells treated with the fliC mutant or the NT control. 
. 
 
Figure 5.3: EPEC supernatant induces IL-8 production in HT-29 cells 
HT-29 cells were incubated with wildtype EPEC (WT), EPEC supernatant 
(SN), isogenic fliC mutant strain AGT01 (ΔfliC), or left non-treated (NT) for 6 
h. IL-8 protein levels in cell culture media were assessed by ELISA. Data are 
shown as means ± SE of either three (WT SN) or six independent experiments 
performed in duplicate. ** = P<0.01; *** = P <0.001 versus NT. £ = P<0.05; ££ 
= P<0.01 versus isogenic fliC mutant. 
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5.2.3. L. reuteri ATCC PTA 6475 inhibits EPEC supernatant-
induced IL-8 production in HT-29 cells  
As EPEC SN induced a comparable inflammatory response to EPEC, we 
investigated the impact of L. reuteri on IL-8 induction in HT-29 cells treated 
with EPEC SN or SN diluted 10- to 1000-fold. We identified that non-diluted 
and 10 to 100-fold diluted EPEC SN significantly increased IL-8 production, 
and that ATCC PTA 6475 inhibited IL-8 production in HT-29 cells treated with 
100-fold diluted EPEC SN (data not shown). Therefore, EPEC SN was diluted 
100-fold for further experiments. As anti-inflammatory characteristics have 
been linked to secreted products, L. reuteri-conditioned medium (cell culture 
medium treated with L. reuteri for 6 h) and EPEC SN were co-incubated with 
HT-29 cells for 6 h. As shown in Figure 5.4, only incubation with ATCC PTA 
6475 significantly reduced IL-8 production stimulated by EPEC SN, whereas 
treatment with ATCC 53608 or L. reuteri-conditioned medium had no effect. 
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Figure 5.4: ATCC PTA 6475-mediated inhibition of IL-8 production is 
independent of secreted products 
HT-29 cells were incubated with EPEC supernatant (ESN) and L. reuteri ATCC 
PTA 6475, ATCC 53608 or L. reuteri-conditioned medium, or left non-treated 
(NT) for 6 h. IL-8 levels in cell culture media were assessed by ELISA. Data 
are shown as means ± SE of three independent experiments performed in 
duplicate. ** = P<0.01 versus ESN. 
 
5.2.4. NF-κB translocation in HT-29 cells 
The translocation of NF-κB from the cytoplasm to the cell nucleus is a key step 
in the upregulation of IL-8 protein in response to EPEC infection (Savkovic et 
al., 1997). To determine whether this process was modulated by L. reuteri, a 
protocol for establishing NF-κB p65 (RelA) translocation into the nucleus was 
required. For this purpose, HT-29 cells were incubated with EPEC for 1 and 2 
h or treated with 10 ng/ mL TNF-α for 1 and 4 h. Non-confluent HT-29 cells 
were used to improve visual acuity, and short time points were chosen to 
reduce NF-κB suppression by EPEC effector proteins. 
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While we observed cytoplasmic staining of p65 in all samples, we did not 
detect nuclear translocation of NF-κB in EPEC- or TNF-α-treated HT-29 cells 
(Figure 5.5). This finding suggests that alternative techniques are required to 
investigate changes in NF-κB localisation in HT-29 cells. 
 
 
Figure 5.5: Anti-p65 immunofluorescence staining did not detect NF-kB 
nuclear translocation in HT-29 cells 
HT-29 cells were infected with EPEC for 1-2 h, treated with 10 ng/ mL TNF-α 
for 1-4 h, or remained non-treated. Cells were stained for p65 (green), E. coli 
(red), and cell nuclei (blue). Black and white images of the green channel is 
shown to improve clarity. Images are representative of either two (EPEC) or 
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three (TNF-α) independent experiments performed in duplicate. Scale bars = 
10 µm. 
5.2.5. Influence of L. reuteri on IL-8 production in EPEC-
infected duodenal biopsies 
As L. reuteri inhibited EPEC-induced IL-8 production in HT-29 cells, we further 
investigated the effects of L. reuteri and EPEC on IL-8 protein levels in 
duodenal tissue using pIVOC and evaluated by ELISA. As biopsies were of 
variable size, IL-8 protein levels were adjusted against total protein content of 
the biopsy lysate. As shown in Figure 5.6, there was no significant difference 
in IL-8 protein levels between L. reuteri and non-treated controls, whereas 
EPEC infection significantly increased IL-8 protein content. In contrast to HT-
29 cells, co-incubation with L. reuteri did not significantly affect IL-8 production 
in EPEC-infected tissues. (Figure 5.6). 
 
Figure 5.6: L. reuteri does not affect EPEC-induced IL-8 production in 
duodenal biopsies 
Duodenal biopsies were exposed to L. reuteri ATCC PTA 6475, ATCC 53608, 
EPEC, or left non-treated (NT) for 6 h. In addition, co-incubations of equivalent 
numbers of L. reuteri and EPEC were performed. Each data point represents 
an individual biopsy sample. The median is indicated by a line. * = P <0.05; ** 
= P <0.01; *** = P <0.001 versus NT. 
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5.2.6. The IL-8 response is not suppressed by EPEC during 
infection of duodenal biopsies 
As we did not observe L. reuteri modulation of the IL-8 response in EPEC-
infected biopsies, we investigated whether EPEC suppression of the immune 
response described in cell lines may have obscured any protective effects of 
L. reuteri. Therefore, HT-29 cells were incubated with wildtype EPEC or a 
T3SS-deficient escN mutant (CVD452; Jarvis et al, 1995) for up to 8 h. As 
shown in Figure 5.7A, HT-29 cells produced significantly more IL-8 when 
infected with ΔescN mutant versus wildtype EPEC after 4-8 h of incubation.  
Interestingly, no immunosuppressive effect was observed in human duodenal 
as incubation with T3SS-deficient mutants ΔescN and ΔespB (UMD864; 
Donnenberg et al, 1993a) induced comparable IL-8 levels to wildtype EPEC 
(Figure 5.7B). In addition, infection with a fliC mutant did not induce a 
significant increase in IL-8 levels compared to NT controls.  
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Figure 5.7: The IL-8 response is not downregulated by EPEC during 
infection of duodenal biopsies 
(A) HT-29 cells were incubated with wildtype EPEC (WT) or isogenic escN 
mutant strain CVD452 (ΔescN) for 2-8 h. IL-8 levels in cell culture media were 
assessed by ELISA. Data are shown as means ± SE of three independent 
experiments performed in duplicate. * = P<0.05; **** = P <0.0001 versus WT. 
(B) Duodenal biopsies were infected with either wildtype EPEC, isogenic 
mutants deficient in fliC (AGT01), espB (UMD864), escN (CVD452), or left 
non-treated (NT) for 6 h. IL-8 protein was determined from biopsy lysates and 
is displayed relative to the total protein content of each biopsy. Each data point 
represents an individual biopsy sample. The median is indicated by a line. * = 
P<0.05; ** = P<0.01 versus NT. 
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5.3. Discussion 
The innate immune system is a key component of the host response which is 
responsible for the initial defence against invading pathogens. While the innate 
immune response prevents the vast majority of potential insults, some GI 
pathogens have evolved mechanisms to inhibit inflammation. The weakened 
immune response contributes to the production of diarrhoea in the host. 
Probiotics may offer a solution to reduce the incidence of diarrhoea, as certain 
bacterial strains have been identified as having immunomodulatory 
characteristics. 
In this investigation, we have explored the immunomodulatory effects of L. 
reuteri on EPEC-induced IL-8 protein production using both in vitro and ex vivo 
models. Furthermore, we have examined the role of the T3SS in IL-8 
production during EPEC infection of the small intestinal epithelium. 
 
5.3.1. Role of flagellin and the T3SS in IL-8 induction during 
EPEC infection 
In this study, we determined that EPEC induced the production of the immune 
cytokine IL-8 by HT-29 cells and human duodenal biopsies. As HT-29 cells 
showed a diminished IL-8 response when infected with an isogenic fliC mutant, 
this suggests that flagellin is a major inducer of the IL-8 response during EPEC 
infection. This finding is consistent with previous reports which have identified 
EPEC flagellin as a key inducer of IL-8 production by intestinal HT-29, T84, 
and Caco-2 cells (Khan et al., 2008; Ruchaud-Sparagano et al., 2007; Sharma 
et al., 2006; Zhou et al., 2003). The role of flagellin in IL-8 induction has also 
been demonstrated in paediatric duodenal biopsies, as both wildtype EPEC 
and purified flagella induced IL-8 protein production (Schüller et al., 2009). 
Similar to our own results in duodenal biopsies, infection with a fliC deletion 
mutant resulted in a diminished, although not completely abrogated, IL-8 
response, which suggests other inflammatory factors may be produced by 
EPEC. The induction of IL-8 by a FliC-independent mechanism has been 
shown in non-polarised HT-29 and Caco-2 cells, although the exact 
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mechanism has not been clarified (Khan et al., 2008; Schüller et al., 2009; 
Sharma et al., 2006).  
While EPEC flagellin induces IL-8 protein expression, the T3SS has been 
implicated in down-regulating the innate immune response (Ruchaud-
Sparagano et al., 2007). This effect has been attributed to several effector 
proteins encoded outside the LEE region (Nle) (Nadler et al., 2010; Newton et 
al., 2010; Vossenkämper et al., 2010). NleE prevents the phosphorylation of 
Iκβ kinase (IKK), and thus reduces the degradation of the NF-κB inhibitor IκB, 
inhibiting activation of NF-κB (Nadler et al., 2010). This effect has been 
demonstrated in HeLa and Caco-2 cells as well as isolated dendritic cells and 
has been associated with a diminished IL-8 response (Nadler et al., 2010; 
Newton et al., 2010; Vossenkämper et al., 2010). The inhibitory action of NleE 
is further enhanced by the effector protein NleB, which inhibits the activation 
of NF-κB by reducing GAPDH-mediated ubiquitination of TRAF2, a protein 
involved in TNF-α mediated NF-κB activation (Gao et al., 2013; Nadler et al., 
2010). Furthermore, the effector protein NleC degrades the p65 subunit of the 
NF-κB complex (Pearson et al., 2011; Yen et al., 2010). Notably, the roles of 
these effector proteins have primarily been documented in cancer cell lines, 
and their effect in the in vivo situation remains largely unknown. While we 
observed a T3SS-dependent immunosuppressive effect in EPEC-infected HT-
29 cells, this was not evident during infection of human duodenal biopsies. A 
similar lack of immunosuppression has recently been demonstrated during 
EHEC infection of human colonic biopsies, suggesting a delay or absence of 
this mechanism in human intestinal tissues (Lewis et al., 2016). 
 
5.3.2. Impact of L. reuteri on the EPEC-induced IL-8 response 
in vitro 
In our study, we showed that L. reuteri strains ATCC PTA 6475 and ATCC 
53608 induced IL-8 production in LS174T, but not HT-29 cells. This difference 
could be due to cell line-specific features, such as cell type (goblet cell versus 
enterocyte) and the genetic background of the host, which can impact on 
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probiotic effects (van Baarlen et al., 2013). This has previously been observed 
in L. rhamnosus GG, which stimulated IL-8 production in HT-29 cells infected 
with S. Typhimurium, but reduced IL-8 protein in Caco-2 cells treated with 
flagellin, despite similar methodologies  (Lopez et al., 2008; Pinto et al., 2009). 
While the immune stimulus was different in each of the prior studies (S. 
Typhimurium versus isolated flagellin from Pseudomonas aeruginosa) which 
may have influenced probiotic effects, these findings demonstrate that 
thorough evaluation of probiotics on relevant model systems is necessary to 
determine immunomodulatory characteristics of specific Lactobacillus strains. 
Probiotic immunomodulation of pathogen-induced immune responses by 
intestinal epithelial cell lines has previously been reported, and strain-specific 
anti-inflammatory and immunostimulatory characteristics have been shown. In 
this study, we found that co-incubation with L. reuteri ATCC PTA 6475 and 
ATCC 53608 significantly reduced IL-8 production in EPEC-infected HT-29 
cells. Similar findings have been reported for other Lactobacillus species, such 
as the porcine isolate Lactobacillus sobrius DSM 16698, which upregulated 
anti-inflammatory IL-10 and reduced IL-8 protein content in ETEC-infected 
porcine IECs (Roselli et al., 2007). In addition, pre-incubation of T84 cells with 
L. rhamnosus JB-1 or mixed probiotic VSL#3 prior to infection with Salmonella, 
reduced IL-8 production (Ma et al., 2004; Madsen et al., 2001). In contrast, 
lactobacilli can sensitise cells to pathogenic insult, as the pre-treatment of HT-
29 cells with L. plantarum BFE or L. rhamnosus GG increased the IL-8 
response to S. Typhimurium (Pinto et al., 2009). This effect may be due to 
increased production of TLR2 and TLR5, which detect lipoteichoic acid and 
flagellin, respectively (Pinto et al., 2009).  
As flagellin is a potent inducer of the pro-inflammatory response to many 
pathogens, the effect of lactobacilli on flagellin-induced IL-8 production has 
been investigated in previous studies. Pre-treatment with L. rhamnosus GG 
attenuated IL-8 induction in Caco-2 cells stimulated with flagellin from P. 
aeruginosa (Lopez et al., 2008). Interestingly, anti-inflammatory effects of 
probiotics against a pathogen do not imply reduction of the immune response 
to particular bacterial components, as L. salivarius UCC118 attenuated IL-8 
production in HT-29 cells treated with S. Typhimurium but not with Salmonella 
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flagella (O'Hara et al., 2006). These findings are similar to our own, as L. 
reuteri ATCC 53608 significantly reduced the production of IL-8 by HT-29 cells 
when co-cultured with EPEC. However, there was no reduction in IL-8 protein 
when HT-29 cells were treated with ATCC 53608 and EPEC SN. In contrast, 
L. reuteri ATCC PTA 6475 significantly reduced the IL-8 response to both 
EPEC and EPEC SN. The mechanism behind this strain-specific effect 
remains to be defined but potential explanations will be discussed. 
While EPEC SN contains EPEC flagella (Girón et al., 2002; Zhou et al., 2003), 
it may also comprise additional pro-inflammatory factors, such as LPS, which 
induce the production of IL-8 (Cario et al., 2000; Hoshino et al., 1999; Poltorak 
et al., 1998). Probiotics have previously demonstrated anti-inflammatory 
effects against LPS-induced inflammation, as VSL#3, L. paracasei 1602, 
and L. reuteri 6798 decreased the production of TNF-α in LPS-treated ileal 
and colonic explants from IL-10-deficient mice (Madsen et al., 2001; Peña et 
al., 2005). Interestingly, L. reuteri ATCC PTA 6475, ATCC PTA 4659, and 
ATCC PTA 5289 inhibited LPS-induced IL-8 production in porcine IECs and 
rat ileum (Liu et al., 2010). As we utilised SN rather than EPEC-derived LPS 
or flagellin, further experimentation is required to determine whether L. reuteri 
inhibits IL-8 production induced by these specific components. These findings 
would elucidate the host signalling pathways through which L. reuteri 
modulates the innate immune response. Additionally, as EPEC-derived 
flagella induce IL-8 production in duodenal biopsies (Schüller et al., 2009), it 
would be interesting to investigate whether L. reuteri inhibited flagellum-
induced IL-8 production in duodenal samples. 
As mentioned previously, production of IL-8 and other pro-inflammatory 
cytokines is mediated by the transcription factor NF-κB. A number of 
Lactobacillus strains, such as L. rhamnosus GG and JB-1, as well as L. 
plantarum ATCC 8014, have been shown to inhibit NF-κB activation by 
preventing IκB degradation in HeLa, T84, and Caco-2 cells (Ko et al., 2007; 
Lopez et al., 2008; Ma et al., 2004). Unfortunately, we were unable to 
determine whether ATCC PTA 6475-mediated IL-8 reduction in EPEC-
infected HT-29 cells was dependent on NF-κB activation, as 
immunofluorescence staining of NF-κB was unsuitable to detect nuclear 
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translocation in HT-29 cells treated with EPEC or TNF-α. This was consistent 
with a previous study reporting the absence of nuclear NF-κB 
immunofluorescence staining in IL-1β-treated HT-29 cells, whereas Caco-2 
cells demonstrated distinct NF-κB nuclear localisation (Jobin et al., 1997). 
However, use of electrophoretic mobility shift assays and ELISA showed 
nuclear localisation in IL-1β-treated HT-29 cells, although at lower levels than 
treated Caco-2 cells (Jobin et al., 1997; Sibartie et al., 2009). These findings 
suggest that immunofluorescence microscopy is unsuitable to determine 
changes in NF-κB localisation in HT-29 cells, and alternative methods such as 
mobility shift assays or ELISA should be used.  
Some Lactobacillus strains secrete factors inhibiting immune stimulation by 
pathogens. The mechanism behind this inhibition is often undefined, and 
possibly dependent on bactericidal effects. However, pre-incubation of 
Salmonella with supernatant from L. acidophilus LB, L. casei 2756, L. curvatus 
2775, or L. plantarum 2142 reduced IL-8 induction in Caco-2 cells (Coconnier 
et al., 2000; Nemeth et al., 2006). Alternatively, some Lactobacillus strains 
secrete products which directly impact on the immune state of the host cell. 
For example, L. reuteri ATCC PTA 6475 SN reduced production of TNF-α by 
LPS-treated monocytes and macrophages from children with active Crohn’s 
disease (Jones & Versalovic, 2009; Lin et al., 2008). This has been linked to 
the production of the immunoregulatory compound histamine, which is derived 
from the essential amino acid L-histidine (Thomas et al., 2012). ATCC PTA 
6475-derived histamine activates the histamine H2 receptor, which reduces the 
production of TNF-α via inhibition of the MAPK pathway in monocytoid cells 
(Thomas et al., 2012). These findings contrast our own observations, as the 
conditioned medium of ATCC PTA 6475 did not attenuate the production of 
IL-8 by HT-29 cells stimulated with EPEC SN. These differences may be due 
to differences in cell type (IECs versus monocytes), cytokines investigated (IL-
8 versus TNF-α), or bacterial culture conditions (as histamine may not have 
been produced during our experiments). Taken together, our findings 
demonstrate that L. reuteri ATCC PTA 6475 and ATCC 53608 have 
immunomodulatory effects on IECs. These effects are independent of 
secreted products and thus may be dependent on the presence of the bacteria 
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at the epithelium.. Further investigation is required to define the mechanism 
behind the reduction in IL-8 protein levels in L. reuteri ATCC PTA 6475- and 
ATCC 53608-treated IECs, such as the impact of L. reuteri cell surface 
proteins on the innate immune response. An improved understanding of the 
mechanisms behind this effect will further validate the probiotic potential of 
these anti-inflammatory bacteria on the inflamed epithelium. 
 
5.3.3. The effect of L. reuteri on the EPEC-induced IL-8 
response ex vivo 
In contrast to findings in HT-29 cells, incubation with L. reuteri did not reduce 
IL-8 production in EPEC-infected duodenal biopsies. As L. reuteri did not 
penetrate the mucus layer, this could imply that adhesion to the epithelium is 
necessary for modulation of the immune response. This has previously been 
demonstrated by L. rhamnosus GG, which required the SpaCBA pilus for 
epithelial binding and inhibition of IL-8 expression in Caco-2 cells (Lebeer et 
al., 2012). Similarly, adherent live L. rhamnosus JB1 were required to inhibit 
IL-8 production in stimulated T84 and HT-29 cells (Ma et al., 2004). It is 
important to note that trauma of tissue removal induced inflammation in 
biopsies, as non-treated samples produced elevated levels of IL-8. The 
induction of the innate immune response due to tissue removal is a technical 
limitation of pIVOC when investigating the innate immune response. 
Therefore, it would be interesting to assess the anti-inflammatory effects of L. 
reuteri using an in vivo model, which would not present with background 
inflammation. 
Additionally, the immune status of the host can also impact on probiotic 
immunomodulation, as L. rhamnosus GG downregulated the immune 
response to milk in hypersensitive patients, but increased the expression of 
immunostimulatory receptors in the control group (Pelto et al., 1998). Active 
inflammation can also sensitise the epithelium to probiotics, as TNF-α-treated 
HT-29 cells showed enhanced IL-8 protein levels when subsequently exposed 
to L. plantarum BFE 1685 or L. rhamnosus GG, whereas neither strain induced 
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IL-8 production in non-treated cells (Pinto et al., 2009). Furthermore, the 
incubation of L. rhamnosus GG, L. plantarum NCIMB8826, and L. 
paracasei B21060 with tissue samples from patients with UC and CD caused 
severe degradation of biopsy tissue, whereas incubation with healthy samples 
did not alter tissue structure (Tsilingiri et al., 2012). 
Moreover, it is important to note that the immunomodulatory effects of 
probiotics may be cell-specific, as L. rhamnosus GG and L. plantarum 
NCIMB8826 did not induce IL-8 production in Caco-2 cells, but stimulated IL-
12 and TNF-α expression in human peripheral blood monocytes (Mileti et al., 
2009). Furthermore, L. rhamnosus GG and L. plantarum NCIMB8826 
amplified the progression of colitis in DSS-treated mice (Mileti et al., 2009). 
Crucially, these characteristics are strain-specific, as L. paracasei B21060 
reduced the symptoms of DSS-induced colitis versus mice without the 
probiotic (Mileti et al., 2009). In addition to chemically-induced inflammation, 
lactobacilli also decreased inflammation induced by pathogens. L. johnsonii 
La1 reduced keratinocyte-derived protein chemokine (KC; mouse cytokine 
homologous to human IL-8) serum levels in mice with ongoing H. pylori 
infection, and L. paracasei ssp. paracasei NTU 101 decreased IL-1β and IL-6 
expression in EHEC-infected mice (Sgouras et al., 2005; Tsai et al., 2010). 
Anti-inflammatory effects have also been described in human studies, as L. 
reuteri ATCC 55730 and ATCC PTA 5289 decreased IL-8 and TNF-α levels in 
patients with active gingivitis (Twetman et al., 2009).  
As previous studies have demonstrated that probiotics can deliver anti-
inflammatory effects during acute inflammation events, it would be interesting 
to investigate the impact of ATCC PTA 6475 and ATCC 53608 on inflamed 
tissue samples using the pIVOC model; to determine whether the anti-
inflammatory characteristics we observed were applicable to an inflamed 
milieu. Furthermore, future study into the role of epithelial binding on 
immunomodulation of intestinal samples would be beneficial for developing 
our understanding of how probiotics modulate the innate immune response. 
Aspiration of the mucus layer has been demonstrated on murine duodenal 
tissue (Atuma et al., 2001; Gustafsson et al., 2012). Therefore, this approach 
could be applied to human duodenal biopsies, to investigate whether epithelial 
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contact with the epithelium is necessary for L. reuteri immunomodulation. 
Additionally, it would be interesting to assess the impact of L. reuteri on EPEC-
induced IL-8 production in paediatric biopsies. As the immune system matures 
with age, the inflammatory response to EPEC infection may differ between 
adult and paediatric samples (Levy, 2007). 
 
5.4. Summary 
In this part of the study, we demonstrated that L. reuteri ATCC PTA 6475 and 
ATCC 53608 inhibited IL-8 induction in EPEC-infected HT-29 cells. This effect 
appeared to be dependent on L. reuteri adhesion to the host epithelium, as we 
did not observe IL-8 inhibition by L. reuteri supernatants or biopsy samples 
with an intact mucus layer. While the specific mechanisms behind L. reuteri 
immune modulation remain undefined, our findings demonstrate that ATCC 
PTA 6475 and ATCC 53608 can modulate the innate immune response 
induced by EPEC infection. 
The innate immune system provides a key barrier against EPEC infection of 
the intestinal epithelium. The secretion of T3S proteins weakens the 
inflammatory response which inhibits EPEC clearance but contributes to the 
production of diarrhoea in the host. Modulation of the inflammatory response 
by anti-inflammatory probiotics could reduce diarrhoeal symptoms in these 
patients. Therefore, the identification of probiotics with anti-inflammatory 
characteristics is an important area of research for developing therapies to 
reduce the burden of EPEC-induced diarrhoea.  
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The aim of this PhD project was to evaluate the potential of Lactobacillus 
reuteri to reduce pathogenesis of enteropathogenic Escherichia coli infection. 
In particular, the effects of L. reuteri on 1) EPEC binding to the intestinal 
epithelium, 2) mucus production, and 3) the innate immune response were 
characterised. To investigate these effects, mucus- and non-mucus producing 
intestinal epithelial cells (HT-29 and LS174T cells, respectively) and duodenal 
biopsies were utilised as models of the human intestinal epithelium.  
In the first part of this study, we identified that L. reuteri inhibited EPEC binding 
to intestinal epithelium at the mucus and epithelial level. These effects were 
strain-specific and included competition for binding receptors and the inhibition 
of EPEC dispersal across the epithelial surface. The protective effects 
observed were also dependent on the intestinal epithelial model used, which 
emphasised the requirement for physiologically relevant model systems. 
Therefore, future studies should investigate whether L. reuteri ATCC PTA 
6475 and ATCC 53608 inhibit EPEC colonisation of the intestinal epithelium 
in animal trials and clinical studies. 
A limitation of this study was the use of non-polarised IECs, as the human 
intestinal epithelium demonstrates distinct apical and basolateral polarisation 
of cell surface receptors. Thus, it would be interesting to assess the efficiency 
of L. reuteri binding to polarised cells which may have an alternative 
distribution of receptors on the apical surface than non-polarised cells. 
Additionally, polarised cells could be used to investigate the impact of L. reuteri 
on EPEC-induced changes to TJ integrity, a key mechanism behind the 
induction of diarrhoea in vivo. However, it is not possible to polarise HT-29 
cells, thus alternative small intestinal models, such as Caco-2 cells, 
xenografts, or intestinal biopsies, would be required. Furthermore, while we 
assessed the impact of L. reuteri monocultures on EPEC infection, mixed 
probiotic cultures have been suggested to deliver greater benefits to the host. 
Therefore, it would be interesting to investigate the impact of L. reuteri co-
cultures on EPEC pathogenesis. 
We also examined the impact of L. reuteri and EPEC on mucus production 
and determined that these bacteria significantly increased and decreased 
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MUC2 protein levels in LS174T cells, respectively. The effect of probiotic 
bacteria on the production of mucus has previously been poorly investigated, 
thus our data provide evidence that certain L. reuteri strains influence GI mucin 
levels. A limitation of this study was that we determined relative changes in 
fluorescence rather than total change in mucin protein. Therefore, it would be 
beneficial to confirm that the change in fluorescence which we identified 
corresponded with a significant change in MUC2 protein, by analysis of de 
novo mucin synthesis or Western blot. Future research should investigate the 
mechanism behind L. reuteri-induced change in MUC2 levels and determine 
whether ATCC PTA 6475 induced de novo mucin synthesis or enhanced 
mucus secretion, as well as the role of L. reuteri epithelial binding, cell surface 
proteins, and secreted products on mucus production.  
In the final part of this study, we determined that L. reuteri inhibited IL-8 
production by EPEC-infected intestinal epithelial cells. This is the first study to 
identify that L. reuteri ATCC PTA 6475 and ATCC 53608 can modulate the 
production of IL-8 protein by enterocytes in response to infection. As these 
anti-inflammatory effects appear to be dependent on epithelial binding, it 
would be interesting to investigate whether L. reuteri modify the innate immune 
response of intestinal samples with a compromised mucus layer. Additionally, 
future studies should assess the impact of L. reuteri on other pro- and anti-
inflammatory markers, such as IL-1β, IL-6, and IL-10 to further elucidate the 
mechanisms behind L. reuteri immunomodulation.  
In summary, the findings from this PhD demonstrate that L. reuteri ATCC PTA 
6475 and ATCC 53608 can protect the human intestinal epithelium against 
EPEC infection. These effects were particularly pertinent to ATCC PTA 6475, 
which inhibited EPEC microcolony dispersal, enhanced the levels of MUC2, 
and inhibited EPEC-induced IL-8 protein production. The characterisation of 
L. reuteri protective effects provides further evidence for the selection of these 
lactobacilli in the prevention of EPEC-induced acute infectious diarrhoea. 
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